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ABSTRACT
Carnitine supplementation has been shown to protect animals from 
ammonia toxicity following an ammonium acetate infusion and to alter body 
composition (i.e. increase lean mass and decrease body fat) in younger 
animals. The aims of this study were to address the questions of whether:
1) carnitine lowers blood ammonia levels of rats fed high protein;
2) carnitine decreases the weight gain and body fat of older animals fed 
high fat; 3) carnitine decreases glucose-induced insulin secretion; and 
4) consumption o f a high fat diet increases total serum carnitine content. 
Sprague Dawley retired female breeder rats (n-64) were stratified by weight 
and randomly assigned to one o f the following 8 treatment groups for an 8 
week study: carnitine (0%, 0.1%), protein (14%, 35%) and fat
(4%, 35%). The study was analyzed as a 2 X 2 X 2 factorial with repeated 
measures and ANOVA. At 2 and 8 weeks, serum levels o f ammonia, urea, 
glucose, insulin, carnitine, and nonesterified fatty acids were obtained. An 
oral glucose tolerance test was performed on week 5 and insulin and 
glucose were measured. Body composition measurements were obtained 
for all rats at the end o f the study. Inclusion of dietary carnitine to rats fed 
high protein resulted in a trend for lower serum ammonia and significantly 
lower glucose at 2 but not 8 weeks, with no effect on urea nitrogen levels. 
Insulin levels for these rats were lower at 2 week, but by 8 week had 
become higher. Before and after the glucose load was administered insulin 
levels were significantly higher for these rats. Carnitine did not enhance
x
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fatty acid oxidation or increase lean tissue, instead there was a tendency for 
greater abdominal fat as percent o f body weight. We conclude that 
cam itine’s effect on blood ammonia and glucose levels was short-lived and 
that witn time carnitine may lead to weight gain and thus to a loss of insulin 
sensitivity. Consumption o f a high fat diet does not seem to lead to an 
increase in total serum carnitine content. In addition the benefits o f carnitine 
on body composition are not present in older non-growing animals.
xi





During the past two decades the prevalence o f obesity in individuals 
of diverse cultural backgrounds has increased, with the total number of 
obese persons in the United States ranked among the highest in the world 
(Wolf and Colditz 1998, Kuczmarski et al. 1994). The Centers for Disease 
Control reported an increase in the prevalence o f obesity, from 12% in 1991 
to 18% in 1998. Even though a steady increase in obesity was observed 
across all states, sexes, age groups, races, and educational levels, the most 
drastic increase was observed in younger adults, people with some college 
education, and Hispanics (Mokdad et al. 1999). Today more than 50% of 
adults in the United States are overweight, based on a body mass index 
(BMI) > 25 kg/m2 and 22% of the adult population is obese (BMI > 30 kg/m2) 
(Flegal et al. 1998). Obesity is a major risk factor in the development o f 
chronic diseases such as coronary heart disease, type 2 diabetes, breast, 
colon, and endometrial cancer, and certain musculo-skeletal disorders. In 
addition, obesity can exacerbate many chronic conditions (e.g. 
hypertension, dyslipidemia) that can further deteriorate the quality o f life of 
the individual (W olf and Colditz 1998). In the United States, obesity related 
medical conditions are the second leading cause o f death after smoking- 
related illnesses with an estimated loss o f 280,000 lives each year (Allison
1
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et al. 1999a). In 1995, in the United States the total cost attributed to obesity 
was $99.2 billion, with approximately $51.6 billion associated with direct 
medical costs and $47.6 billion associated with indirect medical costs. Non­
insulin dependent diabetes mellitus (NIDDM) accounts for 63% ($32.5 
billion) o f the direct economic cost of obesity (Wolf and Colditz 1998). The 
total economic costs o f overweight and obesity in the United States are 
outrageous, with direct costs representing 5.7% of the National Health 
Expenditure (W olf and Colditz 1998), which are comparable to the direct 
costs o f cancer, 5% (Schuette et al. 1995). Estimates taking into account 
the increased mortality rate associated with obesity indicate that the direct 
health care costs o f obesity are still high, compromising 4.32% of the 
National Health Expenditure (Allison et al. 1999b). The 4.32% does not 
reflect the increased number of people who are at an increased risk of 
becoming obese that are still young enough to not be seen. Thus, reducing 
the costs associated with obesity and improving the health status and quality 
o f life should be a primary public health concern.
The development of obesity has been attributed to both genetic and 
environmental factors. However, since our genes have not changed during 
the relatively short period o f time in which obesity has increased, it is the 
changes in the environment that have led to the rise in obesity. There are 
many environmental factors that can affect the components o f energy 
balance, both intake and expenditure. The contributions to energy balance 
observed with changes in energy expenditure seem to be small compared to
2
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those of energy intake. There is evidence indicating that positive energy 
balances are caused by loss o f appetite control and increased energy 
intake, rather than by defects in energy expenditure (Grossman and 
Despres 1996, Poppitt 1995). A continuous state of positive energy balance 
has been shown to cause gradual weight gain that can eventually lead to 
obesity (Poppitt 1995).
The composition of the diet may be an important factor contributing to 
the higher incidence of obesity in certain populations. Consumption of high- 
fat diets has been shown to result in overconsumption o f food, which may 
lead to an increase in fat deposition, and eventually to obesity (Poppitt,
1995, Salmon and Flatt 1985). The hyperphagia associated with high fat 
diets is caused by the combination of the high fat and high energy content o f 
the diets. High-energy dense diets have a greater fat content than that of 
lower energy dense diets. Consumption o f a high-fat, high-energy dense 
diet should be accompanied by a decrease in the total amount of food 
consumed to avoid a state of positive energy balance and thus weight gain. 
The amount of fat that can be oxidized is also an important determinant in 
body energy regulation and is thus an important factor in the development of 
obesity (Flatt 1995). Weight maintenance is achieved when the amount of 
carbohydrate and fat oxidized is equivalent to that consumed in the diet. 
Consumption o f a high carbohydrate diet during periods o f positive energy 
balance reduces the amount o f fat oxidized. High fat, high energy dense 
diets lead to an increase in fat oxidation, but if the amount o f calories
3
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consumed are in excess, fa t oxidation will decrease leading to increased 
body fat and weight gain (Flatt 1995, Poppitt 1995). In an effort to improve 
body weight, Americans are now consuming less fat as percentage o f total 
calories, but the amount o f calories consumed has increased. Therefore, 
although the percentage o f calories from fat is down the total amount of fat 
consumed has remained the same or increased causing an increase in 
energy consumption and increased weight gain (Allred 1995).
According to the Continuing Survey o f Food Intakes by Individuals 
(CSFII 1994-1996) Americans consuming the typical Western diet are eating 
a diet that is still too high in fat and low in some nutrient dense foods.
Results o f the CSFII (94-96) indicated that the mean daily caloric intake 
consumed by men and women ages 20 and over was 15.8% and 15.8% 
from protein, 33.4% and 32% from fat, 49.3% and 51 % from carbohydrates, 
and 1.5% and 1.2% from alcohol, respectively (USDA 1998). The caloric 
intake was overall less then the Recommended Dietary Allowance (RDA), 
with mean intake being 88% o f the RDA for calories and females 30 years of 
age or older having a caloric consumption in the upper range (70%) of the 
recommended intake (USDA 1998). The reported energy intake o f the 
participants does not reflect the observed increase in obesity. It is possible 
that the RDA established for energy is too high or that the survey was 
skewed (Katz 1998). Furthermore, a decrease in the amount o f physical 
activity could also be a contributing factor to the increase in obesity. Protein 
consumption was greater than the RDA for all participants, even those
4
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consuming the lower amounts o f protein. Females over 70 years of age 
consumed 113% and both male and female children consumed more than 
200% o f the RDA for protein (USDA 1998).
Many more Americans are now consuming diets that are approaching 
a balance but there is still need for more improvement (Katz 1998). For 
instance, individuals trying to lose weight are consuming diets, such as 
“Sugar Busters”, that are high in fat and protein. The amount o f 
carbohydrate and calories consumed in these diets is reduced, with most 
starchy, sugary foods and desserts being eliminated. Individuals consuming 
these diets seem to attribute the weight loss to the reduction in the 
carbohydrate content o f the diet and an effect on glucose regulating 
hormones, but in reality most o f these diets are calorie-restricted and it is the 
decrease in energy consumption that leads to the weight loss. In addition, 
high protein diets supplemented with additional protein sources are being 
consumed in an effort to increase muscle mass and weight gain. Protein 
supplements are perhaps the most common ergogenic aid or dietary 
supplement used by athletes today (Applegate and Grivetti 1997). Athletes 
are now consuming not only basic protein supplements but are also 
consuming supplements with specific amino acids, such as the branched 
chain amino acids, arginine, and taurine, which claim to serve as an energy 
source, increase levels o f growth hormone, and increase weight gain. It is 
also common for athletes to consume protein and amino acid beverages 
during and after exercise (Applegate and Grivetti 1997).
5
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HORMONAL INFLUENCES
Insulin is a peptide hormone that helps regulate the metabolism of the 
macronutrients. Adequate amounts o f insulin are needed for the proper 
oxidation and storage o f carbohydrates (Groff et al. 1995). In addition, 
insulin helps promote uptake of amino acids into muscle cells and prevent 
breakdown o f existing protein (Karam 1997). Insulin’s actions in fat 
metabolism are to provide fatty acids and glycerol for re-esterification to 
triacyglycerols and to prevent the breakdown of existing triacylglycerol 
molecules (Karam 1997). Insulin functions by activating or inactivating 
enzymes involved in the oxidation and synthesis of these nutrients, allowing 
for adequate metabolic processes to occur. When the normal functions of 
insulin are impaired the metabolism of the macronutrients will be disrupted 
and this may lead to the development of metabolic disorders. Decreased 
insulin secretion and decreased insulin sensitivity are two defects by which 
the actions o f insulin can become impaired. In addition, insulin has also 
been shown to act as an adiposity signal in the central nervous system 
leading to decreased food intake, weight loss, and increased thermogenesis 
(Schwartz et al. 1992).
The relationship between insulin resistance and obesity has been 
studied extensively. There is still controversy about whether it is the 
condition o f obesity that causes insulin resistance or if the presence of 
insulin resistance is what leads to the development of obesity. The 
complexity o f this relationship makes it harder to identify strategies for
6
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weight reduction and maintenance and to develop more appropriate 
guidelines for people with insulin resistance.
TREATMENTS
There are many programs and strategies available fo r weight 
reduction and weight maintenance, but the number o f American people who 
are obese is higher than before and is starting to reach epidemic 
proportions. Among the available strategies is the low carbohydrate, high 
fat and high protein diet, such as Sugar Busters, Protein Power Plan, Zone 
and the Atkins diet, that is being advocated by many. Eating moderate 
amounts and a wide variety o f foods while increasing physical activity is 
another strategy that is used. In addition, there are many drugs available 
that are being used to suppress appetite, decrease fat absorption, and/or 
increase metabolic rate. Furthermore, use o f supplements that are 
advertised to enhance the oxidation o f fat, increase lean muscle mass, and 
lead to rapid weight loss are viewed as alternative ways to treat obesity.
Carnitine, a trimethylated quaternary amine, plays a crucial role in the 
metabolism of fat and protein. L-camitine is the active isomer o f this 
compound and is obtained from exogenous (diet) or endogenous (synthesis) 
sources. Because o f its role in fat metabolism, the use o f L-camitine as a 
supplement to increase fat oxidation and weight loss is being evaluated. In 
addition, use of supplemental L-camitine to enhance nitrogen utilization and 
promote growth of lean muscle is being advocated as a means o f improving 
body composition. L-camitine has an indirect effect on the metabolism of
7
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glucose because it affects fat and protein metabolism. Therefore, L- 
camitine is also being utilized as a potential treatment for type 2 diabetes. 
L-camitine along with other supplements is being used by many as a way of 
achieving rapid changes in body composition and to ameliorate metabolic 
disorders associated with obesity.
OBJECTIVES
The objectives o f this study were to examine the effects o f 
supplemental dietary L-Camitine on ammonia levels and body composition 
o f rats fed high protein and high fat diets. The specific objectives addressed 
by the study were the following:
• To determine the effects o f dietary carnitine on ammonia levels and urea 
production in rats fed low and high protein diets.
•  To determine if dietary carnitine reduces weight gain and body fat in 
older rats fed a high fat diet.
•  To determine if dietary carnitine reduces glucose-induced insulin 
secretion in rats fed different levels o f protein and fat.
• To determine if consumption o f a high fat diet increases the synthesis of 
endogenous carnitine as indicated by total serum carnitine.
• To determine if dietary carnitine enhances fatty acid oxidation as 
measured by 3- hydroxyacyl CoA dehydrogenase (HOAD) in skeletal 
muscle.
8
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HYPOTHESES
• Inclusion o f dietary carnitine will decrease glucose oxidation and insulin 
secretion.
• Dietary carnitine will decrease serum ammonia levels and increase blood 
serum urea production o f rats fed a high protein diet.
• The addition o f dietary carnitine to rats fed a high fat diet will result in 
decreased weight gain and improved insulin sensitivity.
• Consumption of a high fat diet will increase the synthesis o f carnitine.
• Rats on the high fat diet consuming dietary carnitine will have enhanced 
fatty acid oxidation.
9





Carnitine, an important constituent o f biological systems, is a small- 
molecular weight water-soluble quaternary amine (p-OH-y-N- 
trimethylaminobutyric acid; see Appendix A for structure). L-camitine was 
discovered in 1905, but its crucial role in metabolism was not elucidated until 
1955 (Bremer 1983). Mammals and microorganisms are capable of 
synthesizing carnitine from two dietary amino acids, lysine and methionine.
In humans, biosynthesis o f carnitine from deoxycamitine, the immediate 
precursor o f carnitine, is limited to the liver, brain, and kidneys (Bremer 
1983). In addition, foods o f animal origin such as meat and dairy products 
are significant sources of exogenous L-camitine in human nutrition (Mitchell 
1978). There is no known established human dietary requirement for 
carnitine, but in general consumption of a well-balanced healthy diet 
contains adequate amounts of carnitine and the two amino acids, lysine and 
methionine, needed for carnitine biosynthesis (Kelly 1998). On average, the 
American non-vegetarian diet provides approximately 100-300 mg (0.62- 
1.86 mmol) o f L-camitine daily with endogenous synthesis providing about 
300-600 mg/day (1.86-3.73 mmol) (Feller and Rudman 1988).
The total carnitine pool in a healthy individual is about 100 mmol, with 
the biggest pool found in skeletal muscle (98%) and the remaining amounts
10
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in the liver and kidney (1.5%; Gatti et al.1998). Diet, endogenous synthesis, 
and efficient reabsorption by the kidneys influence plasma carnitine levels. 
Carnitine baseline levels are also influenced by gender, age and nutritional 
status (Gatti et al.1998). The concentration o f carnitine varies across 
species and different tissues. In mammalian tissues, the highest 
concentration o f carnitine is in the heart and skeletal muscle. Tissue 
carnitine concentration is related to the specific functions o f this compound. 
Fatty acid and amino acid catabolism are among the metabolic pathways 
dependent on carnitine for proper functioning.
The role o f L-camitine in the oxidation o f long-chain fatty acids in 
animal tissues has been well established. Carnitine has been shown to 
enhance long-chain fatty acid oxidation in homogenates o f different tissues 
(Fritz 1955) and in isolated mitochondria (Fritz et al.1962). Carnitine allows 
long chain acyl CoA esters to cross the mitochondrial membrane, which is 
impermeable to CoA compounds (Feller and Rudman 1988). Activated 
long-chain fatty acids need to be transported inside the mitochondria for 
beta-oxidation to occur. On the outer side o f the inner mitochondrial 
membrane, long-chain fatty acylcamitine esters are formed by the enzyme 
carnitine palmitoyltransferase I. These esters can then cross the inner 
mitochondrial membrane. Once inside the inner mitochondrial membrane, 
the fatty acyl CoA and carnitine are regenerated by the enzyme carnitine 
palmitoyltransferase II.
11
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Less is known about the role o f carnitine in amino acid metabolism. 
Carnitine seems to serve a facilitative role if not an obligatory role in the 
catabolism of branched chain amino acids (Borum 1983). The discovery of 
branched-chain acylcamitines lead researchers to believe that carnitine 
might be involved in the transport o f branched chain amino acids into the 
mitochondria. Presence o f the a-keto acid dehydrogenase inside the inner 
mitochondrial memebrane indicated that the branched chain amino acids did 
not need to be transported as branched-chain acylcamitine into the 
mitochondria. Inside the mitochondria the branched chain 2-oxoacids 
(transaminated form o f the branched chain amino acids) get converted to 
their corresponding branched chain acylCoA esters. The proper oxidation o f 
branched chain amino acids requires the removal of the branched chain 2- 
oxoacids to prevent excess formation of CoA inside the mitochondrial matrix 
(Bremer 1983, Hinsbergh et al.1978). Researchers believe that carnitine 
seems to be participating in amino acid metabolism by forming branched 
chain acylcamities thus decreasing the branched chain acylCoA esters and 
providing a buffering effect on the mitochondrial acyl-CoA/CoA ratios 
(Bremer 1983, Hinsbergh et al.1978). The ability of acetyl carnitine to move 
freely across subcellular membranes allows it to  function as a pool from 
which acetyl-CoA is regenerated (Gatti et al.1998). Thus, making it possible 
for metabolic energy to be transported between different organs.
Another role of carnitine in metabolism is to protect cells against toxic 
accumulation o f acyl-CoA compounds. Carnitine traps acyl-CoA
12
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compounds o f either endogenous or exogenous origin by forming carnitine 
esters. These acyl carnitine esters can then be transported to the liver for 
catabolism or to the kidneys for excretion (Feller and Rudman 1988).
It has been suggested that for some individuals and under certain 
conditions carnitine can be considered a conditionally essential nutrient 
(Kelly 1998). Therefore, therapeutic functions o f carnitine for individuals 
with a nutritional deficiency or a genetic defect, are becoming more 
widespread. Primary L-camitine deficiency was first described by Engel and 
Angelini (1973) in the early 1970’s. Primary carnitine deficiency is classified, 
based on the abnormality o f the tissue distribution o f carnitine, into two 
autosomal recessive disorders, myopathic and systemic. In the myopathic 
condition, the concentration of carnitine in muscle is low and plasma levels 
are normal. This deficiency is characterized by muscle weakness and is 
accompanied by an increase in plasma enzymes o f muscle origin. A defect 
in the transport o f carnitine has been proposed as the cause for this 
deficiency. In the systemic condition, carnitine concentrations are low in 
plasma, liver and in skeletal and heart muscle. Symptoms include muscle 
weakness and irregularities of the liver, central nervous system and heart. 
The following conditions can also be observed: encephalopathy, 
hyperbilirubinemia, hyperammonemia, and cardiomyopathy. The defect 
associated with this deficiency is not known (Feller and Rudman 1988). 
Secondary carnitine deficiency is most commonly associated with genetic or 
acquired metabolic defects and seems to occur more often than the primary
13
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deficiency. Some o f the current therapeutic applications o f carnitine include 
treatment o f anorexia nervosa, chronic fatigue syndrome, heart disease, and 
male infertility (Kelly 1998).
INTERACTION WITH MACRONUTRIENTS
Protein
Carnitine is considered an essential compound for proper amino acid 
metabolism. Research has been conducted to determine if carnitine has a 
protective effect against ammonia toxicity, can affect the growth 
performance o f animals and cause variations in body composition. The 
underlying mechanisms of these effects o f carnitine are not always clear. 
Several hypotheses have been proposed to try to elucidate these 
mechanisms.
Ammonia concentrations in nearly all-animal tissues are maintained 
at very low levels. A 5 to 10 fold increase in ammonia concentration in the 
blood induces toxic effects in most species. Functional disturbances of the 
central nervous system accompany these toxic effects (Felipo et al.1988). 
The effect o f hyperammonemia on brain function is not well understood 
making it harder to develop appropriate treatments. In ureotelic species the 
main mechanism used to prevent ammonia toxicity is the production of urea.
In mice, the protective effect of L-camitine on ammonia toxicity was 
reported by O’Connor et al.(1984). Male Swiss albino mice fed a standard 
diet were injected with a single intraperitioneal injection o f 12 mmol 
ammonium acetate/kg of body weight (LD «» = 12 mmol; 0.8 M solution).
14
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Thirty-minutes prior to ammonium infusion, mice were injected 
intraperitoneally with different doses o f L-camitine, 8, 16, 24 and 32 mmol/kg 
o f body weight or with a saline solution. Symptoms o f ammonia toxicity 
were seen rapidly after the injection for the mice who received the saline 
solution. Mice given ammonium acetate with saline solution die between 10 
to 15 minutes, so all o f the mice were sacrificed 10 minutes after the 
ammonium acetate injection; their brains were removed and frozen in liquid 
nitrogen. Enzymatic determination was done for the following metabolites: 
ammonia, lactate, pyruvate, a-ketoglutarate, glutamate, and glutamine.
Mice fed L-camitine had decreased levels of ammonia in the brain and the 
blood (p<0.01) when compared to saline treated mice. L-camitine 
suppressed the mortality associated with acute ammonia intoxication. At the 
lower dosages o f L-camitine the survival rate was 60%, symptoms were 
present but attenuated, and the appearance of toxicity was delayed. At the 
higher dosages, the survival rate for the mice was 100%. Administration of 
L-camitine prevented the accumulation o f glutamine and the decrease in 
glutamate levels was smaller, making the levels o f these two metabolites 
significantly (p<0.01) different than levels in mice injected with saline. 
Increased glutamine synthesis from glutamate leads to an increase in ATP 
consumption and thus a decrease in ATP levels. In addition, glutamine can 
eventually affect the transport o f reducing equivalents (NAOH) into the 
mitochondria via the malate aspartate shuttle causing a decrease in the 
amount o f ATP produced. L-camitine also made levels o f a-ketoglutarate,
15
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which are slightly increased by ammonia, more normal. The increase in 
glutmate might be due to both the decreased conversion to glutamine and 
increased synthesis from a-ketoglutarate. Blood urea nitrogen levels for 
both protected and unprotected mice were sim ilar at the time o f death. 
O’Connor et al.(1984) concluded that the early protective effect o f L- 
camitine was not caused by an increase in urea synthesis. The most 
important protective effect seemed to be the increase in glutamate in the 
brain, which may reflect enhanced ammonia utilization via glutamate 
dehydrogenase, which converts a-ketoglutarate to glutamate. A decrease in 
levels o f glutamate, a major excitatory neurotransmitter in the brain, may 
result in neurological problems, such as coma, during periods o f ammonia 
intoxication.
Costell et al. (1984) examined the effects of L-camitine on urea 
synthesis following acute ammonia intoxication. Male Swiss Albino mice fed 
a standard diet were divided into two groups. One group received saline 
with an intraperitoneal injection with a LD100 o f ammonium acetate (12 
mmol/kg). Another group received an intraperitoneal injection o f L-camitine 
(16 mmol/kg) 30 minutes before the ammonium acetate challenge. Five 
minutes before receiving the ammonium acetate injection animals in both 
groups received a pulse o f (14C) NaHCOa- In addition, an intracardiac 
injection o f 50 ul o f an aqueous (14C) NaHC03 solution containing 2 mCi/ml 
(57.8 mCi/mmol o f specific radioactivity) was administered. After the 
ammonium acetate injection blood samples were drawn from the tail vein at
16
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designated times. Samples were analyzed for plasma 14C urea and 14C 
bicarbonate determination. At sacrifice, the livers were removed and 
hepatic mitochondria were isolated from which the intramitochondrial 
content o f N-acetylglutmate was estimated. Animals not given L-camitine 
exhibited symptoms of ammonia toxicity, such as hyperexcitability and 
seizures, which progressed to death in 15 minutes. A higher synthesis o f 
14C urea was observed for animals protected with L-camitine than for 
animals given ammonium acetate only. The enhancement o f urea synthesis 
observed could be due to an increase in intramitochondrial content o f acetyl 
CoA and synthesis o f N-acetylglutamate caused by higher rates o f fatty acid 
oxidation. In this study, the level o f N-acetylglutamate rose rapidly after the 
ammonium acetate injection and the levels were the same in animals given 
or not given the L-camitine. Thus, L-camitine did not induce a further 
increase on the hepatic intramitochondrial levels o f N-acetylglutamate above 
that induced by ammonia. To summarize, there must be some other factor 
involved in the stimulation of urea synthesis by L-camitine. Alternative 
explanations could include an increase in intramitochondrial ATP or an 
increase in concentration o f some urea cycle intermediates (Saheki et 
al.1980, Fritz and Marquis, 1965).
In a similar study, Deshmukh and Rusk (1988) examined the effects 
of L-camitine on ammonia toxicity. Male Swiss Albino mice (n=47) were 
divided into the following 4 groups: Saline (n=8), L-camitine (n=6), Saline + 
Ammonium Acetate (n=14), and L-camitine + Ammonium Acetate (n=19).
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All groups were maintained on a Purina rodent chow diet. An 
intraperitioneal injection of ammonium acetate (14 mmol/kg of an 0.8 M 
solution), 30 minutes after saline or L-camitine administration, was given to 
mice in groups 3 and 4. Mice were sacrificed 5 minutes after the ammonium 
acetate injection. At this time blood was collected from the heart and the 
brain was removed and frozen in liquid nitrogen. Then blood samples were 
analyzed three hours later for levels of ammonia and urea in serum and 
plasma. This study differed from the one conducted by O’Connor et al. 
(1984) where blood samples were collected from the tail vein. Preliminary 
experiments had been conducted to determine the lethal dose of amonium 
acetate. Mice were injected intraperitoneally with different dosages of 
ammonium acetate, ranging from 1-18 mmol/kg. Contrary to the findings of 
O’Connor et al. (1984), the LD100 of ammonium acetate was observed at a 
higher concentration o f ammonium acetate, 14-18 mmol/kg. The 
intraperitioneal injection with L-camitine (16 mmol/kg) did not alleviate the 
symptoms o f hyperammonemia. A rapid increase in serum and liver levels 
o f ammonia was observed after the ammonium acetate injection for mice 
given carnitine or saline, but brain levels did not increase. In contrast, the 
results o f O’Connor et al. (1984) showed that brain ammonia levels did 
increase rapidly in animals that received ammonium acetate. Deshmukh 
and Rusk found that mice treated with ammonium acetate plus L-camitine 
had higher levels of ammonia in the liver than the mice injected with saline 
plus ammonium acetate (p<0.05). The researchers concluded that the
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increase was most probably due to a higher load o f nitrogen derived from 
the carnitine. In addition, the results showed that L-camitine failed to protect 
mice against ammonia toxicity. The higher ammonium dose used by 
Deshmukh and Rusk could explain the lack of an effect o f carnitine on 
ammonia levels.
In a study conducted by Therrien et al. (1997) the efficacy o f L- 
camitine in the prevention o f hepatic encephalopathy, a complex 
neuropsychiatric disorder associated with acute or chronic liver failure, in 
hypearmmonemic conditions was evaluated. Adult male Sprague-Dawley 
rats (n=70) were anesthetized and an end-to-side portacaval anastomasis 
(PCA) surgery was performed to create a portacaval shunt to bypass the 
liver. Thirty-five rats received L-camitine (16 mmol/kg) intraperitoneally 1 
hour before a subcutaneous dose of ammonium acetate (8.5 mmol/l/kg).
The other 35 received a saline injection with the same subcutaneous dose 
of ammonium acetate. Cerebrospinal fluid (CSF) ammonia, lactate, and 
amino acid levels were measured. To collect CSF catheters were inserted 
in the cistema magna space and 24 hours after the operation silastic tubing 
was connected to the catheter for CSF sampling. A 25 ul sample o f CSF 
was drawn just before L-camitine or saline was administered, 10 minutes 
before administration o f ammonium acetate, 30 minutes after ammonium 
administration, and 10 minutes later. Neurological deterioration was not 
observed for any o f the rats in the L-camitine treated group, whereas saline- 
treated rats manifested severe encephalopathy progressing through the loss
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o f righting reflex to coma. The L-camitine treated group had a survival rate 
o f 100% compared with 5% in the saline treated group. Administration of 
ammonium acetate increased CSF ammonia to 0.9S ±0.15 mmol/L and 1.24 
± 0.15 mmol/L at precoma and coma stages, respectively (p<.01). CSF 
ammonia at both stages was significantly (p < .01) reduced in the L- 
camitine-treated group when compared to the saline-treated group. 
Treatment with L-camitine did not led to a significant reduction in plasma 
ammonia nor CSF or brain glutamine levels. However, L-camitine led to a 
significant attenuation o f the CSF lactate increase that was seen for the 
saline treated rats at both precoma (p < .001) and coma stages (p < .001) of 
encephalopathy. Increased CSF alanine levels were also decreased by 
36% at precoma (p < .01) and 34% at coma (p < .05) stages fo r animals 
treated with L-camitine compared with saline-treated animals. The 
attenuation observed suggests that in the L-camitine-treated group 
mitochondrial respiration had been at least partially restored. The enzyme a  
ketoglutarate dehydrogenase, which converts a ketoglutarate to succinyl 
CoA, is inhibited by pathophysiological concentrations o f ammonia.
Inhibition o f this enzyme results in decreased pyruvate oxidation coupled 
with an increase in brain levels o f lactate and alanine. By decreasing CSF 
ammonia levels, carnitine may have prevented the ammonia-induced 
inhibition o f a ketoglutarate dehydrogenase. These results lead the authors 
to conclude that the major protective effect of L-camitine involves a central 
rather than peripheral mechanism. In addition, in patients with liver disease
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the use o f L-camitine to prevent and treat ammonia-precipitated coma could 
be considered a rational approach.
Hearn et al. (1989) did a series o f experiments to determine if L- 
camitine had a protective effect against hyperammonemic conditions in 
male W istar rats. An end-to-side portacaval shunt (PCS) was used to 
induce a chronic hyperammonemic state. In experiment one, PCS 
hyperammoneic rats (n=5) were injected intraperitoneally with L-camitine 
(16 mmol/kg) one hour prior to a LD100 (12 mmol/kg) dose o f ammonium 
acetate via an intraperitoneal injection. In the second experiment, rats were 
given ammonium acetate (n=9), ammonium acetate plus L-camitine 1 hr 
prior to ammonium infusion (n=7), or ammonium acetate plus L-camitine 24 
hr prior to ammonium infusion (n=5). In the last experiment, rats received 
either a saline injection 30 minutes (n=5) or 1 hr (n=4) prior to ammonium 
acetate infusion or L-camitine 30 minutes (n=9) or 1 hr (n=17) prior to 
ammonium acetate infusion. Animals were killed by freeze-blowing, a 
procedure where the forebrain is extruded through a hollow needle and 
rapidly frozen. The brain tissue was deproteinized and the homogenate was 
neutralized. The homogenate was analyzed for the following brain 
metabolites: total acid-soluble carnitine, ammonia, free carnitine, and short- 
chain acylcamitines. The protein pellet was resuspended in KOH for long- 
chain acylcamitine determination. The percentage survival rate for animals 
treated with L-camitine varied across experiments, ranging from 35 to 100%. 
Results o f the first 2 experiments suggested a significant protective effect for
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L-camitine, based on the survival rate o f the animals. Results from the third 
experiment suggested a protective effect that did not reach statistical 
significance. The concentration o f L-camitine increases slowly in the brain, 
as expected for a compound that penetrates the blood-brain barrier poorly. 
Despite this accumulation was observed in moderately large amounts over 
several hours. At 1, 4, and 24 hours following an L-camitine injection, total 
acid soluble carnitine slowly increased in the rat forebrain and was 
significantly different from baseline data, p=0.05, p=0.025, and p=0.025, 
respectively. But the protective effect o f carnitine was completely lost when 
L-camitine was given 24 hr. prior to the ammonium infusion. Thus, this 
increase does not correlate with the protective effect o f L-camitine against 
acute ammonia toxicity. In conclusion, the authors suggest that in rats the 
protective effect o f L-camitine is short-lived; protection is maximal 1 hr after 
administration and undetectable at 24 hr. Therefore, this study suggests 
that protection from toxicity depends mainly on peripheral rather than central 
L-camitine dependent mechanisms.
According to Felipo et al. (1994) L-camitine prevents ammonia 
toxicity by preventing glutamate neurotoxicity. Primary cultured neurons 
were prepared from the cerebellum of 8 day-old Wistar rats. Before addition 
of glutamate (1 mM) to the cells some of the cells were pre-incubated with 
carnitine. To determine the effect of L-camitine on glutamate binding to 
different types of glutamate receptors, cells were incubated with glutamate 
(labeled and unlabeled), and Tris-citrate with or without carnitine. Binding o f
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different receptors to glutamate was determined by subtracting the binding 
determined in samples containing unlabeled glutamate and unlabeled 
glutamate receptors (N-methyl-D-aspartate-NMDA, kainate, and 
quisqualate). Results indicated that L-camitine prevented glutamate toxicity, 
in a dose-dependent manner, by increasing the affinity o f glutamate for the 
quisqualate receptor and decreasing the affinity for the NMDA receptor. It 
has been shown that acute ammonia toxicity is mediated by activation of the 
NMDA receptor (Felipo et al.1988). Activation of the NMDA receptor by 
glutamate results in an increase in cytoplasmic levels o f Ca2+ that lead to 
neuronal death. Thus, L-camitine prevents glutamate toxicity by 
preferentially activating the quisqualate receptor and preventing an increase 
in cytoplasmic Ca+2 and the neurotoxicity prompted by activation o f the 
NMDA receptor. By preventing the glutamate neurotoxicity carnitine could 
stop the development o f ammonia toxicity.
Results o f the studies conducted by O'Connor et al. (1984) and 
Costell et al. (1984) in mice, and Therrien et al. (1997) and Heam et al. 
(1989) in rats, and Felipo et al. (1994) in primary cultured neurons provide 
evidence to support the protective role of carnitine in the treatment of 
ammonia toxicity. But each study attributed the protective effect to a 
different mechanism; thus the exact mechanism that affords this protective 
effect remains to be elucidated. The study by Deshmukh and Rusk (1988) 
in mice is the only one that found a lack of a protective effect on carnitine on 
ammonia toxicity. Therefore, there seems to be some promise to support
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the use o f L-camitine as a therapeutic treatment for conditions that alter the 
normal levels o f ammonia in the blood and brain.
The effect of L-camitine on growth performance and body 
composition o f animals and athletes is also being investigated. The use of 
carnitine as a supplement in animal feed has drawn attention because o f its 
potential to enhance the protein-sparing action o f fat and promote growth (Ji 
et al.1996). In humans, studies with carnitine supplementation have been 
conducted to determine the relationship between plasma carnitine 
concentration and variation in body composition (Gatti et al.1998, Amodio et 
al.1990).
Ji et al. (1996) examined the biochemical actions o f carnitine at the 
cellular and subcellular levels in Atlantic Salmon (Salmo salar). Four 
hundred and eighty Atlantic Salmon fry (Penobscot-strain) were transferred 
to 12 tanks (n=40). The fish were reared under simulated natural 
photoperiods and were accustomed to the control diet for 2 wk. Before the 
fish were assigned to dietary treatments they were anesthetized, blotted with 
paper towels, and weighed. Body weight and length were recorded for the 
fish in each tank. Fish were fed one o f four diets for 6 wk: control (camitine- 
free), and carnitine supplemented 4.6, 11.5 or 23 mmol/kg wet weight o f 
finished diet. A daily ration of 3% of the body weight was achieved by using 
automatic feed dispensers. Four different experiments were conducted. 
Experiment 1, was a preliminary trial to examine growth and feed conversion 
in fish fed the different diets. In experiment 2, changes in body composition
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were measured and preliminary data were collected for biochemical 
responses. Experiment 3, included an analysis o f biochemical responses to 
dietary carnitine. Experiment 4, was conducted with 2-yr old salmon and 
results were compared to metabolic measurements from isolated 
hepatocytes from juvenile salmon (Experiment 3). Specific growth rate and 
the feed conversion coefficient were calculated for all experiments. Protein 
content was determined in isolated liver mitochondria and hepatocytes by 
the biuret method. Proximate analysis o f tissue composition was conducted 
in three fish, randomly chosen, from each o f 2 tanks per diet. Fish were 
fasted for 16-18 hr, scales were removed and filets and skins were excised 
from both sides. The visceral organs, minus the posterior intestine were 
also removed. The filets and viscera were immediately frozen and stored 
until the time of analysis. Samples were thawed, minced with a small 
electric coffee grinder, and moisture, ash, fat (Soxhlet extraction method), 
and protein (Kjeldahl method) content were determined. The following 
parameters were also determined: free amino acids in blood and liver, fatty 
acid oxidation in mitochondria, flux through pyruvate carboxylase (PC; 
converts pyruvate to oxaloacetate) in liver mitochondria, flux through the 
branched-chain a-keto acid dehydrogenase complex (BCKDH; converts a- 
keto acid to corresponding CoA compound) in liver mitochondria, and 
protein synthesis.
No significant (p>0.05) differences were observed in the body 
weights, specific growth rates (percentage change in body weight/day), or
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feed conversion for juvenile salmon fed the carnitine-free or carnitine 
supplemented diets. Supplemental carnitine did not have an apparent 
influence on efficiency o f feed conversion (p>0.05). Proximate analysis of 
the filets and visceral organs o f juvenile salmon indicated that carnitine 
supplementation decreased lipid content, in a dose-dependent manner, by 
as much as 73% (p< 0.005). Protein concentration increased, in a dose- 
dependent manner, by as much as 62% for fish fed carnitine (p< 0.005). 
Liver from 2-yr old salmon and juvenile salmon fed carnitine oxidized 
palmitate at rates that were 2.5 (p<0.05) and 1.5 times (p<0.001), 
respectively, the rates observed with liver from carnitine deprived cohorts. 
Plasma concentrations o f proline, valine, and cysteine were significantly 
(p<0.05) greater for juvenile salmon-fed the carnitine-supplemented diet. 
The liver concentration o f all 3 of these amino acids plus leucine, isoleucine, 
histidine, and glycine was significantly (p<0.05) greater for juvenile fish fed 
carnitine. Camitine-fed salmon had a significantly (p<0.001) greater PC flux 
(81% greater), but no difference in BCKDH flux, when compared with 
salmon not fed carnitine. The capacity for protein synthesis, measured by 
incorporation o f radiolabeled methionine into acid-insoluble material, was 
significantly greater (p<0.05) for juveniles and 2-y-old salmon fed the 
carnitine diets. In conclusion, the mechanism for carnitine-induced changes 
in nitrogen metabolism could be explained by the enhanced protein 
synthesis and increased PC flux. By increasing the ratios o f acetyl 
CoA:CoA-SH and ATP:ADP ratios carnitine might stimulate flux through PC
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and reduce flux through the BCKOH complex. Thus increasing the supply o f 
carbon for synthesis of nonessential amino acids (via increased PC) and the 
supply o f branched-chain oc-keto acid for re-amination to the branched chain 
amino acids (via reduced BCKDH).
The practice of weaning pigs at a young age has motivated 
nutritionists to develop feasible feeding practices that can help promote 
maximum growth rate (Owen et al.1996). To evaluate the effect of dietary L- 
camitine on growth performance and body composition of early-weaned 
pigs, Owen et al. (1996) conducted two experiments. In experiment 1, 120 
weanling pigs were allotted into 6 groups (2X3 factorial arrangement o f 
treatments). Each group consisted o f 4 pigs per pen with five replications 
(pens) per treatment. Two levels o f soybean oil (0 or 10%) and 3 levels o f L- 
camitine (0, 500, 1,000 ppm) were given from day 0 to 14 after weaning. 
Fourteen to thirty-five days after weaning, levels were reduced to 0 or 5% 
and 0, 250, and 500 ppm for soybean oil and L-camitine, respectively. In 
the second experiment, 180 weanling pigs were distributed in a 2X3 
factorial. Each group consisted o f 6 pigs per pen and 5 replicates per 
treatment. L-camitine was fed at 2 different levels, 0 or 1,000 ppm, for the 
first 14 days after weaning. Pigs for each o f these diets were then fed 0,
250, or 500 ppm o f L-camitine from day 14 to 35. On days 7 and 28, blood 
samples were collected via vena cava puncture for all pigs. Plasma was 
analyzed for urea N and nonesterified free fatty acids. To determine initial 
body composition measurements, 12 pigs were selected randomly at day 0
27
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and carcass composition for the whole animal was calculated. At the end of 
the experiment, 14 pigs from the following treatments were slaughtered: 0 or 
1,000 ppm L-camitine from day 0 to 14 and 0 or 500 ppm L-camitine from 
day 14 to 35. Carcass composition measurements were determined using 
the 1990 Association o f Official Analytical Chemists (AOAC) methods. The 
average value for initial body composition measurements was subtracted 
from composition measurements obtained at day 35 after weaning. Crude 
daily lipid and protein accretion rates were calculated by dividing this 
difference by 35 days.
In the first experiment, L-camitine and soybean oil had no significant 
(p>0.10) effect on pig performance for the first 14 days. The gain:feed ratio 
significantly (p <0.05) improved from day 14 to 35 with increasing dietary L- 
camitine. Twenty eight days after weaning, plasma urea N concentrations 
significantly increased (p<0.05) with increasing L-camitine. In the second 
experiment, carcass moisture and protein percentages were not significantly 
(p>0.10) influenced by dietary L-camitine. On day 35, Pigs fed 1,000 ppm 
(day 0 to 14) o f L-camitine had significantly (p<0.05) less carcass lipid and 
daily lipid accretion rates whether they were fed or not fed L-camitine from 
day 14 to 35. The authors concluded that L-camitine improved the gaimfeed 
ratio and reduced carcass lipid accretion in early-weaned pigs. But that 
further investigations are needed to determine the optimal levels or 
sequence o f L-camitine supplementation.
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To investigate the relationship between plasma carnitine and acetyl 
carnitine levels and body composition, Gatti et al. (1998) conducted a study 
in 33 well-trained athletes, 14-49 years o f age (26 males and 7 females). 
Subjects were fasted for 4 hours and blood samples were taken and 
analyzed for plasma carnitine and acetyl carnitine concentrations. 
Bioelectrical Impedance Assay (BIA) was used to determine body 
composition measurements of the subjects. A significant negative 
correlation was found between plasma acetyl carnitine and fat free mass 
(FFM) in kilograms (p< 0.0001) and as percent o f body mass (p<0.01). A 
significant (p<0.01) positive correlation was found between percent fat mass 
(as % o f body mass) and plasma acetyl carnitine. The authors concluded 
that the negative correlation between plasma acetyl carnitine and muscular 
mass variation might be due to a metabolic muscle improvement in relation 
to muscular FFM increment. This might provide evidence that muscle 
metabolism changes in relation to plasma acetyl carnitine concentration. 
Contrary to these results, a study conducted by Amodio et al. (1990) found 
no relationship between triceps skinfold measurements and carnitine plasma 
levels.
To determine what effects a hyperammonemic animal model has on 
body composition, Miffana et al. (1989) conducted a study in male Wistar 
rats (150-200 g). Rats were fed for 6 wk either a diet containing 20% (w/w) 
ammonium acetate (n=7) or a standard control diet fed ad libitum (n=7) or 
pair fed (n=7). Body composition measurements were obtained for rats fed
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ammonium acetate (n=4) and the standard ad libitum (n=4) diet. Moisture 
content was determined by lyophilization, lipids were extracted with 
chloroform/methanol, and the nitrogen content o f the defatted extract was 
determined by the Kjeldahl method. Prior to body composition analysis, the 
weight of the following organs was recorded: brain, liver, kidney, and 
gastrocnemius muscle. In addition, the following metabolites were 
determined: Free carnitine in blood (n=5), free carnitine in liver (n-7), acetyl 
carnitine and long-chain acyl carnitine in liver (n=7), acetyl CoA (n=7), 
ketone bodies in blood (n=5), and ketone bodies in liver (n=7).
Rats fed the ammonium acetate diet had a lipid content (per g of wet 
wt) that was reduced to about one half that of rats fed standard diet 
(p< 0.001). The protein content o f rats fed the ammonium acetate was 
significantly greater (p< 0.001) than for rats fed the standard diet. Relative 
weights o f brain, liver and kidney increased significantly (p<0.02) for rats fed 
the ammonium acetate diet. There was no s ign ifican t difference in the 
weight of the gastrocnemius muscle. Therefore, the decrease in body 
weight associated with animals fed ammonium acetate was mainly due to 
loss of adipose tissue. Levels o f blood carnitine significantly (p < 0.001) 
decreased by 34% for rats fed the ammonium acetate diet when compared 
to pair fed and ad libitum controls. Long-chain acylcamitine levels were 
significantly (p < 0.001) increased in the liver by 60-70% in rats fed 
ammonium acetate compared to levels of rats fed the control diet. Acetyl
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CoA levels were also significantly (p < 0.001) increased by 47% for rats fed 
the ammonium acetate diet. Blood ketone bodies were significantly 
(p < 0.001) higher for rats fed the ammonium acetate diet. In conclusion, 
higher long-chain acylcamitine levels indicated increased transport o f long- 
chain fatty acids into the mitochondria for oxidation. Increased beta- 
oxidation lead to higher levels o f acetyl CoA, which when in excess can get 
converted to ketone bodies and used as an energy source. Ingestion of 
ammonium acetate altered the lipid metabolism of these rats and resulted in 
a significant decrease in body lipid content.
Results o f the studies conducted by Ji et al. (1996), Owens et al. 
(1996) and Gatti et al. (1998) indicate that carnitine promotes changes in 
body composition by increasing protein synthesis. Carnitine seems to 
induce changes in nitrogen metabolism by increasing the supply o f carbon 
for synthesis o f non-essential amino acids. The effect on body composition 
have only been seen in younger animals, but the results o f Gatti et al. (1998) 
point to an effect o f carnitine on body composition o f adult athletes.
Fat
The role o f L-camitine in energy metabolism has prompted 
researchers to evaluate its effectiveness in reducing the degree o f adiposity 
in animals. An important factor in the regulation of lipid metabolism is the 
level of carnitine in each tissue (Shimura and Hasegawa 1993). The 
condition o f obesity accelerates the rate of lipid synthesis and or lipid 
deposition, which leads to an unbalanced metabolic condition, and
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accumulation o f lipids. Therefore, evaluation o f the effects o f compounds, 
such as L-camitine, may help improve lipid metabolism in obesity.
Shimura and Hasegawa (1993) conducted a study in rats to 
determine the changes in lipid concentrations in the liver and serum of rats 
fed a high fat diet supplemented with L-camitine. Two different experiments 
were conducted with 4 wk old Male W istar rats. In the first experiment, 16 
rats were divided into 2 groups o f eight and fed a diet high in fat (30% com 
oil) without or with carnitine (0.3%) for 1 week or 2 weeks. Rats on the high 
fat diet with carnitine were pair-fed with intake o f rats fed the high fat without 
carnitine. In experiment 2, thirty-two rats were divided into 2 groups of 
sixteen and fed one of the following diets for a 3 wk period: Control diet (5% 
com oil) or high fat (30% com oil). Rats on the control diet were pair-fed 
with intake of the high fat diet. Half o f the rats (n=8) from each of these 
groups were fed the following diets for 3 more wk: High fat diet with carnitine 
(30% and 0.3%, respectively) or control diet with carnitine (5% and 0.3%, 
respectively). After each feeding period, rats were fasted for 12 hours and 
blood was collected and analyzed for triglyceride (TG), total cholesterol 
(Choi), and phospholipids (PL). A t this time, the liver was removed and 
assayed for total amount o f lipid. Adipose tissue around the kidneys and 
epididymis was weighed and used as an index o f body fat.
In the first experiment, rats fed the high fat diet with carnitine showed 
a significant (p<0.05) decrease in body weight compared with rats fed the 
high fat without carnitine. At week 1, TG levels o f rats fed high fat with
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carnitine were significantly (p < 0.05) lower than levels o f rats fed high fat 
without carnitine. By 2 weeks, rats fed high fat with carnitine showed a 
significant (p< 0.05) decrease (25%) in the amount o f total lipids compared 
with rats fed high fat without carnitine. PL levels also decreased significantly 
(p< 0.05) for rats fed high fat with carnitine. In experiment 2, rats fed the 
high fat diet with carnitine had a significant (p < 0.05) decrease in total lipids, 
TG, and Choi when compared to rats fed the high fat diet without carnitine. 
Body weight was not significantly different for rats fed the high fat diet with 
or without carnitine, but the weight o f body fat had a tendency to decrease 
for rats fed the carnitine. Rats fed the control diet with carnitine had no 
significant difference in total lipids and body weight when compared to rats 
fed the control diet without carnitine. They concluded that, addition of 
carnitine to the high fat diet depressed lipid accumulation and decreased 
lipid levels in the liver and serum. The effect of carnitine was still present 
even if rats were first fed a diet high in fat without carnitine for 3 wk. 
Furthermore, rats administered the control diet did not experience a change 
in their lipid levels with the addition o f carnitine.
Incorporation of L-camitine into diets o f broiler chickens is being 
utilized to reduce the degree of adiposity and maximize the degree of lean 
tissue (Rabie and Szilagyi, 1998). Deposition o f fat depends to a great 
extent on the appetite of the broiler, particularly when diets o f different 
energy contents are fed. Thus, nutritionists are trying to find a solution to 
this problem by means of dietary manipulations. The study conducted by
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Rabie and Szilagy (1998) investigated the response to supplemental dietary 
L-camitine o f broiler chickens fed on diets with different levels o f 
metabolizable energy (ME). One hundred and eighty, 1-day-old Hybro 
broiler chicks were fed a commercial starter diet from day 1 to day 18.
Three isonitrogenous diets with 13.5,12.8 or 12.2 megajoules (MJ)/kg o f ME 
with or without supplemental L-camitine (50 mg/ kg o f diet in the form of 
Camiking 50:50 mix L and D) were used during the experimental period, 18 
to 53 days o f age. Each treatment group o f 10 birds was replicated three 
times for a total o f 30 birds per group. The diet with 13.5 MJ ME/kg served 
as the control diet. Weekly feed intake, energy intake, body weight gain, 
and feed conversion were used to evaluate the performance o f broiler 
chickens. To examine the effects o f L-camitine on fat deposition, 6 birds 
from each treatment were decapitated. Measurements for carcass yield and 
components (weights and percentages of eviscerated carcass, giblets, total 
edible parts, and breast yield), abdominal fat (absolute weight and 
percentage of body weight) and composition of the edible meat o f broilers 
were obtained.
L-camitine supplementation did not affect feed or energy intake. 
There was no interaction between supplemental L-camitine and dietary 
energy level with respect to feed or energy intake throughout the 
experimental period. Dietary energy level had a significant (p < 0.0001) 
effect on body weight gain. Body weight gain was reduced over the 
experimental period when dietary energy level was decreased from 13.5 to
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12.2 MJ ME/kg o f diet, except during the feeding period o f 46-53 days of 
age. Body weight gain was significantly (p < 0.0001) higher for the first 2 
weeks o f the study and over the entire experimental period for broilers fed L- 
carnitine. During the period from 25 to 32 days of age there was a 
significant (p < 0.02) interaction between L-camitine and dietary energy level 
with respect to body weight gain and feed conversion. Carnitine caused an 
increase in body weight at the higher energy level, but did not affect body 
weight at the lower energy level. Body weight gain was higher for broilers 
fed the highest energy level with L-camitine compared to broilers fed the 
highest energy level without L-camitine. Feed conversion increased for 
broilers fed the lowest energy level with L-camitine. The relative weight of 
abdominal fat (proportion o f total body weight) was significantly lower for 
broilers fed L-camitine (p < 0.0003) and lower dietary energy levels (p < 
0 .0002).
The authors concluded that the reduction in absolute weight of 
abdominal fat content in response to L-camitine may be in part attributed to 
an increased rate o f fatty acid oxidation within the mitochondria induced by 
L-camitine. Loss o f fatty acids could in turn result in a reduction o f hepatic 
lipogenic capacity. The authors acknowledge the possibility that other 
factors might also be responsible for regulation of the rate o f fat 
accumulation and point out the results o f Ji et al. (1996) conducted in 
Atlantic salmon as an alternative explanation. Ji et al. (1996) believed that 
improved utilization o f dietary nitrogen, achieved through more efficient fat
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oxidation, could be responsible for the improved body weight gain observed 
in response to dietary L-camitine. The lower body weight observed for birds 
on the lowest level o f dietary energy compared with the higher energy levels 
could be attributed to a less efficient utilization of dietary energy or 
insufficient energy intake for weight gain. The effect o f L-camitine at higher 
energy levels in relation to body weight gain is probably not related to the 
energy level itself. Instead it might be influenced by the composition of 
dietary fat since L-camitine is most important for the oxidation o f long-chain 
fatty acids.
Gross et al. (1998) conducted a study to evaluate the effects of 
supplemental carnitine or chromium on weight loss and body composition 
during periods o f weight reduction. Thirty-six adult obese beagle dogs 
(males n=24 and females n=12) with > 30% body fat were used in this study. 
Animals were blocked by percent body fat and sex and randomly assigned 
to 1 o f 4 dietary treatments. The dietary treatments were as follows: the 
control diet (high fiber low calorie), control diet plus 200 ppb chromium 
picolinate, control diet plus 300 ppm L-camitine, and control diet with both 
chromium picolinate and carnitine. Body composition was determined using 
DXA (Hologic WDR 2000). Measurements were taken at baseline, at wk 2, 
4, 8 and monthly thereafter until all o f the beagles had body fat that was less 
then 20%.
Energy intake, food intake, and protein intake were sim ilar for all 
treatments. Dogs achieved a weight loss of 2.5% of initial body weight per
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wk over 12 wk to reach the 20% body fat. The main effect o f carnitine was 
to significantly (p < 0.05) increase lean body mass and there was a trend 
(p < 0.1) for greater body weight. The dogs supplemented with carnitine had 
a significantly (p < 0.05) greater loss in fat than dogs supplemented with 
chromium. Dogs fed chromium did not have a significant increase in lean 
body mass. The researchers concluded that during the weight loss period 
added carnitine but not chromium increased the lean body mass o f the 
beagles.
The results o f Shimura and Hasegawa (1993), Rabie and Szilagyi 
(1998) and Gross et al. (1998) indicate that addition of carnitine to the diets 
o f young and older animals can lead to an increase in fat oxidation causing 
a reduction in the amount o f fat as percent o f body weight. Rabie and 
Szilagyi (1998) and Gross et al. (1998) observed a trend for an increase in 
body weight, whereas Shimura and Hasegawa (1993) found no difference in 
body weight. When there was an increased weight gain observed it was 
attributed to an increase in lean body mass.
Carbohydrates
Carbohydrate metabolism is a complex process that is affected by 
many different factors. High levels of both protein and fat in the diet can 
alter this process. Therefore, addition o f dietary L-camitine may exert an 
indirect effect on carbohydrate metabolism by enhancing the metabolism of 
protein and fat.
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A relationship has been observed between high levels o f ammonia 
and impaired glucose metabolism. It has been shown that 
hyperammonemia causes an increase in levels of epinephrine (Schlienger et 
al.1975). Epinephrine, an adrenomedullary hormone, raises plasma 
glucose concentrations by stimulating the production of glucose and limiting 
glucose utilization in certain tissues (Marker et ai.1998). Epinephrine exerts 
these metabolic effects by stimulating glucagon release through a P2 - 
adrenergic pathway and lim iting insulin secretion via an a2. adrenergic 
pathway (Marker et al.1998, Schlienger et al.1975).
Schlienger et al. (1975) conducted a study to evaluate the 
abnormalities o f glucose metabolism observed in hyperammonemic rats. 
Forty-five male Wistar rats weighing 250-300 grams were divided into 3 
groups (n=15). A tracheotomy was performed to obtain blood samples from 
the carotid artery. In addition, a catheter was introduced in the femoral vein 
to inject the test solution, saline or ammonium acetate. The control group 
received an infusion of 2 ml o f a 0.9 g/100 ml saline solution for 95 minutes. 
A second group of rats received an infusion o f ammonium acetate at a low 
dose (0.50 umol/kg body weight/min NH4+). The last group was infused with 
a high dose o f ammonium acetate, 1.70 umol/kg/min NH4+. Blood glucose 
and plasma insulin levels were determined before and at the 60th minute o f 
infusion. Blood ammonia levels were measured every 10 minutes during the 
infusion period. An intravenous glucose tolerance test was performed at the 
60th minute o f infusion. An injection of 1 g glucose/kg o f body weight using a
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50 g/100 ml solution was given to all groups. Blood sugar was measured 
every 5 minutes for 35 minutes.
Basal ammonia levels were 51 ± 2.50 ug/100 ml for rats in the control 
group with no change during the saline infusion. Rats in the low NH4+ 
infusion had a rapid increase in ammonia levels, 250 ±12  and 
275 ± 1 5  ug/100 ml, at 60 and 95 minutes respectively. Rats in the high 
NH4+ had a more marked hyperammonemia that reached 926 ± 60 and 
1010 ± 68 ug/100 ml at 60 and 95 minutes, respectively. Sixty-minutes after 
the infusion, the blood glucose levels o f the control and low NH4+ were 
unchanged. Blood glucose levels significantly (p<0.01) increased during the 
high NH4+ infusion, rising from 98 ± 3 to 127 ± 7 mg/100 ml at the 60th 
minute. After the glucose load blood glucose levels were higher for the 
group o f rats receiving the NH4+ infusion. But only the blood glucose values 
of the control and high NH4+ group were significantly (p < 0.01) different. 
Insulin vales, 60 minutes after start of infusion, were not significantly 
different from initial levels for all 3 groups. During the 10 and 20th minute o f 
the glucose tolerance test insulin levels o f the low NH4+ group were 
significantly (p<0.001) different from basal levels. There was no insulin 
response to the glucose load for rats fed high NH4+ and the insulinogenic 
index tended toward 0. The authors concluded that an ammonium infusion 
in rats brings about an alteration in carbohydrate metabolism and its 
regulation. The abnormalities observed are dependent on the amount o f
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ammonium infused. The alteration in the metabolism of carbohydrates may 
be due to a direct effect o f NH4+ on the pancreas.
Chronic consumption o f a high protein diet by certain individuals, 
such as athletes, people consuming a typical Western diet, and people on 
fad diets, could potentially affect the regulation o f carbohydrate metabolism. 
Therefore, a reduction in the levels o f ammonia by supplementing the diets 
o f these individuals with carnitine could possibly prevent metabolic disorders 
associated with glucose metabolism.
The functions of carnitine in the mitochondria are essential for proper 
regulation o f metabolic processes. Particularly, in the metabolism of lipids 
regarding both oxidative and synthetic processes. The consequences these 
effects may have on the metabolism o f glucose have not been fully 
explained, but a close relationship has been observed between metabolic 
processes using fat and those oxidizing carbohydrates (Grandi et al.1997).
Thirty-years ago, the glucose fatty acid cycle was proposed to try to 
explain defective glucose metabolism in NIDDM (Non-Insulin Dependent 
Diabetes Mellitus) (Randle et al.1963). Randle and associates hypothesized 
that elevated levels of fatty acid oxidation could interfere with the uptake and 
metabolism o f glucose in muscles, resulting in glucose intolerance and 
insulin insensitivity. There is now some experimental evidence that 
contradicts this hypothesis.
It has been shown that L-camitine stimulates the activity of the 
pyruvate dehydrogenase complex, which converts pyruvate to acetyl CoA,
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by decreasing the intramitochondrial ratio o f acetly-CoA/CoA via the 
trapping o f acetyl groups. The concurrent decrease of acetyl-CoA in the 
cytosol contributes to the activation o f the glycolytic pathway (Mingrone et 
al.1999). Broderick et al. (1991) showed that the glucose oxidation rates in 
control hearts were markedly decreased in the presence of fatty acids in the 
perfusate. A significant increase in glucose oxidation followed by a parallel 
decrease in palmitate oxidation was observed when the carnitine 
concentrations were raised. This effect was not observed in the absence of 
fatty acids implying that L-camitine might act to switch fuel substrate 
utilization in cells (Broderick et al.1991).
There is some evidence to suggest that L-camitine, via increased 
fatty acid oxidation, will interfere with glucose metabolism. There is also 
some indication that acute administration of L-camitine improves insulin- 
mediated glucose uptake. Therefore, a better understanding of the effects 
that carnitine may have on glucose metabolism in the presence or absence 
o f fatty acids could contribute to the improvement of the metabolic control of 
this macronutrient.
In a study conducted by Mingrone et al. (1999) the effects o f L- 
camitine on insulin mediated glucose uptake and oxidation in type II diabetic 
patients was evaluated. The subjects in the study were non-obese healthy 
volunteers (n=20) and type II diabetic patients (n=15). Subjects underwent 
a short-term (2 hours) euglycemic hyperinsulinemic clamp with simultaneous 
constant infusion of L-camitine (0.28 umoles/kg body weight/minute). The
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same procedure was repeated on a different day with a saline infusion 
instead of L-camitine. The order o f infusions was randomly selected. To 
maintain the glycemia o f diabetic patients below 100 mg/dl a small bolus 
dosage of short-acting human insulin was administered until the study 
began. Every 30 minutes arterial blood samples were collected during the 
clamp and insulin, non-esterified fatty acid, and lactate concentrations were 
measured. Respiratory gas exchange measured by an open-circuit 
ventilated hood system was started 60 minutes before the start o f the study 
and continued during the 180 minutes of the study. Energy expenditure, 
respiratory quotient (RQ) and substrate oxidation rates were calculated.
In both groups, whole body glucose uptake was significantly (p 
<0.001) higher during the L-camitine infusion when compared to the saline 
infusion. The glucose uptake of healthy controls and diabetic patients was 
48.66 ± 4.73 and 35.90 ± 5.00 umol/kg/minute without carnitine and 52.75 ± 
5.19 and 38.90 ±5.16 umol/kg/minute with carnitine, respectively. Glucose 
oxidation, measured by indirect calorimtery, was significantly (p< 0.001) 
increased only in the diabetic patients with the carnitine infusion (17.61 ± 
3.33 umol/kg/minute) when compared to the saline infusion (16.25 ± 2.95 
umol/kg/minute). Both groups had a significantly (p < 0.001) higher glucose 
storage rate (umol/kg/minute) with the carnitine infusion. Plasma lactate 
concentrations o f the diabetic patients significantly (p < 0.0003) decreased 
during L-camitine infusion when compared to saline. In conclusion, constant 
L-camitine infusion in diabetic patients led to an improvement in insulin
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sensitivity and had a significant effect on whole body insulin-mediated 
glucose uptake in normal subjects. In diabetic patients, L-camitine 
administration increased glucose oxidation and glucose taken up by the 
tissues appeared to be utilized immediately as a fuel. The decrease in 
plasma lactate levels suggests that the effect o f carnitine may be due to 
activation o f pyruvate dehydrogenase, whose activity is decreased, in insulin 
resistant sates.
Grandi et al. (1997) examined the ability o f carnitine in influencing 
glucose-stimulated insulin secretion. The researchers were interested in 
determining any potential that carnitine might have in improving utilization of 
glucose. Twenty-five patients (17 males and 8 females, mean age=42.6 yr) 
hospitalized in the Medical Clinic at Modena University for disorders 
unrelated to metabolic disease were used in this study. Patients with fasting 
blood glucose levels below 100 mg%, with no signs o f glycosuria, and a 
body mass index under 28 for men and 25 for females were enrolled in the 
study. The study was divided into 2 phases that were separated by a 48-h 
period. In phase 1, a 5% glucose-enriched solution was administered 
intravenously with a set 2-h infusion time. At time 0,60 , and 120 minutes, 
blood samples were taken from the medial cubital vein, which is found at the 
junction between the elbow and the upper arm. Blood samples were taken 
30, 60, and 120 minutes after the infusion was discontinued. Phase 2, 
consisted of the same subjects receiving the same 5% glucose solution with 
the addition of 2 g o f carnitine. Blood samples were collected for phase 2
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following the same protocol o f phase 1. Plasma blood glucose and insulin 
levels were determined from the samples collected.
Carnitine induced a reduction in blood glucose levels that was 
statistically (p <0.05) significant only in the first sample taken after 
termination o f infusion (91.3 ± 6.3 vs 98.6 ± 9.9 mg/dl). The pattern of 
insulin secretion was different for the 2 phases. In phase 2, carnitine 
administration reduced significantly (p < 0.05) the total insulin secretion 
range when compared to phase 1 (4923 ± 975 vs 5516 ± 1335 mU/ml). 
During the first hour after infusion, only the subjects receiving carnitine had 
a significant (p < 0.05) decrease in insulin at 30 minutes (23.4 ± 6.3 vs 30.3 
± 10.0 mU/ml) and at 60 minutes (10.4 ± 2.1 vs 17.6 ± 5.6 mU/ml). In 
addition, post-infusion insulin ranges were significantly (p < 0.05) lower for 
subjects receiving carnitine (1004 ± 196 vs 1525 ± 454 mU/ml). In 
conclusion, insulin secretion is signficantly reduced and blood gluose levels 
are transiently decreased when glucose is given with an acute 
administration o f carnitine. Thus, laying the basis for improved peripheral 
glucose utilization. The assumption was made that the increased levels of 
blood carnitine led to the transport o f acetyl-CoA molecules from the inner 
mitochondrial matrix to the cytosol. Consequently, the inner mitochondrial 
ratio o f acetyl-CoA/CoA is reduced and the pyruvate dehydrogenase 
enzyme remains active leading to an increase in glycolytic activity.
To examine the effects o f L-camitine administration on the severity of 
diabetes, Paulson et al. (1984) conducted a study in male Sprague-Dawley
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rats weighing 200-250 grams. Rats were divided into the following 4 groups: 
saline control (n=13), carnitine control (n=14), saline diabetic (n=22), and 
carnitine diabetic (n=16). An intravenous injection o f streptozotocin (60 
mg/kg) was used to induce diabetes. Twenty-four hours after the 
administration o f streptozotocin, either saline (0.9% NaCI) or L-camitine (3 
g/kg/day) was injected intraperitoneally for 14 days. During sacrifice, blood 
samples were collected and serum was assayed for glucose, triglycerides, 
free fatty acids, ketones, and carnitine. Tissues were removed and freeze- 
clamped in liquid nitrogen. Total carnitine concentrations in the heart were 
assayed.
Diabetic rats treated with carnitine had a significant (p < 0.05) 
decrease in serum glucose levels when compared to saline treated diabetic 
rats, 398 ± 12  and 490 ±13  mg/dl respectively. Serum levels of ketones 
(0.61 ± 0.12 vs. 1.18 ± 0.13 mmol/L), triglycerides (244 ± 25 vs. 705 ±112 
umol/Ldl), and free fatty acids (0.40 ± 0.04 vs. 0.73 ± 0.05 mmol/l) were 
significantly (p <0.05) lower for carnitine treated diabetic rats when 
compared to saline treated diabetic rats. Carnitine administration to the 
nondiabetic rats had no effect on serum glucose, increased serum ketones, 
and decreased triglycerides and free fatty acid levels when compared to 
saline-treated nondiabetic rats. In the diabetic rats, L-camitine prevented 
the decrease in total myocardial carnitine content (p < 0.05). Paulson et al. 
(1984) concluded that chronic therapy with carnitine may reduce the severity 
of diabetes mellitus and improve myocardial performance.
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The results o f other researchers contradict those observed by 
Mingrone et al. (1999), Grandi et al. (1997) and Paulson et al. (1984). It has 
been shown that compounds that decrease lipid oxidation and the activity of 
carnitine palmitoyl transferase I can decrease glucose levels in normal and 
diabetic rodents and humans (Martin et al.1991, Mandarino et al.1984, W olf 
etal.1982).
Barnett et al. (1992) conducted a study to examine the longitudinal 
effects of inhibiting fatty acid oxidation with Etomoxir in m ildly diabetic rats. 
Male Sprague Dawley rats (150 g) were randomly assigned to one o f 3 
treatment groups. Two of the groups were rendered m ildly diabetic by an 
intravenous injection o f 55 mg/kg of streptozotocin. Rats in the third group 
received an injection with citrate buffer and were used as controls. The 
diabetic rats were randomly assigned to a treatment group that received 
Etoxomir (12.5 mg/kg/day) or a diabetic control group. Etoxomir is a specific 
inhibitor of long chain fatty acids that mediates its effect by inhibition of 
carnitine palmitoyltransferase I. All rats were fed ad libitum a diet high in fat 
composed of butter, wholemeal flour, and skim milk powder (50% energy 
from fat, 30% from carbohydrate, and 20% from protein). Rats were fasted 
for 16 hours and blood was obtained to measure glucose, insulin, 
triglycerides, and free fatty acids at 3 days, 1 week, and at 4 weeks o f 
treatment.
At the end o f the study, diabetic rats treated with Etomoxir (n=10) had 
significantly (p < 0.02) higher body weights than the diabetic control group
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(n= 10; 234 ± 11 vs 202 g ± 13). Fasting plasma glucose levels were 
significantly (p < 0.001) higher throughout the study in the diabetic rats when 
compared to the controls. Diabetic rats treated with Etoxomir (n=22) had 
significantly (p < 0.001) lower fasting plasma glucose levels over the 4 week 
period when compared to the diabetic controls (n = 8; 17.6 ± 2.4 vs 22.3 ±
1.9 mmol/l). Lower glucose levels were first observed after one week of 
treatment and this reduction was maintained for the remainder of the study. 
Throughout the entire study, there were no significant differences in plasma 
insulin levels for all groups of rats. Fasting plasma triglyceride levels were 
significantly (p < 0.001) lower in the Etoxomir treated diabetic rats (n=23) 
compared to the levels o f diabetic controls (n=19), 0.32 ± 0.07 and 0.98 ± 
0.14 mmol/l respectively. During the 4-week period, serum free fatty acid 
levels were significantly (p < 0.001) lower following treatment with Etoxomir 
(1.52 ± 0.26 vs 3.51 ± 0.69 mEq/l). In conclusion, inhibition of fatty acid 
oxidation by Etoxomir decreased fasting glucose concentrations without 
alterations in insulin levels. This is consistent with an improvement in insulin 
sensitivity. Inhibition of fatty acid oxidation improved the metabolism of 
carbohydrate in a rodent model of diabetes.
These results are supported by sim ilar studies conducted by Barnett 
et al. (1996) and Martin et al. (1991). Barnett et al. (1996) conducted a 
study using a rat model that is genetically predisposed to develop NIDDM 
when fed a standard chow diet. The authors concluded that an increased 
rate of lipid oxidation and glucose turnover (based on HGP-hepatic glucose
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production) may be associated with the development o f NIDDM in 
genetically predisposed animals. Using diabetic male Sprague Dawley rats 
weighing 200*250 g, Martin et al. (1991) studied the mechanisms of the 
glucose lowering effect o f a compound (B 827-33) known to inhibit carnitine 
palmitoyltransferase I. The results suggested that the decrease in glucose 
observed after inhibition of fat oxidation appears to be dependent on the 
nutritional status o f the animal, the decrease being more important in the 
starvation state than the postabsorptive state. In addition, the results 
confirmed that compounds that inhibit lipid oxidation could be used to treat 
some diabetic patients if their hypoglycemic action continues on a long-term 
basis.
According to the results conducted by Mingrone et al. (1999), Grandi 
et al. (1997) and Paulson et al. (1994) in diabetic humans and rats, carnitine 
improves insulin sensitivity and peripheral utilization of glucose. The 
improvement seems to be due to activation of the pyruvate dehydrogenase 
enzyme, which increases the activity o f the glycolytic pathway. In the 
studies conducted by Barnett et al. (1996 and 1992) and Martin et al. (1991) 
inhibition of fatty acid oxidation lead to an improvement in carbohydrate 
metabolism. Thus, according to these results use o f carnitine, which 
increases the oxidation o f fats, should not result in an improvement in the 
metabolism of carbohydrates.
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INSULIN
INTRODUCTION
The pancreas is made up o f two distinct organs, the exocrine 
pancreas and the endocrine pancreas. The endocrine pancreas is the 
source of insulin, glucagon, somatostatin, and pancreatic polypeptide. It 
consists of 0.7-1 million small endocrine glands, the islets of Langerhans, 
that are scattered within the glandular substance o f the exocrine pancreas. 
The islets contain 4 ceil types, alpha (a), beta ((3), delta (5), and phi ($), 
which are not distributed uniformly throughout the pancreas. The beta cells, 
which are located in the innermost part o f the endocrine pancreas, are 
responsible for the secretion o f insulin (Karam 1997).
Insulin is a peptide hormone consisting o f 51 amino acids found 
within two peptide chains, A (21 amino acids) and B (30 amino acids). Two 
disulfide bridges connect these 2 chains together and an intrachain disulfide 
bridge links position 6 and 11 in the A chain (Hadley, 1996). In normal 
adults the human pancreas secretes about 40-50 units o f insulin per day. 
During fasting the basal concentration of insulin in the blood averages 
10 uU/mL (0.4 ng/mL, or 69 pmol/L). In healthy individuals insulin 
concentrations, after a standard meal, seldom rise above 100 uU/mL 
(Karam 1997).
Preproinsulin, a precursor molecule of insulin, js  produced in the 
rough endoplasmic reticulum of pancreatic B cells. Almost immediately after 
it is synthesized, microsomal enzymes cleave this precursor forming
49
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
proinsulin. Proinsulin is a single chain containing 86 amino acids, that 
includes the A and B chains o f the insulin molecule and a connecting section 
o f 35 amino acids. The proinsulin is transported to the golgi apparatus and 
packaged into clathrin coated secretory granules. Maturation of the granule 
is accompanied by loss o f the clathrin coating and the conversion of 
proinsulin into insulin and a small connecting peptide, C-peptide. Mature 
secretory granules contain equimolar amounts o f insulin and C-peptide and 
small amounts o f proinsulin. The C-peptide has no known biological activity 
(Karam 1997).
Insulin secretion is regulated by several factors, some which exert a 
direct and immediate effect on the B-cells o f the pancreas and others that 
exert a delayed and either a direct or indirect effect on insulin release 
(Malaisse, et al.1979). Factors exerting a direct and immediate effect 
include certain nutritional factors (glucose), hormones (catecholamines and 
gastrointestinal), and neurohumoral responses (cholinergic transmitters). 
There is a delayed effect in insulin release during certain situations, such as 
nutritional (fasting), endocrine (pregnancy), and ontogenic (perinatal period) 
conditions (Karam 1997).
Insulin’s major role is to promote the storage of ingested nutrients. 
This role corresponds to the adaptive responses of peripheral tissues to 
changes in energy balance. After a meal is consumed the release of insulin 
leads to the disposition o f absorbed nutrients (Schwartz et al.1992). The B- 
cells are capable o f detecting the following fuel molecules, glucose, amino
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acids, fatty acids, and ketone bodies. O f these molecules only glucose is 
capable o f initiating insulin secretion. The other fuel molecules can increase 
insulin secretion only in the presence o f glucose (Meglasson and 
Matschinsky, 1986). When an exogenous stimulus (e.g. ingested meal with 
glucose), causes the B-ceils to release insulin the response is biphasic in 
nature (Karam 1997). An increase in glucose concentration leads to an 
initial short-lived increase in insulin, the early phase. The concentration of 
peripheral insulin increases reaching its early phase peak concentration in 
peripheral blood 30-45 minutes after a meal is ingested (Karam 1997). A 
steady glucose concentration leads to a gradual decrease in insulin released 
followed by an increase in the amount o f insulin released that corresponds 
to the late phase o f insulin secretion (1-3 hours after ingestion o f meal).
Previous research indicated that insulin is not required for the 
metabolism o f glucose in the brain. The inference was then made that 
circulating insulin was incapable o f crossing the blood-brain barrier (BBB) 
and therefore had no effects on the brain. While the first belief remains true, 
the second one has been challenged. Both insulin and insulin receptors 
have now been identified in the adult mammalian brain. Brain insulin seems 
to be derived largely from the circulation and there is evidence to suggest 
that its delivery into the brain may be facilitated by a specific BBB transport 
system (Schwartz et al.1992, Woods et al.1990).
There is extensive data supporting the hypothesis that insulin has a 
function as a peripheral adiposity signal to the CNS (Schwartz et al.1992,
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Woods et al.1990). First, plasma insulin levels are directly influenced by 
changes in energy balance and adiposity. Second, there is evidence 
supporting a dose-dependent entry o f circulating insulin into the central 
nervous system in several species. Third, the high concentrations o f insulin 
receptors in the neurons o f brain regions involved in the regulation o f 
feeding have been documented. Finally, there is a marked reduction in food 
intake following central or peripheral administration of insulin causing an 
increase in sympathetic nervous system activity and thermogenesis. 
Therefore, peripheral insulin levels, which rise when adiposity increases, 
induce a state of negative energy balance by acting within the central 
nervous system causing a reduced caloric intake, increased energy 
expenditure, and eventually loss of adiposity (Schwartz et al.1992). 
INTERACTIONS WITH MACRONUTRIENTS
The interactions o f insulin with the macronutrients are associated with 
the endocrine effects of this hormone on three major tissues specialized for 
storage of energy: liver, muscle, and adipose tissue. Insulin acts to promote 
the formation of certain substances (anabolism), while inhibiting the 
breakdown of other substances (catabolism).
In the liver, insulin promotes glycogen synthesis and storage by 
changing the activity of enzymes in the glycogen synthesis pathway. Insulin 
triggers a pathway that dephosphorylates glycogen synthase thereby 
activating the enzyme. Insulin exerts these effects via a cascade of 
reactions that lead to multiple phosphorylations. The binding o f insulin to its
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tyrosine kinase receptor leads to the phosphorylation and activation of an 
insulin-sensitive protein kinase. In turn, a subunit on protein phosphatase 1 
is phosphorylated. This activated protein phosphatase 1, leads to the 
dephosphorylation of glycogen synthase, phosphorylase kinase, and 
phosphorylase a. The dephosphorylated forms o f phosphorylase kinase 
and phosphorylase a are inactive, thereby the degradation o f glycogen is 
blocked (Stryer 1995). The maximum capacity storage o f glycogen in the 
liver is in the range o f 100-110 g (Karam 1997). In addition, insulin inhibits 
gluconeogenesis by decreasing the activity o f specific enzymes, fructose 1,6 
biphosphatase, and phosphoenol pyruvate carboxykinase and promotes 
glycolysis by increasing the activity of other enzymes, glucokinase, 
phospofructokinase and pyruvate kinase (Karam 1997, G roff et al.1995, 
Wallis et al.1985).
In the fed-state, the synthesis of protein, triglycerides, and very low- 
density lipoproteins is increased in the liver by the actions o f insulin. A 
higher rate of protein synthesis produced by insulin appears to be due to an 
increase in transcription rates (Wallis et al.1985). Insulin enhances the 
action of intravascular lipoprotein lipase, thus increasing the availability and 
uptake of free fatty acids. Additionally, increased glycolytic activity provides 
a source of glycerophosphate that can be re-esterified with fatty acids (Groff 
et al.1995). The anticatabolic effects o f insulin include the inhibition of 
hepatic glycogenolysis, ketogenesis, and gluconeogenesis (Karam 1997).
53
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
In muscle tissue, the synthesis o f glycogen is promoted by insulin and 
the newly formed glycogen replaces the stores expended by muscle activity. 
The enhancement o f glycogenosis is attained by increasing the transport of 
glucose into muscle cells due to an increase in the number o f glut 4 
receptors in the plasma membrane, increasing the activity o f glycogen 
synthase, and inhibiting glycogen phosphorylase a. The capacity for 
glycogen storage in muscle is approximately 500-600 g. Lack o f glucose-6- 
phosphatase lim its use o f this stored glycogen to only this tissue except 
when the muscle supplies the liver with lactate that can then be converted 
into glucose (Karam 1997).
Another action o f insulin in muscle cells is to promote the synthesis of 
proteins by increasing the transport o f amino acids as well as stimulating 
ribosomal protein synthesis. The anticatabolic actions of insulin on protein 
metabolism vary according to the different tissues (Meek et al.1998). The 
predominant effect o f insulin in skeletal muscle is by an effect on translation, 
where it apparently increases the rate o f initiation. However, in heart muscle 
or slow twitch red muscle fiber (e.g. soleus) a deficiency in insulin does not 
result in an instant change in the rate of initiation (Wallis et al.1985, Karam 
1997). Another effect o f insulin on protein is to control the rate o f 
degradation o f intracellular protein. The rates of protein degradation in both 
heart and skeletal muscle are reduced by insulin. This reduction seems to 
be due to an effect o f insulin on the lysosomal system (Wallis et al.1985).
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The function o f insulin in adipose cells is to promote the storage o f 
triglycerides. Insulin induces the production o f endothelial bound lipoprotein 
lipase, which leads to hydrolysis o f triglycerides found in circulating 
lipoproteins. By augmenting the transport of glucose into fat cells insulin 
increases the availability o f glycerol phosphate, which is used in the 
esterification o f free fatty acids into triglycerides. Furthermore, to prevent 
lipolysis o f stored triglycerides insulin inhibits the action o f hormone- 
sensitive lipase, an intracellular enzyme. This enzyme is active in the 
phosphorylated form and increased levels of cyclic AMP facilitate 
phosphorylation. Insulin inhibits this enzyme by lowering the levels o f cyclic 
AMP, possibly by increasing the activity o f phosphohdiesterase (cleaves 
cAMP to inactive 5’AMP), which lead to diminished activity o f the adipose 
tissue hormone-sensitive lipase (Karam 1997, Wallis et al.1985).
INSULIN RESISTANCE
Non-insulin dependent diabetes mellitus (NIDDM) is a heterogeneous 
disorder identified by abnormalities in both the secretion and action o f insulin 
(DeFronzo et al.1992, Dinneen et al, 1992). Some patients with NIDDM 
may have abnormal beta cell function that leads to impairment in insulin 
secretion. Others may have impairment in hepatic or peripheral tissue 
sensitivity to insulin (Pacoe and Storlien, 1990). Although a lot o f research 
has been conducted to determine the etiology and pathogenesis o f this 
disorder many questions remain unanswered. For example, does obesity 
lead to insulin resistance or does insulin resistance lead to obesity?
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The development o f obesity has been attributed to both genetic 
components and lifestyle factors. Physical inactivity and consumption o f 
high fat diets are among the most important lifestyle factors contributing to 
the problem. Obese people are at an increased risk o f developing insulin 
resistance, hypertension, dyslipidemia, heart disease, non-insulin dependent 
diabetes mellitus, and certain types of cancer (Pi-Sunyer 1993). It has been 
postulated that obesity in combination with physical inactivity leads to the 
development o f hyperinsulinemia. The enlargement o f adipose cells during 
obesity leads to a decrease in the number o f insulin receptors present in the 
cell membrane o f those cells. The body responds to the decrease in 
number o f receptors by increasing the amount of insulin produced and this 
induces an up-regulation in the synthesis o f insulin receptors. The higher 
insulin levels eventually lead to a down-regulation o f insulin receptors, which 
causes a decrease in the amount of insulin released. It is the down and up 
regulation of these receptors that leads to the development of 
hyperinsulinemia (Karam 1997). High levels o f insulin lead to an impaired 
suppression o f hepatic glucose production and a decrease in peripheral 
glucose uptake. In the presence of both of these conditions insulin 
resistance develops. There is still some debate about whether insulin 
resistance develops first in peripheral (muscle) or splanchnic tissues (liver 
and gastrointestinal tract). A decrease in glycogen synthesis, glucose 
oxidation, glucose transport, and insulin receptor synthesis accompanies the 
development o f insulin resistance (De Fronzo et al.1992). If insulin
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resistance persists the beta cells can no longer compensate and overt 
impaired glucose tolerance develops. Fasting blood glucose levels 
abovel 15 mg/100ml (6.4 mmol/l) are observed in people with impaired 
glucose tolerance. These high fasting glucose levels eventually lead to 
beta-cell damage and development o f fasting hyperglycemia. According to 
Starling’s curve, fasting blood glucose levels of 140 mg/dl (7.8 mmol/l) 
cause a rapid decline in insulin secretion. It is at this point that non-insulin 
dependent diabetes mellitus develops. NIDDM is sustained by the condition 
of increased hepatic gluconeogensis observed when fasting glucose levels 
are maintained at 140 mg/dl (Harris 1996, DeFronzo et al.1992). This 
hypothesis postulates that the condition of obesity leads to the development 
of insulin resistance.
According to Thorbum et al. (1999) the opposite condition can also 
be true, insulin resistance may lead to accumulation o f excess fat and 
development o f obesity. Presence o f insulin resistance is associated with 
development o f several aspects o f a condition known as Syndrome X. 
Syndrome X has been used to characterize a cluster o f abnormalities that 
include obesity, glucose intolerance, hypertension, insulin resistance, and 
dyslipidaemia (Thorbum et al.1999). Individuals with this syndrome are at a 
risk of developing type II diabetes and heart disease (Ferranini et al.1991). 
The features of Syndrome X were studied in transgenic and control rats of 
different ages (1, 3, 6, and 17 months) who were fed either chow or cafeteria 
food for 6 months (Thorbum et al.1999). Transgenic rats came from a
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homozygous colony overexpressing a non-insulin responsive 
phosphoenolpyruvate carboxykinase gene. This rate-limiting gluconeogenic 
enzyme that catalyzes the conversion o f oxaloacetate to 
phosphenolpyruvate is tightly regulated by insulin. Results showed that 
presence of this unresponsive gene was related to early development of 
fasting and postprandial hyperinsulinemia, fasting hypercholesterolaemia 
and mild obesity. This lends support to the hypothesis that insulin 
resistance can trigger the development o f syndrome X. Addition of a high- 
fat cafeteria diet lead to an even greater manifestation of syndrome X 
possibly because consumption o f high fat induces more severe insulin 
resistance. Barnard et al. (1998) observed that Fischer rats fed a high fat 
diet developed insulin resistance after only 2 weeks, hypertriglycerademia at 
2 months, obesity at 5 months, and hypertension at 12 months. These 
results support those of Thorbum et al. (1999) and verify that insulin 
resistance independent of obesity can be the principal cause of syndrome X 
and thus obesity.
GLYCEMIC INDEX
The glycemic index was initially developed as a tool for shaping the 
diets o f diabetic patients. The index is based on the blood glucose level o f a 
single food when compared to the blood glucose level found after 
consumption o f an equivalent amount o f pure glucose. The standard used 
for healthy individuals is glucose, whereas wholemeal bread and cottage 
cheese is the standard for diabetic individuals. The index is reported as the
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area under the blood glucose response curve fo r a single food considered 
as a percentage o f the area after the same amount o f carbohydrate as 
glucose is consumed (Crapo 1984). The overall usefulness of the glycemic 
index classification is being re-evaluated in the clinical setting. Among the 
controversial issues is the contention that the classification of single foods 
could not predict the glycemic response to mixed meals because other 
noncarbohydrate components were not present (Hollenbeck et al.1988). 
Furthermore, there is concern about the methodologic variables, such as 
food portion size, that can markedly affect the interpretation of the response 
and the glycemic index values (Wolever et al.1991). Other researchers 
believe that knowledge o f the glycemic effects o f single foods might be of 
use for studying the physiologic effects o f whole diets (Jenkins et al.1981). 
Therefore, there is still debate over the clinical utility o f the glycemic index.
Studies have shown that differences in glycemic index correspond to 
differences in the rates of digestion and absorption o f carbohydrates from 
different foods (O'Dea et al.1981, Bymes et al. 1995). Starchy foods with a 
high amylopectin (branched-chain form o f starch) content have been shown 
to promote the development of insulin resistance in rats. These foods are 
digested and absorbed more quickly than starches containing a high 
amylose (straight chain form of starch) content and thus produce a greater 
postprandial insulin and glucose response (Bymes et al. 1995). Foods that 
are absorbed more slowly delay gastric emptying and this results in more 
constant blood glucose and insulin responses. Reductions in blood glucose
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levels after a meal seem to have only a modest effect on overall blood 
glucose levels, but these changes may be beneficial for some diabetic 
patients. Therefore, the use of high carbohydrate diets with low glycemic 
index starchy foods with fiber may be beneficial for individuals with diabetes 
(Wolever et al.1991).
ORAL GLUCOSE TOLERANCE TEST
The oral glucose tolerance test (OGTT) is used to determine the state 
of impaired glucose tolerance and non-insulin dependent diabetes. Glucose 
tolerance is the result o f two conditions, delivery o f insulin to the target cells 
and the sensitivity o f those cells to the actions o f insulin. The poor 
reproducibility and lack of a controlled physiological stimulus limits the 
usefulness o f the OGTT in the determination of the pathophysiology of 
diabetes (Phillips et al.1994).
Other methods available that can be used to measure insulin 
secretion and insulin resistance include the intravenous glucose tolerance 
test and the euglycaemic clamp, respectively. But the complexity, 
invasiveness, and labor intensity o f these methods make them difficult to 
conduct in large-scale studies. Therefore, researchers have had to depend 
on the OGTT to evaluate the degree of insulin sensitivity and insulin 
secretion (Phillips et al.1994). The results of a study conducted by Phillips 
et al. (1994) indicated that measurements o f insulin and glucose during the 
OGTT can be used to estimate the roles of insulin secretion and insulin 
resistance.
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Reaven et al. (1983) conducted a study to examine the effects o f diet 
on insulin secretion and action in 12 month old male Sprague-Dawley rats. 
Rats were randomly assigned to one of the following 3 dietary treatments 
(n=13): standard chow (4.2 kcal/g), calorie-restricted diet (1.4 kcal/g), 
sucrose diet (3.6 kcal/g) with 60% of the calories from sucrose, 29% from 
protein, and 11% fat. Rats were maintained on the diets for 10-11 months. 
An oral glucose tolerance test was performed with the glucose load (0.9 g) 
administered based on an approximation of lean body mass. Blood from the 
tail vein was obtained at baseline and at 30, 60,120, and 180 minutes after 
the load. Plasma glucose and insulin concentrations were determined.
Baseline plasma glucose levels were comparable for all 3 groups. 
The pattern o f change in plasma glucose levels was similar for rats in all 
groups. At 60 minutes, the glucose levels o f the rats fed the calorie- 
restricted diet were significantly (p < 0.01) lower than that of the other 2 
groups. Rats fed the sucrose diet had higher plasma glucose levels at the 
individual time points when compared to rats fed chow but the levels did not 
reach statistical significance. Baseline insulin concentrations were 
significantly different among the groups, with rats on the calorie restricted 
diet having the lowest and rats on the sucrose diet having the highest 
concentrations. Rats in all 3 groups had a sim ilar pattern o f insulin response 
after the glucose load. Levels o f insulin for rats fed the sucrose diet were 
higher at every time point when compared to rats fed chow. Total insulin 
response was significantly (p < 0.01) different among groups, the values for
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chow-fed, sucrose-fed, and calorie-restricted rats were, 525 ± 61, 831 ± 68, 
and 306 ± 25 uU/ml, respectively. The authors concluded that rats fed a 
calorie-restricted diet were more insulin sensitive than both rats fed a chow 
and sucrose diet. Rats fed a sucrose diet were more insulin resistant.
DIET COMPOSITION 
ENERGY BALANCE
The increase in the incidence of obesity worldwide has raised 
concern about the adverse effects o f this condition and has made the 
regulation o f body weight a major public health issue (Flatt 1995). Body 
weight maintenance can be attained by achieving a balance between energy 
intake and energy expenditure. Although on a day to day basis nutrient 
intake and physical activity vary greatly weight maintenance is still achieved. 
Because, variations in daily energy expenditure are small, it is the changes 
in food intake that greatly affect energy balance. Therefore, the major 
mechanism responsible for weight maintenance is the adjustment o f food 
intake to energy expenditure (Flatt 1995). There are many factors that may 
influence food intake in individuals, but it is not clear as to which o f these 
play dominant roles in the regulation of food intake (Poppitt and Prentice 
1996, Duncan et al.1983).
Despite the variations in nutrient intake body composition remains 
relatively stable indicating that some compensatory changes are occurring. 
Three types o f compensatory responses are possible: changes in food 
intake, changes in the composition of the fuel mix oxidized, and changes in
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energy expenditure (Flatt 1987). Factors affecting food intake include the 
amount and type o f fat in the diet indicating that the energy density o f the 
diet can affect energy intake, satiety, and eating time (Horton et al.1995, 
Duncan et al.1983). Changes in substrate and hormone concentrations 
influence the distribution o f the fuel mix oxidized which affects the amount 
and type of nutrients stored (Flatt 1995).
To meet the body’s energy requirements the composition o f the fuel 
mixture oxidized changes throughout the day. The human body tries to 
minimize variations in protein content and to maintain glycogen stores within 
a specific range. Because the body has the capacity to store more fat than 
glycogen and protein, energy balance can be offset by gains or losses of fat 
(Flatt 1995).
The relative proportion of the fuel mixture oxidized determines the 
respiratory quotient (RQ). Carbohydrate oxidation results in a RQ close to 
1, whereas oxidation o f fat results in a RQ of 0.7. Consumption o f a diet 
high in fat or carbohydrate decreases or increases, the RQ, respectively.
For the RQ to equal the FQ (food quotient) the individual has to oxidize the 
same amount o f fat and carbohydrate as he or she is consuming. 
Consumption of a diet that produces a RQ > FQ leads to storage of fat and 
weight gain, since less fat is oxidized than consumed. Consumption of a 
diet that produces a RQ < FQ leads to a reduction in body fat and weight 
loss because more fat is being oxidized than what is consumed (Westeterp, 
K.R., 1993).
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According to J. P. Flatt (1995), the oxidation of carbohydrate and 
protein is adjusted for intake, whereas fat oxidation is determined by the gap 
between total energy expenditure and amount o f energy provided by protein 
and carbohydrate. Fat oxidation is impaired in individuals after consumption 
of meals even if the fat content is greater than the carbohydrate content.
The fuel mixture oxidized contains a lesser proportion of fat than that 
present in the diet leading to storage o f the remaining amount. Flatt’s theory 
does not take into account the concept o f energy balance and how this can 
affect the type of macronutrient that is oxidized. Other research indicates 
that it is during periods of positive energy balance that consumption of a 
high fat diet will cause a decrease in the amount o f fat oxidized. 
Consumption of high fat diets during periods of energy balance do cause an 
increase in the amount o f fat oxidized (Horton et al. 1995).
Diet composition is an important determinant of body weight 
maintenance. In rats, long term consumption of diets high in fat has been 
shown to cause obesity regardless of total energy intake (Warwick and 
Schiffman 1992). Short-term (2 weeks) consumption o f a high fat diet during 
periods of energy balance in humans caused a shift in substrate oxidation 
so that oxidation more closely reflected the composition of the diet, thus 
preventing weight gain (Hill 1991). Animals consuming diets o f different 
caloric densities adjust by eating more on a low-calorie diet and less on a 
high calorie diet. Rats fed a high energy dense diet experience a rapid 
increase in body weight before these compensatory changes take place
64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
causing a higher weight gain overall (Johnson et al.1986, Roy et al.1999 
unpublished manuscript). Horton et al. (1995) conducted a study in lean 
and obese men to determine how energy balance and fuel oxidation change 
with fat and carbohydrate overfeeding. Consumption o f high carbohydrate, 
as well as consumption of high fat, led to increased carbohydrate and fat 
oxidation, respectively, and increased total energy expenditure. Excess 
consumption of calories from fat had an effect on fat fuel oxidation, but lead 
to a greater and faster accumulation o f fat then when carbohydrates were 
consumed in excess. Once glycogen stores are filled excess carbohydrate 
consumption does lead to fat accumulation. Horton et al. (1995) observed 
that obese subjects, when compared to their lean counterparts, had a higher 
RQ when both fat and carbohydrate was consumed in excess, indicating a 
higher proportion o f carbohydrate oxidation.
AMMONIA CONCENTRATION
Conditions, such as cirrhosis, that have been shown to affect normal 
functioning of the liver are associated with increased levels o f ammonia in 
the brain and blood. Abnormalities in glucose metabolism have also been 
reported in these patients. In addition, studies conducted in 
hyperammonemic rats showed that high levels o f ammonia altered 
peripheral glucose uptake and inhibited endogenous insulin secretion 
(Schlienger and Imler 1978, Schlienger et al.1975). Levels o f ammonia 
were increased for rats rendered hyperammonemic by either an exogenous 
infusion o f ammonium acetate or with a chronic endogenous portal stricture,
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when compared to levels in the controls. Ammonium infused rats had blood 
ammonia levels o f 385 ± 40 ug/100 ml (226.4 ± 23.52 umol/l) 10 minutes 
after infusion and then the level rose progressively to 550 ± 70 ug/ml (323 ±
41.1 umol/l) 60 minutes after infusion. For portal-strictured rats, basal 
hyperammonemia was observed with high ammonia levels remaining 
constant throughout the study, 216 ± 28 ug/100 ml (127 ± 16.5 umol/l).
High dietary protein intakes may lead to the development o f a 
hyperammonemic condition sim ilar to that observed in the portal-strictured 
rats. There exists the possibility that if high protein diets and/or amino acid 
supplements are consumed for prolonged periods o f time blood ammonia 
may increase to levels that can possibly alter glucose metabolism. In the 
United States, individuals who eat the typical Western diet consume protein 
in amounts that exceed the recommended dietary allowance for this nutrient 
(USDA 1998). Furthermore, people consuming fad diets such as, “Sugar 
Busters", “The Zone”, and “The Protein Power Plan”, may be affected by 
increased ammonia concentrations. In addition, athletes consuming protein 
or amino acid supplements in an effort to increase lean body mass accretion 
could also be affected by chronic exposure to elevated levels o f ammonia. 
These levels may not be as high as ammonium infusions in animals but 
long-term effects could be damaging to health.
SYNTHESIS OF CARNITINE
Studies have indicated that the composition o f the diet can have an 
effect on blood levels o f free and esterified carnitine and on the excretion of
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urinary carnitine. Results o f studies conducted in both animals and humans 
indicate that there may be an increased need for carnitine in the tissues 
when the fat content o f the diet is increased.
Cederbald (1987) observed that healthy males consuming a high fat 
diet (54% o f energy) (n-7) had increased levels o f free carnitine in plasma 
and urinary excretion of both free and acyl carnitine. These levels were 
significantly (p < 0.05) greater than the levels obtained when a high 
carbohydrate diet was consumed (51%). Cederbald concluded that the high 
fat content o f the diet could have increased the absorption o f dietary 
carnitine. In addition, an increase in endogenous synthesis of carnitine 
could have resulted from the higher lipid load provided by the high fat diet. 
The tissue demand for carnitine could have been increased on the high fat 
diet to allow for higher rates o f fatty acid oxidation and compensate for the 
loss o f urinary carnitine.
Seccombe et al. (1978) conducted a study in young white W istar rats 
to determine the effect o f different diets on blood levels of free and esterified 
carnitine. Animals were exposed to either a high fat diet, with long-chain 
triglycerides (n=8, cottonseed oil) or medium-chain triglycerides (n=10, 
coconut oil), or a diet high in carbohydrates (n-8). Serum free carnitine 
levels were significantly (p < 0.0001) lower in rats fed either the long-chain 
triglyceride diet (20 ± 2.2 uM) or the medium-chain triglyceride diet (19.4 ±
1.1 uM) compared to animals fed the high carbohydrate diet (39.2 ± 2.2 uM). 
Total serum carnitine content was significantly (p < 0.001) lower for rats fed
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the long-chain triglyceride diet (34.4 ± 1.9 uM) than those fed the medium- 
chain triglyceride (47.5 ± 2.5 uM) or the high carbohydrate diet (51.6 ± 2.9 
uM). The authors concluded that the decrease in total carnitine seen with 
the long-chain triglyceride diet might be due to a greater demand by the 
tissues for carnitine so that fatty acids can be oxidized.
These results do not necessarily indicate that supplemental dietary 
carnitine is required under high dietary fat conditions. An additional 
exogenous source o f carnitine may not be required because synthesis of 
carnitine in the body may always be adequate. However, studies continue 
to address this possibility.
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The study was a completely randomized design with 2 X 2 X 2  
factorial arrangements o f treatments. The study was undertaken to 
determine the effects o f dietary carnitine on glucose, fat, and protein 
metabolism o f rats that were fed either high fat and/or high protein. Female 
retired breeder rats (9 months old) were used as an animal model since 
weight gain and changes in glucose and fat metabolism are most commonly 
associated with older adults. Furthermore, rats fed a diet high in fat become 
obese and are recognized as models o f the effects of a high fat diet on 
insulin resistance (Storiien, 1986). Treatment groups are shown in Table
3.1.
Table 3.1 Dietary treatment groups by percent weight o f diet
Dietary Treatment Carnitine Protein Fat
NLL No Carnitine,Low Protein, Low Fat 0% 14% 4%
NLF No Carnitine, Low Protein,High Fat 0% 14% 35%
NPL No Carnitine, High Protein, Low Fat 0% 35% 4%
NPF No Carnitine, High Protein, High Fat 0% 35% 35%
CLL Carnitine, Low Protein, Low Fat 0.1% 14% 4%
CLF Carnitine, Low Protein, High Fat 0.1% 14% 35%
CPL Carnitine, High Protein, Low Fat 0.1% 35% 4%
CPF Carnitine, High Protein, High Fat 0.1% 35% 35%
ANIMALS
Seventy-two 9 month old female retired breeder rats (Harlan Sprague 
Dawley, Madison, Wisconsin), from the same colony, age and weight 
matched, were used in this study. The study protocol was approved by the
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Louisiana State University Institutional Animal Care and Use Committee 
(see Appendix B). The rats were housed individually in w ire cages 
containing a food cup and a water bottle and were maintained on a 12:12 
lighting schedule, with lights coming on at 7:00 a.m. and off at 7:00 p.m.. 
The rats were allowed to adapt to their new environment for 2 days and 
were fed the standard AIN-93M diet during this period. On the third day the 
rats were weighed and randomly assigned to one o f nine treatment groups 
(eight dietary and one baseline). The rats were stratified from the heaviest 
to the lightest and divided into eight weight groups o f nine rats each, i.e. the 
first heaviest nine rats were one group, the next heaviest nine rats were 
another group and so on. After this stratification by weight, one rat from 
each o f the 8 groups was then assigned to one of nine groups, labeled A-I. 
Then the A-I groups were randomly assigned to one of the nine treatment 
groups. The mean body weight o f the treatment groups (n=9) was 307.3 ± 
4.60 g, with weights ranging from 243 to 356 g.
Baseline rats were maintained on the standard diet for a total o f six 
days and were sacrificed on the 7th day. Before sacrifice an oral glucose 
tolerance test was performed to determine the amount o f time needed for 
glucose and insulin levels to decline. The baseline carcasses were frozen 
(-20°C) for future body composition measurements. One of the baseline 
rats died the day of the oral glucose tolerance test and a small tumor in the 
neck region was detected in another.
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EXPERIMENTAL METHODOLOGY
Diet
The rats were randomly assigned to a low fat/low protein, a low 
fat/high protein, a high fat/low protein, or a high fat/high protein diets with or 
without carnitine. The low fat/low protein diet was the basic diet for this 
experiment and is the AIN-93M diet formulated for maintenance o f adult 
rodents (Table 3 .2 ).
The carbohydrate content (sucrose and cornstarch) o f the other diets 
was adjusted from this basic diet to allow for increased protein in the high 
protein diet (35% by wt) or increased fat in the high fat diet (35% by wt). 
Amounts o f all other nutrients were a fixed amount so that they remained at 
AIN-93M concentrations (by wt). The other diets are illustrated in tables 3.3- 
3.5. The level o f L-camitine (0.1%) used in this study was determined from 
a previous rat study (Rebouche 1983). Rats fed diets that were 
supplemented with 0.1% to 1.0% of L-camitine had increased L-camitine 
concentrations in serum and all tissues; however, at higher levels (0.5%- 
2.0%) the L-camitine produced diarrhea in these rats (Rebouche 1983).
To obtain a carnitine concentration of 0.1%, 2 grams of Camiking 
(50% mixture D and L) was added to every kilogram o f diet prepared. The 
sucrose content o f the diet was reduced by the amount o f Camiking added 
to the diets (i.e. 2 g). To avoid confusion among the different dietary 
treatments a small amount o f blue dye (.33 g/kilo o f diet) was added to the 
carnitine diets.
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Table 3.2. Basic diet for experiment- AIN 93 M diet.
1 In g r ed ien t Amount needed per kilo Amount for study
Grams %
Sucrose 100 10.0 1.8 kilograms
Casein 140 14.0 2.52 kilograms
Cornstarch 466 46.6 8.39 kilograms
Dextrinized Cornstarch 155 15.5 2.79 kilograms
Soybean Oil (with BHT) 40 4.0 720 grams
Crisco ■ ■ ■ ■  -
Cellulose Fiber 50 5.0 900 grams
Methionine 1.8 .18 32.4 kilograms
Mineral Mix (AIN 93) 35 3.5 630 grams
Vitamin Mix (AIN 93) 10 1.0 180 grams
Choline Bitartrate 2.5 .25 45 grams
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Table 3.3. High protein and low fat diet.
In g r ed ien t Amount needed per kilo Amount for study
Grams %
Sucrose 71 7.1 .64 kilograms
Casein 350 35.0 3.15 kilograms
Cornstarch 330 33.0 2.97 kilograms
Dextrinized Cornstarch 110 11.0 .99 kilograms
Soybean Oil (with BHT) 40 4.0 360 grams
Crisco
Cellulose Fiber 50 5.0 900 grams
Methionine 1.8 .18 32.4 kilograms
Mineral Mix (AIN 93) 35 3.5 630 grams
Vitamin Mix (AIN 93) 10 1.0 180 grams
Choline Bitartrate 2.5 .25 45 grams
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Table 3.4 Low protein and high fat diet.
In g r ed ien t Amount needed per kilo Amount for study
Grams %
Sucrose 57 5.1 1.8 kilograms
Casein 140 14.0 2.52 kilograms
Cornstarch 266 26.6 8.39 kilograms
Dextrinized Cornstarch 88 8.8 2.79 kilograms
Soybean Oil (with BHT) 40 4.0 720 grams
Crisco 310 31.0 6.2 kilograms
Cellulose Fiber 50 5.0 900 grams
Methionine 1.8 .18 32.4 kilograms
Mineral Mix (AIN 93) 35 3.5 630 grams
Vitamin Mix (AIN 93) 10 1.0 180 grams
1 Choline Bitartrate 2.5 .25 45 grams
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Table 3.5. High protein and high fat diet.
In g r ed ien t Amount needed per kilo Amount for study
Grams %
Sucrose 28 2.8 .56 kilograms
Casein 350 35 7 kilograms
Cornstarch 130 13 2.6 kilograms
Dextrinized Cornstarch 43 4.3 .86 kilograms
Soybean Oil (with BHT) 40 4.0 .80 kilograms
Crisco 310 31.0 6.2 kilograms
Cellulose Fiber 50 5.0 900 grams
Methionine 1.8 .18 32.4 kilograms
Mineral Mix (AIN 93) 35 3.5 630 grams
Vitamin Mix (AIN 93) 10 1.0 180 grams
1 Choline Bitartrate 2.5 .25 45 grams
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To prepare the basic AIN-93M diet the macronutrients were weighed 
and added to a large mixing bowl. The micronutrients were sieved 
sequentially into a large bowl and combined with the macronutrients. 
Specific instructions on how to prepare the basic AIN-93M diet can be found 
in Appendix C. The same procedure was used to prepare the low fat/high 
protein diet with or without carnitine and the low fat/low protein diet with 
carnitine. For the carnitine diets the Camiking was added with the 
micronutrients.
To prepare the high fat diets each macronutrient was weighed and 
placed in its own container. The individual micronutrients (vitamins, 
minerals, etc.) were weighed and sieved sequentially into a large bowl. The 
macronutrients (except the fat) and micronutrients were then sieved 
sequentially into a large bowl and mixed together (See Appendix C).
The diets were stored frozen (-20°C) in either Rubbermaid containers 
or in Ziploc bags. The-low fat diets were prepared in 6-kilogram batches, 
whereas the high fat diets were prepared in 1-kilogram batches. Three six- 
kilogram batches o f the low fat diets and 11 one-kilogram batches of the 
high fat diets were prepared for this eight-week study.
The amount o f kilocalories per gram of diet for the low fat diets and 
the high fat diets are shown in Table 3.6. The percentage o f kilocalories 
coming from the macronutrients for the low protein low fat diet, the high 
protien low fat, the low protein high fat diet, and the high protein high fat diet 
are listed in Table 3.7.
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Table 3.6 Amount of energy per gram of diet.
Name o f diet Kilocalories per Gram diet
NLL, NPL, CLL & CPL 3.9
I NLF, NPF.CLF & CPF 5.4
Table 3.7 Percentage o f kilocalories from the macronutrienl s in each diet.
Name of diet % Carbohydrate % Protein % Fat
NLL & CLL 76.2 14.5 9.3
NPL & CPL 54.6 36.1 9.3
NLF & CLF 31.6 10.3 58.1
NPF & CPF 16.1 25.8 58.1
EXPERIMENTAL PROCEDURES
Food intake and body weight was recorded three times a week for the 
entire length of the study. The weight o f the food cup plus food was 
recorded before and after each feeding. To determine the amount o f food 
consumed the difference was calculated. To weigh the rats, a bucket was 
placed on a balance, the balance was brought to zero using small weights, 
and then rats were individually placed in the bucket and weighed. At week 
2, blood (1.5 ml) was obtained from the orbital sinus while rats were under 
isoflurane anesthesia using an anesthesia chamber followed by a nose cone 
to effect following the technique used by Dr. Stout from the LSU School of 
Veterinary Medicine. The blood was spun down in the centrifuge and the 
serum was aliquoted into 3 different centrifuge tubes. Serum samples were 
analyzed for L-camitine, glucose, insulin, nonesterified fatty acids, ammonia, 
and urea nitrogen.
During week 5 o f the study, an oral glucose tolerance test was 
performed, blood (0.7 ml) was obtained from the orbital sinus before and
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120 minutes after the glucose load and the serum was analyzed for insulin 
and glucose. The rats were anesthetized with isoflurane using an 
anesthesia chamber followed by a nose cone to effect. An oral gavage was 
performed using an oral glucose load (3.0 g/kg of body weight) that was 
given via an 18 gauge 3” ball tipped, gavage needle.
At the end o f the study (wk 8), the rats were anesthetized using 
isoflurane and blood (1.3 ml) was obtained from the orbital sinus. The blood 
collected was used to measure end point levels o f L-camitine, glucose, 
insulin, nonesterified fatty acids, ammonia, and urea nitrogen. Rats were 
sacrificied by cardiac puncture using a syringe and needle. After sacrifice, 
the heart, soleus, liver, gastrointestinal tract and right and left femur were 
removed. Abdominal fa t was removed, weighed, and returned to the 
carcass for future body composition analysis. Carcasses were frozen (- 
20°C) and body composition measurements were made 6 months later.
Different intervals were used to report different measurements 
because all rats were not sacrificed on the same day. Data for 
measurements that were recorded on a weekly basis was reported as a 7 
week interval. Blood was taken for measurement o f hormones and 
metabolites during sacrifice, week 8, therefore these values were reported 
as an 8 week interval. Rats were sacrificed on three different days so the 
intake and weight data recorded during sacrifice week was not documented 
for the same length o f time for all rats. Thus, these measurements could not 
be used to calculate an 8 week interval period.
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LABORATORY ANALYSIS
Enzyme Analysis
To determine the rate of beta-oxidation in skeletal muscle (soleus) 
the enzyme activity o f 3-hydroxyacyl CoA Dehydrogenase was determined. 
During sacrifice the right soleus muscle was removed, weighed, wrapped in 
labeled aluminum foil, frozen in liquid nitrogen, and stored at -  40°C for 6 
months.
Two days prior to the analysis, a homogenizing buffer was prepared 
and stored in the refrigerator (4°C). Enough buffer was prepared to analyze 
64 samples (150 ml o f buffer) by using 175 mM KCL, 2 mM EDTA and 10 
mM Tris stock. The mixture was stored in the refrigerator to obtain a final 
temperature o f 4°C. The pH of the buffer was brought up to 7.4 by adding 
acid or base as needed.
To prepare the homogenate the soleus muscle was thawed, cleaned 
(connective tissue removed) and > .03 grams of tissue were weighed. The 
tissue was placed in a 16 X 100 mm glass tube to which the homogenizing 
buffer was added to prepare a 5% homogenate (w/v). To determine the 
amount o f homogenizing buffer needed the weight o f the sample was 
multiplied by 19, for a 1/20 dilution. To homogenize the samples a 
Brinkman Homogenizer (Model PCU-11) was used. The blade o f the 
homogenizer was placed all the way to the bottom of the sample and the 
knob was rotated clockwise. A beaker o f ice was kept under the test tube to 
keep the sample chilled at all times. The sample was homogenized until an
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opaque white liquid sample was obtained (Askew et al. 1975, Williamson et 
al. 1971). To prevent the breaking down of proteins in the tissue the 
samples were carefully homogenized and not allowed to foam very much. 
The homogenized samples were parafilmed and stored in the freezer until 
the next day (one entire day was needed to homogenize 64 samples).
The day the analysis was conducted, a 100 mM potassium 
phosphate buffer, NADH solution, and acetoacetyl CoA solution were 
prepared. A 5-cuvette holder spectrophotometer (Spectronic 601, Milton 
Roy, Chicago, IL.) was used to run the assay. The spectrophotometer was 
turned on at least 30 minutes prior to the first reading to allow for warm up. 
For every run only two homogenized samples were thawed. The samples 
were run in duplicate. A specific amount of phosphate buffer, which 
depended on the concentration o f the homogenate, was added to a labeled 
test tube. Based on the protocol the amount of buffer added to obtain the 
dilution factor for the specific muscle sample analyzed was either 1.4 or 1.9 
ml. The homogenized sample was vortexed, 100 pi were pipeted 3 times, 
the sample was vortexed, and then 100 pi were added to the labeled test 
tube. Again the sample was vortexed. To a 1.6 ml cuvette, 700 pi o f 100 
mM phosphate buffer, 100 pi o f NAOH, and 10 pi o f diluted homegenate 
were added. The samples were then placed in the spectrophotometer and 
allowed to equilibrate for 2 minutes. The reaction was initiated by adding 10 
pi of 2 mM acetoacetyl CoA and inverting the cuvette (a parafilm strip was 
used to cover the top). The absorbance was recorded at 340 nm every 15
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seconds for 5 minutes. The average change in optical density per minute 
was determined (pmoles/g/min) (Askew et al. 1975, Williamson et al. 1971). 
Refer to Appendix D for detailed explanations of the procedures and 
calculations used in this analysis.
Serum Carnitine Analysis
Hill’s Science and Technology Center (Lonza, Topeka, Kansas) 
analyzed the samples for total serum L-camitine concentrations.
Serum Insulin Analysis
Insulin was measured using Coat-A-Count® Insulin, a solid-phase 1251 
radioimmunoassay (Diagnostic Product Corporation, Los Angeles, CA). 
Insulin antibody is immobilized to the wall o f a polypropylene tube used in 
this assay. In this procedure,125 l-labeled insulin compete? fo r sites, on 
insulin-specific antibody, with insulin in the rat blood sample. Decanting the 
supernatant terminates the competition and allows for isolation o f the 
antibody-bound fraction of the radiolabeled insulin. The coated tubes can 
be decanted without loss o f antibody-bound material and thus results in a 
good separation. See Appendix D for serum insulin assay protocol.
Serum Ammonia Analysis
Ammonia was measured using a Sigma Diagnostic Kit (Sigma 
Diagnostics Procedure No. 170-UV, Sigma Diagnostics, St., Louis Missouri) 
which provides a quantitative enzymatic determination of ammonia at 340 
nm. Ammonia levels reflect urea cycle activity in relation to glucose, protein 
and nucleic acid metabolism. The procedure is based on the reductive
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amination o f 2-oxoglutarate using reduced nicotinamide adeninde 
dinucleotide phosphate (NADPH). The end products o f the reaction are 
glutamate and nicotinamide adenine phosphate (NAD) and the enzyme 
involved is glutamate dehydrogenase (GLDH). The oxidation o f NADPH 
decreases the absorbance at 340 nm, the decrease being proportional to 
serum ammonia concentrations. Refer to Appendix D for serum ammonia 
assay protocol.
Serum Glucose Analysis
Glucose concentration was measured with the Beckman DU-640 
Spectrophotometer (Beckman Instruments, Inc.) utilizing the glucose 
oxidase method. Glucose is first oxidized to gluconic acid and hydrogen 
peroxide. In the presence of peroxidase, the hydrogen peroxide reacts with 
4-aminoantipyrine and p-hydroxybenzene sulfonate to form a quinoneimine 
dye. The dye has a maximal absorbance at 505 nm and the intensity of the 
color produced is directly proportional to the glucose concentration in the 
sample. See Appendix D for serum glucose assay protocol.
Serum Nonesterified Fatty Acid analysis
The concentration of nonesterified fatty acids in serum was obtained 
using the colorimteric ACS-ACOD method (Wako Chemicals USA, Inc., 
Richmond Virginia). Refer to Appendix D for serum nonesterified fatty acid 
assay protocol.
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Serum Urea Nitrogen analysis
Serum urea nitrogen was measured using the Beckman DU-640 
spectrophotometer following the method reported by Laborde et al. (1995). 
Refer to Appendix D for serum urea nitrogen assay protocol.
BODY COMPOSITION ANAYSIS
Body composition analysis was performed to determine the percent 
fat, protein, moisture and ash on the baseline rats (n=7) and on the rats 
(n=8) assigned to the eight dietary treatments. The methods utilized for 
preparing the rat carcasses for body composition analysis were those 
reported by Klinger et al. (1996). Frozen carcasses minus the liver, heart, 
right soleus, gastrointestinal tract, and right and left femur were used for this 
analysis. To prepare the carcasses for body composition analysis the 
frozen carcasses were thawed 24 hours prior to the start o f the analysis. 
Each carcass was individually wrapped in a biohazard bag that had been 
labeled with the rat ID number. The carcasses were then autoclaved for 60 
minutes at 125°C at the Life Science facilities. The autoclaved carcasses 
were left at room temperature for approximately 30 minutes to allow for cool 
down.
The carcasses were then cut into small pieces using scissors. First, 
the fur and skin were removed and cut into small thin strips. Care was taken 
to ensure that the sizes of the pieces were of equal length. Secondly, the 
muscle and abdominal fat were cut into fine pieces. This procedure was 
much easier due to the nature o f the material being cut, but likewise care
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was taken to ensure that pieces were small enough to grind in the omni 
mixer. Lastly, the bones were cut into small pieces to make it easier for the 
mixer to break down the remaining bone fragments.
The cut carcasses were placed in plastic jars that fit onto the mouth 
o f the omni mixer. Deionized water was added to each container before the 
mixture was homogenized. The total amount of deionized water added 
consisted of the weight of the rat carcass plus 50 ml. This amount o f water 
was needed to ensure that the blades of the homogenizer could reach the 
carcass material, mix the contents o f the jar, and produce a homogenous 
mixture. The carcass material plus deionzed water corresponding to the 
weight of the carcass was first homogenized for two minutes. The contents 
on the side o f the ja r were then washed down with 50 ml o f deionzed water. 
This was done to guarantee that the material that was forced to the upper 
part of the ja r was washed down into the homogenate. The mixture was 
homogenized for another 2 minutes. The homogenate was poured into two 
pre-labeled tubes and placed in the freezer (-20°C) until the different 
analyses were performed (approximately one week). Glass jars containing 
some extra homogenate were stored in the freezer and the remaining liquid 
was discarded. The nature of the homogenate was liquid and o f brownish 
color.
To determine the percent moisture content, one o f the tubes that 
contained the frozen homogenate was thawed for six hours. Small beakers 
were labeled with the rat ID number and weighed. Five grams of sample
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were placed in each beaker and the contents were dried in the oven, set at 
105°C for 18 hours. The amount o f time that the samples remained in the 
oven was determined from a test sample. The time at which the beaker 
weight no longer changed was used as the time needed to dry the samples 
and determine percent moisture. The following formulas were used to 
calculate the percent moisture: 1) Weight o f beaker plus the 5 gram sample 
-  Weight of beaker with dried sample/Weight of original sample (5 grams) X 
100 = Percent moisture. To take into account the water added during 
homogenziation the following formulas were used: 1) Percent 
moisture*[Carcass weight + water added (grams)] = total grams o f water 
associated with carcass. 2) Total grams o f water associated with carcass -  
grams of water added to carcass = grams o f water in carcass 3) Grams of 
water in carcass/carcass weight in grams = Percent moisture in carcass 
accounting for dilution.
To determine the percent ash content of the sample a wet ashing 
procedure was conducted on the dried samples used for moisture 
determination (Keenan et al. 1991). To char the samples, the samples were 
placed in the muffle furnace (Lindberg General Signal P48038) overnight 
(500°C). Each beaker was labeled and a diagram with the location of each 
sample was prepared. The beakers were removed from the furnace and 
allowed to cool. Approximately one ml o f nitric acid was added in a fume 
hood to the samples and samples were set on a hot plate for a few hours 
until the samples dried. The beakers were once again placed in the muffle
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furnace overnight and the process was repeated until the ash was no longer 
black or gray in color. The following formulas were used to calculate the 
percent ash o f the sample: 1) Weight o f beaker plus 5 gram sample -  
Weight of beaker with ashed sample = grams left in sample after ashing 
procedure. 2) Weight o f original sample (5 grams) - grams left in sample 
after ashing/Weight o f original sample (5 g) X 100 = percent ash of aliquoted 
sample. The calculation of percent ash has to take into account the water 
added during the preparation o f the homogenate. The following formulas 
were used to calculate the percent: 1) Percent ash*[Carcass weight + water 
added (grams)] = Grams of ash in carcass. 2) Grams o f ash in 
carcass/Weight o f carcass (grams) = Percent ash accounting for dilution.
To determine the percent fat content the Soxtec method o f extraction 
was used (Soxtec Instrument HT-1043 extraction unit) following the Offical 
Methods of Analysis o f the Association of Offical Analytical Chemists (1990). 
Two to three grams of sample were weighed and placed in a pre-weighed 
aluminum tube containing a thimble. The samples were covered with sand 
and a piece of cotton was placed on top of each tube. In addition, aluminum 
cups used to collect the fat extract were pre-weighed for all samples. The 
tubes with samples were placed on the instrument with the collecting cups 
underneath. To each tube 40 ml o f solution containing ethyl ether were 
added. The tubes were boiled for 30 minutes, rinsed with solution for 45 
minutes, and the final extraction procedure was conducted in 15 minutes. 
The aluminum cups with the extract were then weighed. To calculate the fat
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percent the following formulas were used: 1) Aluminum cup weight with fat 
extract -  original aluminum cup weight = total grams of fat extracted. 2 )
Total grams o f fat extracted/weight o f the sample = percent fat in the 
sample. To account for the dilution factor the following formulas were used:
1) Percent fat*[Carcass weight+water added (grams)] -  Grams of fat in 
carcass. 2) Grams of fat in carcass/Weight o f carcass (grams) = Percent fat 
accounting for water dilution.
To determine the percent o f protein in the sample a blot digestion 
method accompanied by auto analysis was performed according to 
procedure 976.06 in the Offical Methods of Analysis o f the Association of 
Official Analytical Chemists (1990). The sample, 1 to 2 grams, was weighed 
onto white filter circular paper, folded and dropped into big test tubes. 
Sulfuric acid, 20 mis, was added to each tube and brought up to volume with 
water. Immediately after the water was added the tubes were lightly shaken 
to ensure that the paper and sample were dissolved. The tubes were 
placed in a rack and pre-digested for 15 minutes using the Digester 2020 
(Tecator Prestorp Analytical Co.) at 400°C. The tubes were removed and 
cooled for 15 minutes. To each tube the following was added: 1) 3.75 ml of 
Hydrogen peroxide (30%) and 2) 12 g o f Catalyst (10 g o f K2SO4 and 0.3 g 
of C0 SO4)- The tubes were placed on the digester for 1.5 hours and allowed 
to cool for 15 minutes. To ensure that a homogenous sample was taken 
rubber stoppers were placed on each tube and the tubes were shaken. The 
samples were poured into small test tubes and analyzed with the auto
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analyzer. A printout with the percent protein o f the 1 to 2 g sample was 
generated. To calculate the percent of protein in the carcass accounting for 
the water added the following formulas were used: 1) Percent 
protein*[Carcass weight+water added (grams)] -  Grams o f protein in 
carcass. 2) Grams of protein in carcass/Weight o f carcass (grams) -  
Percent protein accounting for dilution.
STATISTICAL ANALYSIS
The study was analyzed using the Statistical Analysis Systems 
statistical software package version 6.12 (SAS Institute, Cary, NC, USA). A 
multivariate technique, Multiple Analysis o f Variance (MANOVA) was used 
to examine the interdependence o f the dependent variables and the effects 
o f the independent factors, carnitine, protein and fat on this relationship. 
Separate MANOVA’s were run for the following groups of dependent 
variables: 1) Carnitine, ammonia, urea nitrogen, glucose, insulin, and 
nonesterified fatty acids, 2) Food intake, energy intake, energy efficiency, 
body weight, and weight gain, 3) Percent moisture, ash, protein, and fat, 
final body weight, total weight gain, and abdominal fat. A univariate 
technique, Analysis o f Variance (ANOVA), was used to analyze the data for 
the oral glucose tolerance test and the enzyme analysis.
Due to the data handling characteristics of the MANOVA technique 
subjects with one missing value (e.g. no carnitine value for week 2) were 
completely removed from the analysis. Too many observations were lost 
when the MANOVA technique was applied to this data set. Therefore, the
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use of the ANOVA technique was considered more appropriate. The data 
set was re-analyzed using the ANOVA technique. ANOVA with repeated 
measures was used for the data collected at 2 and 8 weeks. ANOVA was 
used for single measurements that were collected during week 8 o f the 
study (end point data).
The data was also analyzed for potential outlier values using 
univariate analysis. Each observation that was considered a potential outlier 
was evaluated individually to determine if the observation should be 
included in the data set.
Results were considered significantly different when p < .05. P 
values greater than .05 and less than or equal to .1 were considered a trend 
(.1 > p > .05). Results were summarized in a graphical format where the 
main and interaction effects are specified and error bars indicating the 
pooled standard error o f the mean are included.
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CHAPTER 4 
RESULTS 
FOOD INTAKE AND BODY WEIGHT
Initially, food intake for rats fed the low and high fat diet was not 
different, but after 2 weeks intake o f rats on the high fat diet decreased and 
remained lower (fat*time, p = 0.0001) for the rest o f the study when 
compared to rats fed low fat diets (Figure 4.1; values for all figures can be 
found in Appendix E). This lead to an overall greater food intake for rats fed 
the low fat diets (fat, p = 0.0001). There was no difference in the pattern of 
food intake and overall intake for rats fed the high and low protein diets 
(protein*time, p = 0.67; protein, p = 0.60) and the diets with or without 
carnitine (camitine*time, p = 0.38; carnitine, p = 0.95).
During the first 2 weeks of the study, energy intake for rats fed the 
high fat diets was greater than intake for rats fed the low fat diets, with 
intake becoming sim ilar to that o f rats fed the low fat diets for the rest o f the 
study (fat*time, p = 0.0001, Figure 4.2). There was a trend for rats fed the 
no carnitine low fat diets to have lower energy intakes (camitine*fat*time, p = 
0.06, Figure 4.3) than rats fed the carnitine low fat diets. The trend was 
caused by the intake during weeks 2 and 3, where mean energy intake was 
346.5 ± 16.3 and 363.8 ± 13.9 kcal for rats not fed carnitine with low fat and 
398.0 ± 15.7 kcal and 390.7 ± 13.4 kcal for rats fed the carnitine with low fat 
diets. As shown in figure 4.4, rats in all eight dietary treatment groups 
began the study with sim ilar body weights (p s 1.00). One week after
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Figure 4.4 Initial and weekly body weight for all dietary treatments.
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assignment to the dietary treatments, rats fed high fat had overall a higher 
body weight (fat, p = 0.0001) that remained higher (fat*time, p = 0.0001) for 
the rest o f the study (Figure 4.5). It was the greater energy intake during the 
first 2 weeks of the study that caused the body weight o f rats fed high fat to 
increase and remain higher than that o f rats fed low fat. There was no 
difference in the pattern and overall body weight for rats fed different levels 
of protein (protein*time, p = 0.6; protein, p = 0.5) and carnitine 
(camitine*time, p = 0.8; carnitine, p = 0.97).
For the first 2 weeks o f the study, rats fed the high fat diet gained 
more weight than rats fed the low fat diet, but with time the amount o f weight 
gained became sim ilar to that o f rats fed low fat (fat*time, p = 0.0001; Figure 
4.6). The initial weight gained caused rats fed high fat to have an overall 
greater weight gain than rats fed low fat (fat, p = 0.0001).
Overall, rats fed the high fat diet were more energy efficient than rats 
fed the low fat diet (fat, p = 0.0001, Figure 4.7). During the first 2 weeks of 
the study, rats fed the high fat diet were more energy efficient than rats fed 
the low fa t diet, but energy efficiency for both groups became similar for the 
remainder o f the study (fat*time, p = 0.0001).
SERUM METABOLITES AND HORMONES 
CARNITINE
At 2 and 8 weeks, serum carnitine concentrations were higher 
(p = 0.0001) for rats on the carnitine diets when compared to rats not fed 
carnitine (Figure 4.8). Serum carnitine concentrations were also higher
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Figure 4.7 Energy efficiency for rats fed high and low fat, weight 


















Figure 4.8 Serum carnitine levels for rats fed diet with or without 
carnitine.
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for rats fed the low protein (p = 0.0001, Figure 4.9) and low fat (p = 0.0001, 
Figure 4.10) diets compared to rats fed the high protein and high fat diets, 
respectively. Mean carnitine concentrations for rats fed low protein were 
47.6 ± 1.7 nmol/ml at 2 weeks and 51.5 ± 2.2 nmol/ml at 8 weeks; mean 
carnitine concentrations for rats fed high protein were 41.3 ± 1.8 nmo/ml at 2 
weeks and 39.1 ± 2.4 mol/ml at 8 weeks. Mean carnitine concentrations for 
rats fed low fat were 47.4 ±1 .7  nmol/ml at 2 weeks and 50.8 ± 2.4nmol/ml at 
8 weeks; mean carnitine concentrations for rats fed high fat were 41.5 ± 1.7 
nmol/ml at 2 weeks and 39.9 ± 2.2 nmol/ml at 8 weeks. Overall, the serum 
carnitine concentrations of rats fed carnitine with high protein and high fat 
and low protein and low fat were higher than the concentrations o f rats not 
fed carnitine with high protein and high fat and low protein and low fat 
(camitine*protein*fat, p = 0.01, figure 4.11). As shown in figure 4.12, there 
was a trend for rats that were not fed carnitine with high and low fat to have 
a decrease or an increase, respectively, in carnitine values over time 
(camitine*fat*time, p = 0.07).
AMMONIA
As shown in figure 4.13, with time serum ammonia concentrations 
decreased for animals fed both the high and low protein diets (time, p -  
0.0001). At week 2, the ammonia levels for rats fed the high protein diets 
(134.8 ± 5.3 pmol/l), was higher than levels for rats fed the low protein diets
96

































Figure 4.9 Serum carnitine levels for rats fed high and low protein.
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Figure 4.10 Serum carnitine levels for rats fed high and low fat.
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Figure 4.11 Serum carnitine levels for all dietary treatment groups.
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Figure 4.12 Serum carnitine levels for rats fed high and low fat 
with or without carnitine.
Cam*fat*time p = .0770
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Figure 4.13 Serum ammonia levels for rats fed high and low 
protein diets.
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(116.1 ± 5.4 pmol/l). The higher ammonia level at week 2, but not week 8 
made the overall serum ammonia concentrations higher for rats fed high 
protein (protein, p = 0.007). As shown in figure 4.14, there was a trend for 
rats that were fed carnitine with high protein to have lower levels o f 
ammonia than rats fed high protein without carnitine (camitine*protein, p = 
0.11). At 2 weeks, the mean levels o f ammonia for rats fed carnitine with 
high and low protein were 122.4 ± 7.5 pmol/l and 117.2 ± 7.5 pmol/l, 
respectively. By 8 weeks, the levels were 103.8 ± 8.5 umol/l and 96.6 ± 8.5 
pmol/l, respectively. At 2 weeks, the mean levels o f ammonia for rats not 
fed carnitine with high and low protein were 147.2 ± 7.5 pmol/l and 115.0 
pmol/l ± 7.7, respectively. By 8 weeks, the levels were 104.3 ± 8.5 pmol/l 
and 89.5 ± 8.8 pmol/l, respectively. The difference between serum 
ammonia concentration for rats fed the high and low protein diets was 
greater for the diets without carnitine than with carnitine. Carnitine lowered 
ammonia levels for rats on the high protein diet at 2 weeks, but no longer did 
so during week 8. Carnitine did not decrease ammonia for low protein diets. 
The trend was dominated by the individual ANOVA at 2 weeks 
(camitine*protein, p = 0.08), where animals on the diet with high protein and 
carnitine had ammonia levels that were much lower than those o f rats fed 
high protein without carnitine. The ammonia levels o f rats fed high protein 
with carnitine were similar to those of rats fed low protein with or without 
carnitine. As shown in Figure 4.15, the difference in ammonia concentration
100
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Figure 4.14 Serum ammonia levels for rats fed high and low protein 





















Figure 4.15 Serum ammonia levels fo r all dietary treatment groups.
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between rats fed high protein low fat with or without carnitine was 
numerically greater than the difference between rats fed low protein high fat 
with or without carnitine. There was a trend for ammonia levels to be 
positively correlated at 2 weeks (r = 0.3, p -  0.06) with serum glucose levels 
and a stronger positive correlation was observed at 8 weeks (r = 0.4, 
p = 0.003).
GLUCOSE
At 2 weeks, rats fed carnitine had lower serum glucose 
concentrations than rats not fed carnitine 8.66 ± 0.31 mmol/l, and 9.24 ±
0.31 mmol/l, respectively, but by 8 weeks this had reversed, and rats fed 
carnitine had higher serum glucose concentrations than rats not fed 
carnitine, 8.64 ± 0.24 mmol/l and 8.16 ± 0.24 mmol/l, respectively 
(camitine*time, p = 0.02, Figure 4.16). There was a trend for serum glucose 
concentration to be negatively correlated (r = -0.2, p = 0.08) with carnitine 
concentration at 2 weeks. Serum glucose concentrations of rats fed the 
high protein diets were overall significantly (protein, p = 0.03) higher than the 
levels o f rats fed the low protein diets (Figure 4.17). Rats fed high protein 
had a mean glucose concentration of 9.41 ± 0.30 mmol/l at 2 weeks and 
8.63 ± 0.23 mmol/l at 8 weeks; mean glucose concentration for rats fed low 
protein were 8.49 ± 0.31 mmol/l at 2 weeks and 8.17 ± 0.24 mmol/l at 8 
weeks.
At 2 and 8 weeks, glucose concentrations for rats fed carnitine with 
high protein (8.86 ± 0.44 mmol/l; 9.09 ± 0.34 mmol/l) remained nearly stable,
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but glucose concentrations for rats not fed carnitine with high protein 
decreased from 2 to 8 weeks (9.97 ± 0.42 mmol/l; 8.17 ± 0.32 mmol/l; 
camitine*protein*time. p = 0.03, Figure 4.18). By 8 weeks, serum glucose 
concentrations for rats not fed carnitine with high protein were comparable 
to the levels of rats fed low protein with or without carnitine. Rats fed the 
high fat diet had numerically greater glucose levels than rats fed the low fat 
diet (p = 0.17).
UREA NITROGEN
As shown in figure 4.19, urea nitrogen levels were significantly higher 
(p = 0.0001) for rats fed high protein than for rats fed low protein at 2 weeks 
(6.48 ± 0.16 mmol/ vs. 5.53 ± 0.16 mmol/l) and 8 weeks (7.77 ± 0.21 mmol/l 
vs. 5.76 ± 0.22 mmol/l). Rats fed high protein had a greater increase in urea 
nitrogen than rats fed low protein (protein*time, p = 0.0001). There was no 
difference in the pattern (camitine*time, p = 0.96) and overall (carnitine, p = 
0.75) urea nitrogen levels for rats fed a diet with or without carnitine (Figure 
4.20). Both groups had a slight increase in urea nitrogen levels from 2 to 8 
weeks. At 2 weeks, mean urea nitrogen concentration was 6.04 ±0.16 
mmol/l for rats fed carnitine and 6.00 ±0.16 mmol/l for rats not fed carnitine. 
By 8 weeks, concentrations were 6.80 ± 0.21 mmol/l and 6.73 ± 0.22 mmol/l, 
respectively.
Overall, serum levels o f urea nitrogen for rats fed the low fat diets 
were greater than levels for rats fed the high fat diets (fat, p = 0.001,
Figure 4.21).
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Figure 4.18 Serum glucose levels o f rats fed high and low protein with 
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Figure 4.19 Serum urea nitrogen levels for rats fed high and low 
protein diets.
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Figure 4.21 Serum urea nitrogen levels for rats fed diet with or 
without carnitine
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Urea nitrogen levels for rats fed the low fat diets were 6.25 ±0.16 mmol/l 
and 7.26 ± 0.22 mmol/l at 2 and 8 weeks, respectively. Rats fed the high fat 
diets had urea nitrogen levels o f 5.76 ± 0.16 mmol/l at 2 weeks and 6.27 ± 
0.21 mmol/l at 8 weeks. There was a trend over time for rats on the low fat 
diets to have greater urea nitrogen levels than rats on the high fat diets 
(fat*time, p = 0.11). Urea nitrogen levels increased, from 2 to 8 weeks, for 
rats on the low fat diets, but remained nearly stable for rats fed the high fat 
diets. There was also a trend for rats fed low fat without carnitine to have 
higher urea nitrogen concentrations, and the difference in urea nitrogen for 
rats fed high and low fat was greater for the diets without carnitine than with 
carnitine (camitine*fat, p = 0.09, Figure 4.22). Rats fed the carnitine low fat 
diets had lower urea nitrogen concentration than rats fed the no carnitine 
low fat diets, but rats fed the carnitine high fat diets had greater urea 
nitrogen concentrations than rats fed the no carnitine high fat diets. Urea 
nitrogen concentrations for rats fed carnitine with high fat were 5.95 ± 0.22 
mmol/l at 2 weeks and 6.53 ± 0.30 mmol/l at 8 weeks. Urea nitrogen 
concentrations for rats fed no carnitine with high fat were 5.58 ± 0.22 mmol/l 
at 2 weeks and 6.01 mmol/l ± 0.31 at 8 weeks.
The difference in serum urea nitrogen concentration of rats fed high 
protein with high and low fat was greater than the difference in serum urea 
nitrogen o f rats fed low protein with high and low fat (protein*fat, p = 0.02, 
Figure 4.23). The interaction was dominated by the high protein-low protein 
effect (p < 0.0001) as rats fed high protein with low fat had higher urea
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Figure 4.22 Serum urea nitrogen levels fo r rats fed high and low fat 
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Figure 4.23 Serum urea nitrogen levels fo r rats fed high and low 
protein and fat.
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nitrogen levels than rats fed low protein with low fat. Greater urea nitrogen 
levels were observed for rats on the high protein high fat diet than for rats 
fed the low protein diet with high fat.
INSULIN
As shown in figure 4.24, rats fed the high protein diets had overall 
higher serum insulin concentrations than rats fed the low protein diets 
(protein, p = 0.03). Mean insulin values for rats fed high protein were 6.7 ± 
0.5 pU/ml (1 I.U. = 0.04167 mg international standard) at 2 weeks and 5.9 ± 
0.5 pU/ml at 8 weeks; mean insulin values for rats fed low protein at 2 and 8 
weeks were 5.4 ± 0.5 pU/ml and 4.7 ± 0.5 pU/ml. At 2 weeks, there was a 
trend for serum insulin levels to correlate (r =0.22, p = 0.1) with ammonia 
levels. By 8 weeks, there was a stronger positive correlation (r = 0.44, p = 
0.0004) between insulin and ammonia concentrations. As shown in figure 
4.25, there was a trend with time for rats fed carnitine with high protein to 
have greater serum insulin, whereas rats not fed carnitine with high protein 
had a lower serum insulin (camitine*protein*time, p = 0.07). Serum insulin 
concentrations for rats fed carnitine with low protein decreased slightly from 
2 to 8 weeks, but levels for rats not fed carnitine with low protein remained 
nearly stable. Rats who were fed the no carnitine diets with high and low fat 
had a numerically greater difference in serum insulin concentration than rats 
fed carnitine with high and low fat (camitine*fat, p = 0.15, Figure 4.26). The 
serum insulin concentration o f rats fed low fat without carnitine was 
numerically higher than the concentration for rats fed low fat with carnitine.
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Figure 4.24 Serum insulin levels for rats fed high and low protein.
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Figure 4.25 Serum insulin values for rats fed high and low protein 
with or without carnitine.
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Figure 4.26 Serum insulin levels for rats fed high and low fat with or 
without carnitine.
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But the insulin concentration o f rats fed high fa t without carnitine was 
numerically lower than levels o f rats fed carnitine with high fat. Serum 
insulin levels for rats fed carnitine with high fat decreased from 2 to 8 weeks 
(6.6 ± 0.7 pU/ml; 5.0 ± 0.7 pU/ml), but levels for rats not fed carnitine with 
high fat remained constant (4.8 ± 0.8 pU/ml; 5.0 ± 0.7 pU/ml; 
camitine*fat*time, p = 0.009). Serum insulin concentrations for rats fed the 
no carnitine low fat diets decreased from 2 to 8 weeks (7.4 ± 0.7 p(J/ml; 5.3 
± 0.7 pU/ml), whereas serum insulin concentration for rats fed the carnitine 
low fat diets increased (5.4 ± 0.7 pU/ml; 5.8 ± 0.7 pU/ml).
As shown in figure 4.27, the difference in serum insulin 
concentrations for rats on high protein diets with high and low fat was 
greater than the difference for rats fed low protein diets with high and low fat 
(protein*fat, p = 0.01). Mean insulin values for rats fed high and low protein 
with low fat were 7.8 ± 0.7 pU/ml and 5.0 ± 0.7 pU/ml at 2 weeks and 6.9 ± 
0.7pU/ml and 4.3 ± 0.7 pU/ml at 8 weeks, respectively. Rats fed high 
protein with high fat had insulin values o f 5.5 ± 0.7 pU/ml at 2 weeks and 5.0 
± 0.7 pU/ml at 8 weeks. At 2 and 8 weeks, rats fed a diet with low protein 
and high fat had insulin values o f 5.8 pU/ml ± 0.8 and 5.1 pU/ml ± 0.7, 
respectively. Rats on a high protein diet with low fat had higher insulin than 
rats on a low protein diet with low fat. Insulin values were similar for rats fed 
the low and high protein diet with high fat.
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Figure 4.27 Serum insulin levels for rats fed high and low levels o f 
protein and fat.
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NONESTERIFIED FATTY ACIDS
Serum nonesterified fatty acid concentrations were overall 
significantly lower in rats fed the high fat diets (p = 0.0004, Figure 4.28). 
Mean nonesterified fatty acid concentrations for rats fed high fat were 636.7 
± 42.7 pEq/l at 2 weeks and 628.8 ± 42.5 pEq/l at 8 weeks. For rats fed 
low fat, mean nonesterified fatty acid concentrations were 792.2 ± 43.4 pEq/l 
at 2 weeks and 820.1 ± 43.2 pEq/l at 8 weeks. There was a trend for 
nonesterified fatty acid concentrations to slightly increase or decrease from 
2 to 8 weeks for rats fed carnitine or no carnitine, respectively 
(camitine*time, p = 0.16, Figure 4.29). At 8 weeks, there was a positive 
correlation (r = 0.29, p = 0.03) between nonesterified fatty acids and 
carnitine.
ENZYME ANALYSIS
The activity o f 3-hydroxy-acyl CoA dehydrogenase was not 
statistically different for rats fed diets with (5.40 ± 0.49 pmol/g/min) or 
without carnitine (6.11 + 0.49 pmol/g/min; p = 0.3), high (5.63 ± 0.49 
pmol/g/min) or low protein (5.87 ± 0.49 pmol/g/min, p = 0.7) and high (5.86 ± 
0.49 pmol/g/min) or low fat (5.64 ± 0.49 pmol/g/min, p = 0.8). As indicated 
in Figure 4.30, there was a trend for rats fed the no carnitine diet with high 
and low protein to have a greater difference in enzyme activity than rats fed 
carnitine with high and low protein (camitine*protein, p = 0.12). Rats fed 
carnitine with high protein (5.82 ± 0.70 pmol/g/min) had numercially greater
114

































Figure 4.29 Serum nonesterified fatty acid levels for rats fed diet with 
or without carnitine.
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Figure 4.30 3-hydroxy acyl CoA (HOAD) activity for rats fed high 
and low protein with or without carnitine.
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enzyme activity than rats fed carnitine with low protein (4.97 ± 0.68 
pmol/g/min). Rats not fed carnitine with high protein had numerically lower 
enzyme activity than rats not fed carnitine with low protein, 5.44 ± 0.68 
umol/g/min and 6.77 ± 0.72 pmol/g/min, respectively.
BODY COMPOSITION
The results for body composition analysis indicated that percent fat, 
protein, moisture, and ash were not affected by the amount o f carnitine in 
the diet. As shown in figure 4.31, rats fed the carnitine and no carnitine diet 
had similar percentages fo r fat (carnitine, p = 0.2), protein (carnitine, p -  0.2) 
moisture (carnitine, p = 0.6), and ash (carnitine, p = 0.5). However, rats fed 
the high and low fat diet had significantly different percentages o f body 
protein, fat, and moisture (Figure 4.32). The percentage o f protein in the 
body o f rats fed the high fat diet, 20.3%, was significantly (fat, p -  0.05) 
lower than the percentage found in rats fed the low fat diet, 21.5%. Rats fed 
the high fat diet had a significantly higher percentage o f fa t than rats fed the 
low fat diet (24.7% vs. 16.7%; fat, p = 0.0001). The moisture content of rats 
fed the high fat diet was significantly lower than that o f rats on the low fat 
diet (54.2% vs. 59.8%; fat, p = 0.0001). There were no significant 
differences in body composition for rats fed different amounts o f protein (fat 
percent, p = 0.9; protein percent, p = 0.4; moisture percent, p = 0.4; and ash 
percent, p = 0.6). Percentages for body composition o f all eight dietary 
treatments groups are shown in Table 4.1.
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Figure 4.32 Body composition analysis for rats fed high and low fat 
diets.
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17.71 ±1.64 20.33 ± 0.84 57.75 ±1.45 4.82 ±0.30 100.61 ±1.06
CPL
(n=8)
17.10 ±1.64 21.45 ±0.84 60.96 ±1.45 4.50 ±0.30 104.00 ±1.06
CLF
(n=8)
25.69 ±1.64 19.45 ±0.84 55.24 ±1.45 4.72 ±0.30 105.10 ±1.06
CPF
(n=8)
25.20 ±1.64 20.86 ±0.84 52.91 ±1.45 4.42 ±0.30 103.39 ±1.06
NLL
(n=7)
15.72 ±1.75 22.15 ±0.89 61.40 ±1.55 4.49 ±0.33 103.76 ±1.14
NPL
(n=8)
16.12 ±1.64 22.06 ±0.84 59.03 ±1.45 4.82 ±0.30 102.04 ±1.06
NLF
(n=7)
23.04 ±1.75 20.67 ± 0.89 55.52 ±1.55 4.38 ±0.33 103.61 ±1.14
NPF 
(n—8)
24.67 ±1.64 20.12 ±0.84 53.26 ±1.45 4.15 ±0.30 102.20 ±1.06
END POINT DATA ANALYSIS
As shown in Figure 4.33, rats fed the high fat diet had a significantly 
greater final body weight (fat, p = 0.0001). Final body weights for rats fed 
the high and low fat diet were 342 ± 5 g and 304 ± 5 g, respectively. Final 
body weight was not significantly different for rats fed the diet with (323 ± 5 
g) or without carnitine (324 ± 5 g; carnitine, p = 0.95). The amount o f total 
weight gained was significantly (p = 0.0001) greater fo r rats fed the high fat 
diet. Rats fed the high fat diet had a total weight gain o f 35 ± 3 g, whereas 
rats fed the low fat diet had a total weight gain o f -2 .5  ± 3 g. Rats that were 
fed a diet high in fat had significantly (fat, p = 0.0001) more abdominal fat 
than rats fed low fat, 25.4 ± 1.1 g and 13.4 ±1.1 g, respectively. As shown 
in figure 4.34, abdominal fat was not significantly different fo r rats fed the 
carnitine diet (20.4 ± 1.1 g) than for rats not fed carnitine (18.4 ± 1.2 g, p -  
0.2). But there was a trend (p = 0.08) for rats fed carnitine to have a greater 
amount of abdominal fat as percent o f body weight when compared to rats 
not fed carnitine, 6.2 ± 0.3% and 5.5 ± 0.3%, respectively (Figure 4.35).
Final body weight was positively correlated with total weight gain (r -  0.78, 
p = 0.0001), abdominal fa t (r = 0.9, p = 0.0001) and percent fat in body 
composition analysis (r = 0.8, p -  0.0001). Abdominal fa t was also 
significantly correlated (r=0.9, p=0.0001) with percent fat in body 
composition.
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Figure 4.33 Final body weight for rats fed high and low fat diets.




Figure 4.34 Abdominal fat for rats fed diet with or without carnitine.
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Figure 4.35 Abdominal fat as percent o f body weight for rats fed diet 
with or without carnitine
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ORAL GLUCOSE TOLERANCE TEST
During the oral glucose tolerance test, rats fed the high protein diet 
had overall numerically greater glucose concentrations (protein, p = 0.18).
At 0 minutes, rats fed high and low protein had a glucose concentration of 
10.59 ± 0.36 mmol/l and 10.68 ± 0.36 mmol/l, respectively. Glucose 
concentration at 120 minutes was 15.83 ± 0.66 mmol/l for rats fed high 
protein and 14.06 ± 0.64 mmol/l for rats fed low protein. Rats on the high fat 
diet had overall greater serum glucose concentrations than rats fed the low 
fat diet (fat, p = 0.0001). Glucose concentration at 0 minutes was 10.43 ± 
0.35 mmol/l for rats fed high fat and 10.83 ± 0.37 mmol/l for rats fed low fat. 
At 120 minutes, the glucose concentration of rats fed high and low fat was 
16.80 ± 0.63 mmol/l and 13.09 ± 0.67 mmol/l, respectively. As shown in 
Table 4.2, rats on all eight dietary treatment groups experienced an increase 
in glucose levels 120 minutes after administration o f the glucose solution 
(time, p = 0.0001). At this point, rats on the high fat and high protein diets 
experienced a significantly greater increase in serum glucose concentrations 
than rats fed the low fat and low protein diets, fat*time, p = 0.01, and 
protein*time, p = 0.03, respectively (figures 4.36 and 4.37).
There was a trend for insulin levels to be greater at both 0 and 120 
minutes for rats fed the high protein diet (protein, p = 0.06, Figure 4.37). 
Insulin levels for rats fed the high protein diet were 5.6 ± 0.6 pU/ml at 0 
minutes and 4.3 ± 0.3 pU/ml at 120 minutes.
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 4.2. Serum glucose evels for oral glucose tolerance test.
Dietary Treatment Glucose -  O min. 
(mmol/L ± SE)
Glucose - 120 min. I 
(mmol/L ± SE)
CLL 10.45 ±0.68 12.85 ± 1.24
CPL 11.07 ±0.79 14.73 ± 1.43
CLF 9.74 ± 0.68 14.95 ± 1.24
CPF 10.33 ±0.73 17.71 ± 1.32
NLL 11.49 ±0.79 11.67 ± 1.43
NPL 10.32 ±0.68 13.11 ± 1.24
N L F 11.03 ± 0.68 16.78 ± 1.24
NPF 10.63 ±0.68 17.76 ± 1.24
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Figure 4.36 Serum glucose and insulin levels for rats fed high (A) and 
low fat (B) diets before (0 min) and after (120 min) 
glucose administration.
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Figure 4.37 Serum glucose and insulin levels for rats fed high (A) and 
low protein (B) before (0 min) and after (120 min) glucose 
administration.
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Rats fed the low protein diet had insulin levels o f 4.3 ± 03 pU/ml and 3.8 ± 
0.3 pU/ml at 0 and 120 minutes, respectively. As shown in figure 4.38, there 
was a greater difference in insulin concentrations for rats fed high and low 
protein with carnitine than for rats fed high and low protein with no carnitine 
(camitine*protein, p = 0.02). At 0 and 120 minutes, rats fed the high protein 
diet with carnitine (6.4 ± 0.8 pU/ml and 4.7 ± 0.5 pU/ml) had greater serum 
insulin concentrations than rats fed the low protein diet with carnitine (3.5 ± 
0.8 pU/ml and 3.3 ± 0.5 pU/ml). But serum insulin concentrations for rats 
not fed carnitine with high protein (4.9 ± 0.8 pU/ml and 3.9 ± 0.5 pU/ml) were 
lower than levels for rats not fed carnitine with low protein (5.1 ± 0.9 p U/ml 
and 4.2 ± 0.5 pU/ml).
As shown in figure 4.36, serum insulin concentrations for rats on the 
low fat diet decreased significantly over time (fat'tim e, p = 0.005). Rats fed 
the high fat diet had serum insulin concentrations of 4.4 ± 0.6 pU/ml and 4.8 
± 0.3 pU/ml at 0 and 120 minutes, respectively. At 0 and 120 minutes, rats 
fed the low fat diet had serum insulin concentrations of 5.5 ± 0.6 pU/ml and 
3.3 ± 0.3 pU/ml. Serum insulin concentrations for rats fed high and low 
protein with different amounts o f fat are shown in figure 4.39. At 0 and 120 
minutes, serum insulin concentrations for rats fed high protein with high fat 
were 4.4 ± 0.8 pU/ml and 5.3 ± 0.5 p ll/m l and for rats fed high protein with 
low fat concentrations were 6.9 ± 0.8 pU/ml and 3.3 ± 0.5 pU/ml. Rats fed 
low protein with high fat had serum insulin concentrations of 4.4 ± 0.8 pU/ml 
at 0 minutes and 4.2 ± 0.5 pU/ml at 120 minutes. Rats fed low protein with
127




















































Figure 4.38. Serum glucose and insulin levels for rats fed high and low 
protein with or without carnitine before (0 min) and after (120 min) glucose 
administration; A=Cam Hi Pro, B-Cam  Lo Pro, C=No Cam Hi Pro, D=No 
Cam Lo Pro
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Figure 4.39 Serum glucose and insulin levels for rats fed high and low 
protein and fat before (0 min) and after (120 min) glucose administration; 
A= Hi Pro Hi Fat, B=Hi Pro Lo Fat, C= Lo Pro Hi Fat, D= Lo Pro Lo Fat
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low fat had serum insulin concentrations o f 4.1 ± 0.9 pU/ml and 3.3 ± 0.5 
pU/ml at 0 and 120 minutes, respectively. With time, the difference in insulin 
levels for rats fed the high protein diet with high and low fat was greater than 
that o f rats fed the low protein diets with high and low fat (protein*fat*time, p
= 0.03).
130
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CHAPTER FIVE 
DISCUSSION
We investigated the effects o f supplemental dietary carnitine on rats 
fed high and low protein and fat diets. The study was conducted because of 
reported benefits o f carnitine. We hypothesized that carnitine would protect 
rats from the negative effects of high ammonia and reduce obesity caused 
by a high fat diet.
Previous studies have been performed using ammonium infusions 
rather than high dietary protein. These studies have been conducted to look 
at the changes in ammonia concentrations and the symptoms that 
accompany these changes during liver failure. Patients with acute or 
chronic liver disease may experience an increase in levels o f ammonia in 
the blood and brain. This can lead to the development o f hepatic 
encephalopathy, a complex neuropsychiatric disorder. High levels of blood 
ammonia during hepatic encephalopathy will eventually lead to stupor and 
coma (Schlienger et al. 1975). Although it is unlikely that consumption of a 
high protein diet will cause these serious complications it is not known if 
prolonged consumption of a high protein diet may lead to high enough levels 
of ammonia in the blood, which could potentially increase the levels in the 
brain. Today many athletes consume a high protein diet that is also 
supplemented with protein and amino acids and many people are now 
following high protein weight loss diets. Therefore, we fe lt it was important
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to determine if carnitine has a protective effect when a high protein diet is 
consumed.
Although carnitine has been shown effective in increasing lean mass 
and decreasing fat conflicting results from previous reports made us 
uncertain o f the effects o f carnitine on glucose and insulin metabolism. We 
had hypothesized that carnitine would decrease weight gain by causing an 
increase in fat oxidation and that the increase in fat oxidation would lead to a 
decrease in glucose induced insulin secretion. An increase in fat oxidation 
has been proposed to lead to diabetes (Barnett et al. 1996, Randle et al. 
1963).
In addition, supplementation w ith carnitine has been shown to 
increase lean mass and decrease body fat leading to lower weight gain in 
younger animals. Since studies with carnitine are rarely conducted with 
older animals we wanted to determine if carnitine’s effects on body 
composition would be the same as those observed in younger animals.
In our study, we found a tendency for carnitine to lower ammonia two 
weeks into the study leading to a beneficial effect on glucose metabolism, 
but we observed no effect o f carnitine on fa t oxidation, body fat, or lean 
mass. In fact, we observed a tendency towards obesity in carnitine fed rats 
at the point o f sacrifice at eight weeks with dietary carnitine. This greater 
body fat many have been responsible for the changes we observed in the 
response o f glucose to insulin between two and eight weeks.
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Schlienger and Imler (1978) found that blood ammonia levels o f rats 
increase rapidly when an endogenous hyperammonemic state is produced 
via a portal stricture. At 2 weeks, the blood ammonia concentration 
observed in rats in our study who consumed high protein (135 pmol/l) was 
higher than that o f the hyperammonemic rat model created by Schlienger 
and Imler (1978) via a portal stricture (127 pmol/l). Two weeks into the 
study rats consuming high protein had already increased ammonia levels, 
but by 8 weeks (the second ammonia measurement) rats were able to adapt 
to the higher protein intake with lower ammonia levels. The decrease in 
ammonia levels observed at 8 weeks for rats fed high protein was 
accompanied by a significant increase in serum urea nitrogen levels. 
Therefore, rats seem to have compensated by increasing the production of 
urea, possibly by synthesizing more enzymes and intermediates needed in 
the urea cycle. Although there are no reports indicating that consumption of 
high protein can greatly increase blood levels o f ammonia our results 
demonstrate that this occurs, at least initially. Thus, the possibility exists 
that in humans short term consumption o f a high protein diet can lead to 
increased ammonia concentrations. Consumption o f a high protein diet is 
expected to increase the urea production rate (Forslund et al. 1998). 
Although these levels of ammonia are probably not high enough to cause 
toxicity, they may lead to a disruption in the metabolism of other nutrients.
As reported by Schlienger et al. (1975) high levels o f ammonia inhibit the 
release o f insulin from the pancreas and thus decrease glucose oxidation.
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In addition, the length o f the adaptive process in rats and humans needs to 
be determined. This process may be longer than the 2 week period 
observed in our rats, since our next measurement was at 8 weeks. Thus 
blood ammonia levels may remain elevated for several weeks.
Previous studies conducted to look at the effects o f carnitine in the 
treatment o f ammonia toxicity have used either an intraperitoneai injection of 
ammonium acetate or a portacaval shunt to induce a hyperammonemic 
condition. O’Connor et al. (1984) and Hearn et al. (1989) observed, under 
these types of conditions, a protective effect o f carnitine at lethal doses of 
ammonia in mice. The protective effect observed by Hearn et al. (1989) was 
short-lived, with protection being maximal only when carnitine was given 1 
hour prior to an ammonium acetate injection. Carnitine given 24 hours prior 
to the injection no longer had a protective effect. Contrary to these findings, 
Deshmuk & Rusk (1988) and Therrien et al. (1997) found that carnitine had 
no effect on blood levels o f ammonia. The lack of a beneficial effect of 
carnitine observed by Deshmuk & Rusk (1988) may have been due to the 
higher lethal dose o f ammonium acetate used in their study. Rats in our 
study were rendered hyperammonemic via a method that is less invasive 
and can be induced by consumption of a high protein diet. Therefore, the 
results of our study have more applicability to human studies that will 
examine the effects o f carnitine supplementation on the treatment o f 
conditions, such as insulin resistance, that may be induced by changes in 
dietary protein and fat levels. As hypothesized, dietary carnitine did
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decrease serum ammonia levels o f rats fed high protein, but because the 
rats were able to adapt to the high protein diet they did not need the 
supplemental carnitine by 8 weeks, making the protective effect o f carnitine 
limited to a few weeks.
Rats in our study who were fed high protein did compensate by 
increasing urea nitrogen levels by 8 weeks or possibly earlier, but urea 
synthesis was not greater when carnitine was added to the high protein diet. 
Contrary to what we had hypothesized, the benefits of carnitine were not 
due to its ability to enhance urea nitrogen synthesis as measured by blood 
urea nitrogen levels. These results are also supported by those o f O'Connor 
et al. (1984) who observed sim ilar urea nitrogen levels for mice given saline 
or carnitine after an intraperitoneal ammonium acetate injection. However, 
urinary nitrogen was not measured in our study or that o f O’Connor et al. 
(1984) so increases in urea nitrogen formation may have lead to shunting 
any increased urea nitrogen to the urine. It is important to mention that in 
our study rats fed the diet high in fat and protein with carnitine had 
numerically greater urea nitrogen concentrations than rats fed the diet high 
in fat and protein without carnitine. Therefore, the possibility exists that the 
effects o f carnitine on urea nitrogen concentration for rats fed high protein 
were masked by the presence o f high or low levels o f fat. Contrary to our 
findings and those o f O’Connor et al. (1984), the results of Costell et al. 
(1984) showed that mice given carnitine after an ammonium acetate 
injection had a higher synthesis of blood urea nitrogen, but the mechanism
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responsible for this increase was not elucidated. Use o f an ammonium 
acetate injection probably resulted in a faster increase in blood ammonia 
levels and a greater need for the production o f urea, thereby causing the 
body’s requirement for carnitine to be increased.
We conclude that carnitine seems to protect the rats from developing 
elevated ammonia which may be necessary until they are capable of 
adapting to the high protein load. However, more studies are needed to 
determine the mechanism responsible for this decrease. It is possible that 
the mechanism for this protective effect involves increased urinary excretion 
o f urea, but we did not measure these levels in our study. Previous 
research has also suggested that the protective effect o f carnitine on 
ammonia levels could be due to: enhanced use o f ammonia, via glutamate 
dehydrogenase, for the formation of glutamate (O’Connor et al.1984), 
decreased cerebrospinal fluid ammonia (Therrien et al.1997) or by 
preferential activation of glutamate receptors (i.e., quisqualate) in the brain 
which prevents the increase in cystolic calcium levels and the cell death 
accompanied by this increase (Felipo et al.1994).
Animal and human studies evaluating the indirect effects o f carnitine 
on glucose and insulin metabolism have been relatively short, ranging from 
2 to 24 hours. These studies have not looked at the effects o f carnitine on 
glucose metabolism when a diet high in either protein or fat or both high 
protein and high fat is consumed. Americans consuming the typical 
Western diet tend to eat high amounts o f both o f these macronutrients.
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Body builders and other athletes eat lower fat but often supplement their 
high protein diet with a protein or amino acid supplement. Rats in our study 
were maintained on either a high fat or a high protein diet or both high 
protein and fat for an 8 week period, thus making it more plausible to study 
these indirect effects and making the results more generalizable to humans 
consuming a Western type diet and to athletes. We had hypothesized that 
inclusion of dietary carnitine would enhance fatty acid oxidation and 
decrease the oxidation o f glucose and the secretion of insulin. Increased fat 
oxidation leads to a decrease in glucose intermediates, which are needed 
for insulin to be released. The hypothesis was based on previous research 
and studies that indicated that inclusion of supplemental dietary carnitine 
would lead to enhanced fatty acid oxidation in younger animals (Shimura & 
Hasegawa, 1993, Rabie & Szilagyi, 1998). According to the Randle 
hypothesis (Randle et al. 1963) the increase in fatty acid oxidation could 
interfere with the uptake and metabolism of glucose in muscles, resulting in 
glucose intolerance and insulin insensitivity. In our study, we did not 
observe an increase in fat oxidation at 8 weeks with dietary carnitine added 
to the diet. Thus, we can assume that the main indirect effect o f carnitine on 
glucose metabolism observed in our study was due to its function in protein 
metabolism. Contrary to what we had hypothesized, inclusion o f dietary 
carnitine to the high protein diets initially did decrease glucose induced 
insulin secretion, but with time there was a tendency for carnitine to increase 
the secretion o f insulin.
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After 2 weeks of consumption o f the high protein diet, rats had higher 
glucose and insulin concentrations, with the increased glucose 
concentration associated with high ammonia levels. According to the results 
o f the study conducted by Schlienger et al.(1975) the hyperammonemic 
state observed in our rats at 2 weeks could have led to higher epinephrine 
levels limiting insulin secretion and glucose utilization, thus increasing blood 
glucose levels. Although we observed higher insulin levels for rats fed high 
protein it is possible that insulin function was blunted by high ammonia and 
the amount o f insulin released was insufficient to handle the amount of 
glucose present in the blood. Alternatively, the rats fed high protein may 
have been less sensitive to the insulin secreted compared to low protein fed 
rats.
Glucose levels were lower at 2 weeks if the high protein diet was 
supplemented with carnitine and there was a tendency for the insulin levels 
o f these rats to be lower. This supports our latter hypothesis on insulin 
insensitivity with high ammonia caused by feeding of the high protein diet. 
These results are also in agreement with those of o f Mingrone et al.(1999), 
Grandi et al.(1997), and Paulson et al.(1984) who observed a decrease in 
glucose levels in diabetic humans or diabetic rats that were treated with 
carnitine. The decrease in blood glucose and insulin levels observed in our 
study and in the one conducted by Grandi et al.(1997) was transient, 
indicating that the beneficial effect o f carnitine could be short-lived. Contrary 
to these findings, other researchers have reported that compounds that
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inhibit carnitine paimitoyi transferase I have a glucose lowering effect in 
diabetic rats or rats genetically predisposed to develop NIDDM (Barnett et 
al.1996, Barnett et al.1992, Martin et al.1991).
Glucose levels decreased for rats fed high protein so that by 8 weeks 
levels were sim ilar to those o f rats fed low protein. Because rats fed high 
protein had completely adapted to the higher protein load, the levels of 
ammonia were no longer different than levels o f rats fed low protein, thus 
making their glucose levels sim ilar and eliminating the effect o f carnitine on 
blood glucose levels. Rats fed high protein diets still had higher insulin 
levels when compared to rats fed low protein diets at 8 weeks, but levels 
were lower than at 2 weeks. Presence o f dietary carnitine caused an 
increase, by 8 weeks, in the levels o f insulin for rats consuming the high 
protein diet, reaching levels that were higher than all other groups.
Two weeks into the study, levels o f glucose and insulin of rats fed 
high protein with carnitine were lower than levels for rats fed high protein 
without carnitine. Therefore, at this time carnitine seemed to make rats fed 
high protein more insulin sensitive. Mingrone et al. (1999) also found that 
an L-camitine infusion led to an improvement in insulin sensitivity and whole 
body insulin mediated glucose uptake in diabetic and normal subjects, 
respectively. This effect of carnitine was attributed to its ability to decrease 
plasma lactate levels thereby increasing the activity o f pyruvate 
dehydrogenase. Because we did not measure the level o f lactate or the 
activity o f this enzyme we cannot conclude that the effect o f carnitine
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observed in our study was due to these changes. Grandi et al. (1997) also 
observed a transient effect on insulin secretion with an acute administration 
of carnitine that led to lower blood glucose levels. The assumption was 
made that carnitine increased pyruvate dehydrogenase activity and this lead 
to improved peripheral glucose utilization. In our study, the indirect effect of 
carnitine on glucose metabolism was most probably due to its early 
protective effect on blood ammonia levels. Sometime after 2 weeks, it 
seems that carnitine is no longer needed to improve the hyperammonemic 
conditions created by the high protein load, thus making carnitine more 
available to perform other metabolic functions (i.e., enhance fat oxidation). 
Therefore, addition o f carnitine to the high protein diet did not result in lower 
glucose levels at 8 weeks, but insulin levels for these rats were greater than 
those observed at 2 weeks. Higher insulin levels for these rats may be 
indicative of a transition, from a condition o f normal glucose tolerance with 
insulin sensitive tissues to one o f impaired glucose tolerance and less 
insulin sensitive tissues. This is supported by the tendency towards obesity 
observed at the end o f the study in rats fed carnitine. Because we only took 
measurements at 2 and 8 weeks, we cannot determine when carnitine 
started to have a negative effect on insulin and glucose metabolism. Future 
studies are needed to determine the period at which supplementing high 
protein diets with carnitine will cause a tendency towards a decrease in 
insulin sensitivity.
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We conclude that despite carnitine’s ability to initially decrease the 
glucose and insulin levels of rats fed high protein, our results seem to 
indicate not only that the benefit is short-lived but that with time rats 
consuming carnitine become less insulin sensitive. The decrease in insulin 
sensitivity can lead to lower glucose disposal rates and thus higher glucose 
levels in the blood. Furthermore, if the decrease in insulin sensitivity leads 
to impaired glucose tolerance and to the development o f insulin resistance 
and increased serum insulin, there will be a greater tendency for increased 
fat mass and body weight.
The measurement o f insulin and glucose during an oral glucose 
tolerance test has been previously used to evaluate the degree of insulin 
sensitivity and determine the state o f impaired glucose tolerance (Phillips et 
al.1994). Studies looking at the effects o f diet on insulin secretion and 
sensitivity seem to indicate that consumption o f high fat causes obesity 
which may eventually lead to the development o f NIDDM (Pi-Suyner, 1993). 
It has been shown that after only 2 weeks, rats fed high fat developed insulin 
resistance (Barnard et al.1998). Feeding a high sucrose diet to rats also 
seemed to result in the development o f insulin resistance (Reaven et 
al.1983). In our study, we originally wanted to conduct an oral glucose 
tolerance test to determine if rats fed high fat with or without carnitine were 
less insulin sensitive. A previous study conducted in rats observed that 
blood glucose levels started to decline between two and two and half hours, 
but that insulin levels had already returned to levels observed at baseline
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(unpublished data, personal communication with Boudreaux, M). To avoid 
interfering with measurements taken during week 8 we decided to conduct 
the oral glucose tolerance test during week 5. In addition, because multiple 
blood measurements from the orbital sinus are hard to obtain we did not 
want to cause problems with the animals, which may affect their 
participation for the remainder o f the study. Therefore, we decided to 
determine if two hours after a glucose challenge, glucose levels for rats fed 
high fat took longer to decline when compared to levels o f rats fed low fat 
and if carnitine would decrease insulin sensitivity. But use o f this time frame 
did not allow us to determine at what time point glucose levels increased. In 
addition, the biphasic insulin response curve could not be determined. 
Therefore, we feel that we cannot make conclusions about the state of 
insulin resistance based on the results from our oral glucose tolerance test, 
but can make general statements about differences in glucose metabolism 
observed for the various dietary treatments.
Two hours after the glucose load, glucose levels for rats fed high fat 
and high protein were higher than levels for rats fed low fat and low protein. 
The higher glucose levels observed for rats fed high fat with high or low 
protein indicates that it is the fat content o f the diet that is causing the 
glucose levels to be higher. Addition o f carnitine to the high protein diets 
resulted in higher glucose levels two hours after the glucose load. This 
effect o f carnitine was not observed when rats were fed low protein. It is 
possible that at the time of the oral glucose tolerance test (week 5) carnitine
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was no longer having the beneficial effect o f lowering glucose levels, instead 
carnitine seemed to be causing an increase in glucose levels for rats fed 
high protein. More research needs to be done to determine the change in 
glucose metabolism during carnitine supplementation when a diet high in 
protein and/or protein supplements is consumed.
Animal nutritionists are supplementing the feed of young animals with 
carnitine to try to reduce their lipid accretion rate and improve their growth 
performance. Contrary to what we hypothesized, our results seem to 
indicate that dietary carnitine does not enhance fatty acid oxidation or 
decrease weight gain or fat gain in older rats. If older rats are similar to 
adult humans the use of carnitine by adult humans, such as athletes and 
obese people who wish to improve their body composition, may need to be 
further evaluated before carnitine can be recommended as a dietary 
supplement. This may apply only to adult humans but a study with high 
protein and younger rats is necessary before we can conclusively state this.
Previous research has indicated that addition o f carnitine to the diet 
o f young growing animals will enhance fatty acid oxidation (Rabie & Szilagyi, 
1999, Owens et al.1996, Shimura & Hasegawa, 1993), but we did not 
observe an increase in the enzyme activity o f HOAD for our older retired 
breeder rats who were fed carnitine. In addition, higher non esterified fatty 
acid levels observed at 8 weeks for rats fed carnitine supports this enzyme 
results that carnitine does not increase fat oxidation. This is also supported 
by the numerically greater abdominal fat, and total body fat o f older rats fed
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carnitine. The increased fa t oxidation with carnitine treatment observed in 
younger animals could be because o f an interaction with the higher energy 
requirement and changes in body composition that are experienced during 
periods of growth.
In our study, rats that were fed carnitine had a greater numerical 
amount of total abdominal fa t (p = 0.2) and abdominal fat as percent o f body 
weight (p = 0.08) than those that were not fed carnitine. Regardless o f the 
amount of fat (low or high levels) being consumed, carnitine seemed to 
increase the percentage o f total body fat in the carcass leading to fatter rats, 
but there was no decrease or increase in final body weight (p = 0.9) or total 
weight gain (p = 0.8). The increase in body fat observed with no change in 
body weight was offset by a numerically lower protein content (p = 0.2) of 
carcasses from rats that were fed carnitine.
Contrary to our findings, Shimura & Hasegawa (1993) observed a 
tendency for the weight o f body fat to decrease for 4 week old rats fed high 
fat with carnitine. Previous rat studies have demonstrated that after 2 weeks 
rats can compensate for increased energy density by decreasing the 
amount of food consumed. Our study results support those of Roy et al. 
1999 (unpublished manuscript) and Peterson & Baumgardt (1971) and 
strengthen the hypothesis that rats can adapt to changes in the energy 
density of the diet. Despite the fact that rats fed high fat in our study 
compensated by decreasing food intake, final body weight, abdominal fat, 
total body fat, and weight gain were greater at the end of the study. Thus,
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one can speculate that consumption o f a high fat high-energy dense diet can 
lead to increased body weight and fat before the compensation changes 
occur. Reversal o f dietary-induced obesity is the not the norm in humans, 
but this has been observed when the diet is replaced with a low fat low 
energy dense one combined with physical activity (Shick et al.1998. Bell et 
al.1995). Because at the time the study was designed we were unaware 
that rats can adapt to changes in the energy density o f the diets, rats in our 
study were not pair-fed. We did not pair-feed the rats on the low fat diet with 
carnitine with intake of rats fed high fat with carnitine. The lower food intake 
observed after 2 weeks for rats fed high fat resulted in less carnitine being 
consumed (p = 0.0001). Therefore, rats consuming the high fat diet with 
carnitine may have not obtained the additional amount o f carnitine needed 
to oxidize the excess fat. Had we pair-fed the low fat rats with the amount of 
diet for rats fed high fat then carnitine would have been the same, but it is 
possible that this equalization would not have been high enough to cause 
changes in fat oxidation for rats fed high fat.
Similar to our findings, Shimura and Hasegawa (1993) observed no 
effect of carnitine on body weight, but Rabie and Szilagyi (1999) observed a 
higher weight gain when carnitine was added to the diets o f broiler chickens. 
The greater body weight gain reported by Rabie and Szilagyi (1999) was 
attributed to an increase in lean mass that may have been achieved through 
more efficient fat oxidation and improved utilization of dietary nitrogen. In 
our study, inclusion of dietary carnitine did not result in a greater percentage
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of the carcass composition from protein indicating that there was no 
increase in the amount o f lean mass o f the rats. By increasing the ratio of 
acetylCoA:CoA-SH, carnitine seems to increase the supply o f carbon and 
branched chain a-keto acids for synthesis o f non essential and branched 
chain amino acids. Our results in older animals do not support this 
occurrence.
Results, sim ilar to those o f Rabie and Szilagyi (1999) o f carnitine on 
body composition (i.e. decreased lipid content and increased protein) were 
reported in juvenile salmon (Ji et al.1996) and young pigs (Owens et 
al.1996). These same effects were observed by Gross et al. (1998) in adult 
obese beagle dogs. According to the results o f these studies, the effects of 
carnitine on body composition seem to be limited to younger growing 
animals, with the exception o f the study conducted in adult dogs. Gross et 
al. (1998) observed a beneficial effect of carnitine on body composition of 
older animals, but unlike our older rats the dogs were consuming a high fiber 
low calorie diet. Thus, it is possible that for carnitine to be beneficial in older 
animals the type of diet consumed should not be high in fat or protein and/or 
the level of physical activity needs to be increased. The results o f the study 
conducted in athletes by Gatti et al. (1998) seem to support the latter point.
In well-trained athletes the observed increment in fat free mass was 
associated with a metabolic muscle improvement due to higher levels of 
carnitine in the tissue.
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Rats in our study were fed either a diet high in fat or protein or both. 
According to a study conducted in rats by Mifiana et al. (1989) a 
hyperammonemic state can lead to a decrease in the lipid content and an 
increase in protein content o f the carcass, which can be due to an increase 
in blood levels o f long-chain acylcamitine. Higher levels of long-chain 
acylcamitine seemed to have resulted in an increase in transport o f long- 
chain fatty acids for oxidation. Although we only measured total serum 
carnitine, rats in our study who were fed high protein had lower total 
carnitine concentrations at 2 and 8 weeks, and thus it is unlikely that levels 
o f long-chain acylcamitine were higher at 2 weeks when our rats were 
hyperammonemic. Therefore, we would not expect that the rats fed high 
protein without carnitine experienced a decrease in their lipid content and an 
increase in their protein content due to hyperammonemia. Thereby, 
eliminating the possibility that no effect o f carnitine on fat oxidation was 
observed because of changes in body composition that could have resulted 
from the condition of hyperammonemia.
We hypothesized that feeding a high fat diet would promote the 
synthesis o f endogenous carnitine. Because of carnitine’s function in fat 
metabolism, one could speculate that higher amounts o f carnitine are 
needed to handle the excess fat. Contrary to what we had hypothesized, 
rats fed high fat had lower total serum carnitine concentrations, at 2 and 8 
weeks, than rats fed low fat. It is possible that the tissue requirement for 
carnitine for rats fed high fat was higher, thus causing a decrease in the total
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serum carnitine concentration. Our results are in agreement with those of 
Seccombe et al. (1978) who observed that total and free serum carnitine 
concentrations were lower in rats fed high fat when compared to rats fed a 
high carbohydrate diet. In the study conducted by Cederbald (1987) healthy 
males had an increase in the levels o f free carnitine in plasma after 
consumption o f a high fat diet (54% of energy). The percentage o f energy 
coming from fat was sim ilar to what we used in our study (58%), but we did 
not measure free carnitine levels. Thus, making it hard to compare our 
results to those of Cederbald (1987).
Consumption o f a high fat diet may have led to increased 
endogenous synthesis of carnitine, but if the tissue demand fo r carnitine 
increases, the levels o f serum carnitine may actually decrease. In our study, 
the lack o f an effect of carnitine on fat oxidation as measured by HOAD, 
amount o f abdominal and total fat, and weight gain indicates that the tissue 
demand for carnitine was probably not higher. Unfortunately, Seccombe et 
al. (1978) did not measure rates o f fatty acid oxidation, thus making it hard 
to determine if the tissue requirement for their rats was increased when the 
high fat diet was consumed. An alternative explanation may be that the 
lower total blood serum carnitine for rats fed high fat was due to the lower 
food intake observed for these rats. We conclude that synthesis o f carnitine 
is not always enhanced due to consumption o f a high fat diet.
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CONCLUSIONS
In our study, we tested whether carnitine would protect older rats 
from high ammonia and reduce weight gain for rats fed high protein and/or 
high fat. The beneficial effect o f carnitine on ammonia was evident at two 
weeks but not at eight weeks, and instead o f observing the expected 
decrease in weight gain, we observed opposite effects, a tendency towards 
weight gain.
In our study, we used older rats as an animal model because the 
changes in weight and macronutrient metabolism observed in these rats are 
also frequently seen in older humans. People consuming a high protein diet 
may initially benefit if they supplement their diets with carnitine. The initial 
decrease in ammonia levels may help prevent the development of 
hyperammonemia and future abnormalities in glucose and insulin 
metabolism, but further rat studies and then human studies are needed to 
determine the period for which carnitine supplementation may be beneficial. 
Our results suggest that the benefit of carnitine on glucose and insulin 
metabolism for people consuming a high protein diet will probably be short 
lived. An athlete consuming a diet high in protein that is supplemented with 
carnitine for long periods may become less insulin sensitive and gain weight. 
The increase in body weight will be accompanied by greater accumulation of 
fat and a decrease in lean mass. Furthermore, use o f supplemental 
carnitine by people with NIOOM (type II diabetes) may worsen the condition 
o f insulin resistance and lead to greater weight gain. The recommendation
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for people who are diabetic or consuming high protein diets that want to use 
carnitine as a supplement would be to use it on a short-term basis and/or 
cycle its use. The worldwide increase in the prevalence o f obesity is 
alarming. Therefore, to avoid future weight problems we recommend that 
studies be conducted before carnitine is added to the long list o f alternative 
weight treatment options (i.e. instead of prevention).
Over the years many measures have been adapted to promote 
weight loss. These include fat free products and/or supplements. In the 
past several years consumption o f low fat and fat-free products has 
increased in the United States, but the incidence o f obesity is on the rise. 
Consumption o f these products by many Americans who are trying to lose 
weight, has not proven to be the magic solution many were hoping for. 
Achieving a healthy weight and weight maintenance requires a combination 
of different approaches. Carnitine is promoted by companies as a weight 
loss agent. More animal and human studies are required to determine if 
carnitine can be used as an alternative approach for weight loss.
Older people who are obese and want to use supplemental carnitine 
as a weight loss aid may need to also consume a diet that is low in calories 
and not high in fat or protein. It may be possible that carnitine can help 
reduce body fat and increase lean mass in older people if a well balanced 
diet is consumed. Consumption of a high fat diet may not always lead to 
increased endogenous synthesis o f carnitine. An additional exogenous 
source of carnitine on this type o f diet may not be necessary because a high
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fat diet is probably already high in animal products, which contain ample 
amounts o f carnitine.
LIMITATIONS
In addition to the oral glucose tolerance test conducted at five weeks, 
inclusion o f analysis o f other biological parameters at this same time point, 
such as serum ammonia and urea nitrogen, may have provided a clearer 
representation o f the changes that were taking place during the middle of 
the study. This would have made the interpretation o f the results obtained 
by week eight clearer. Furthermore, to obtain adequate information about 
changes in insulin sensitivity, glucose and insulin measurements would have 
to be made at 0, 30, 60, 90 and 120 minutes after the glucose load. Our 
single time point only allowed us to determine for which dietary group did 
serum glucose decrease faster or slower two hours after the glucose load.
Measurement o f enzymes in the glycolytic pathway would have 
provided a better understanding o f the effects o f carnitine on glucose 
metabolism. It has been speculated that carnitine increases glycolysis by 
enhancing the activity o f pyruvate dehydrogenase. Measuring the levels of 
that enzyme at two and eight weeks could have supported our conclusion 
that carnitine’s beneficial effect on glucose and insulin metabolism is short 
lived and no longer present at eight weeks.
To determine if increased urea in the urine is the mechanism by 
which carnitine lowers the levels o f ammonia, metabolic cages for housing
151
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
rats for collection of urine during the study could have been used. The urine 
collected could have been analyzed for levels o f urinary urea nitrogen. 
FUTURE STUDIES
The major question raised by our study is if carnitine use is 
appropriate for older animals and humans. Carnitine supplement use may 
be beneficial in the short term, several weeks, but nonbeneficial if used for 
many weeks at a time. Future studies are required that frequently measure 
the effect o f carnitine during consumption of a high protein diet and obesity 
for several weeks. These studies then need to be continued on a long-term 
basis to observe possible significant obesity indicators (i.e., a continuos 
increase in body fat and weight). Animal studies can initially be used to 
determine the long-term effects o f carnitine. The results o f these 
investigations can then be used to develop studies to examine these effects 
o f carnitine in humans.
To delineate differences o f carnitine as a supplement for older and 
younger animals consuming high protein diets, a study looking at the effects 
of carnitine on younger and older animals consuming this type of diet is 
needed. Our results seem to indicate that prolonged used of supplemental 
carnitine may make older rats more obese and thus less insulin sensitive. 
Therefore, comparing the effects o f carnitine on younger and older animals 
may help establish at what age carnitine supplementation may be beneficial. 
The key factor may be that carnitine interacts with the growth process to 
enhance lean mass.
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Future studies addressing the mechanism for the protective effect of 
carnitine on ammonia levels need to be conducted. A comprehensive study 
needs to be conducted where urea levels in the blood and urine, ammonia 
levels in the brain and blood, enzymes involved in the urea cycle, and levels 
of amino acids are measured. This type of study can also be used to 
determine if consumption o f a high protein diet in humans can lead to 
increased levels o f ammonia in the blood and brain and if so the length of 
time required for this to happen.
A long-term human study that looks at the effects o f carnitine on 
glucose and insulin metabolism where the type of diet consumed is 
recorded, glucose and insulin levels are measured, and amount o f physical 
activity is recorded needs to be conducted. This type o f study would provide 
answers to some of the questions that were raised in our study.
Furthermore, this type of study would indicate whether or not carnitine 
should be used in the treatment for diabetes.
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DIET PREPARATION
To prepare the basic AIN-93M diet the macronutrients were weighed 
and added to a large mixing bowl. These ingredients were then mixed for 
10 minutes at low speed and then mixed again for 5 minutes (the bowl was 
scraped down between mixes). The micronutrients were sieved sequentially 
into a large bowl. Any crystals left were ground up with a mortar and pestle 
and added to the mixture. The ingredients were then mixed by hand until a 
uniform distribution was obtained. The micronutrients were added to the 
large mixing bowl and combined with the macronutrients. The 
macronutrients and micronutrients were mixed for 10 minutes, the bowl was 
scraped down and then the ingredients were mixed for another 5 minutes. 
The soybean oil was added to this mixture and mixed for 10 minutes, 
scraped down, and mixed for another 5 minutes. The diet was then stored 
frozen in either Rubbermaid containers or in Ziploc bags. Each was labeled 
with the diet type, date, batch number and initials o fthe  person who 
prepared the diet. A small amount o f sample from the last bag or container 
for each diet batch was placed in a tiny plastic bag and labeled for future 
diet analysis.
To prepare the high fat diets each macronutrient was weighed and 
placed in its own container. The individual micronutrients (vitamins, 
minerals, etc.) were weighed and sieved sequentially into a bowl. Any 
crystals left were ground up with a mortar and pestle and added to the 
mixture. The micronutrients were then mixed by hand until a uniform
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distribution was obtained. A  small amount o f each o f the dry ingredients 
(each macronutrient and the micronutrient mix) was sieved sequentially 
through a small mesh into a large bowl. This was done 3 times so that there 
was 3 layers, each one consisting o f a small amount o f each ingredient.
This was done to ensure adequate mixing later. Crystals, from the 
macronutrients, that remained in the mesh were crushed and added to the 
mixture. The ingredients were mixed using a spoon and then sieved with a 
larger diameter screen into the metal bowl o f a small mixer. The metal bowl 
was placed on a large balance and the desired amount o f Crisco was then 
carefully added to top o f this mixture. The specified amount o f soybean oil 
was then added to this pre-weighed mixture. The ingredients were then 
hand mixed until the mixture was uniform. The metal bowl was placed on a 
heavy-duty Kitchen Aid mixer and mixed, at a setting of 4 or 6, for 1 minute. 
A rubber spatula was used to scrape down the sides and bottom o fthe  bowl. 
This process was repeated 2 more times and then the mixture was 
transferred to another mixing bowl. This was done to ensure proper mixing 
o f both the top and bottom parts o f the mixture. The mixture was then mixed 
2 more times in the Kitchen Aid Mixer. After the fifth mixing, the diet was 
very uniform in consistency. The diets were stored and labeled the same 
way as the low fat diets. A small sample was also taken fo r future diet 
analysis.
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APPENDIX D 
ENZYME AND BLOOD ANALYSIS
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HOAD ANALYSIS
1) Preparation of homogenizing buffer
a) Prepare 150 mis o f buffer (this volume is enough for 72 samples)
b) Need a 175mMKCL, 2mM EDTA and 10mM Tris concentration
c) For KCL the molecular weight is multiplied by .15 liters to get amount 
o f grams you need (1.95 grams o f KCL/150 mis)
d) For EDTA you can use the disodium salt since it will go into solution 
more readily. The molecular weight o fthe  salt is 336.2 so 1Mole = 
336.2 so Im iiliMole = .3362. To get a 2mM solution multiply .3362 by 
2 which = .6724g/l. To prepare .15liters multiply .6724g/l X .15liters 
which = .10086g/150mls.
e) For Tris make up 100 mis o f tris stock solution by weighing 1.322 g of 
Trizma HCL and .194 g o f Trizma base. Fill a 150-ml beaker with 
approximately 70 mis o f ultra pure water. Mix acid and base and bring 
up to volume using a volumetric flask. Note the ph o fthe  solution.
f) Dissolve the KCL and EDTA in approximately 85 mis of ultra pure 
water. Add to that 15 mis o fthe  tris stock solution. Store the mixture 
in the refrigeratior for about 30 minutes (temperature o f mixture 
should be 4 °C.
g) Bring the ph o fthe  solution to 7.4 by adding acid or base as needed 
(Note our ph was 7.54).
h) Transfer the solution into two volumetric flasks (100mls and 50 mis) 
and bring them up to volume.
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i) Place the solution back into the beaker and remix using a stirrer and 
stir bar.
j) Recheck the ph o f the solution (Note our ph was 7.42).
2) Preparation o f Homogenate
a) Thaw out sample
b) Clean muscle by removing any connective tissue. Cut with scissors 
perpendicular to muscle and pull away connective tissue using 
tweezers.
c) Weigh muscle, (need at least .03 g o f tissue)
d) To determine amount o f homogenizing buffer multiply weight o f 
muscle (g) X 19. (this is a 5% homogenate o fthe  tissue)
e) Place muscle and buffer in a test tube (Need a tube that is wide 
enough to be used with homogenizer. Can use 16X100 mm tubes)
f) Homogenize sample by placing blade of homogenizer all the way to 
the bottom o f sample. Turn the homogenizer on by rotating knob 
clockwise and carefully move tube up and down. If necessary turn 
knob to get more grinding. Be careful not to cause too much foaming 
of the sample. Keep a beaker of ice under the test tube when 
homogenizing to keep the sample chilled at all times.
g) Place homogenized samples in ice bucket if the assay will be 
conducted immediately after, otherwise parafilm the test tubes and 
store in freezer.
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3) Preparation o f 100mM Potassium Phosphate buffer
a) Weigh 7.242 g o f K2HP04
b) Weigh 1.1424 g o f KH2P04
c) Take a 500 ml beaker and add 500 mis o f ultra pure water and a stir 
bar
d) Place beaker in a magnetic stirrer and gradually add the chemicals
e) Stir until they dissolve
f) Bring ph up to 7.4 at room temperature by adding acid or base as 
needed
4) Preparation o f NADH
a) Make 2 mg of NAOH/ml o f phosphate buffer
b) The first day o fthe  assay we prepared 20 mg of NADH by adding 10 
mis o f phosphate buffer prepared in step 3 (this was enough to run 46 
samples and some was left)
c) The second day of the assay we prepared 30 mg o f NADH by adding 
15 mis o f phosphate buffer
d) You can make larger quantities of the NADH and store frozen for later 
use
5) Preparation o f Acetoacetyl CoA
a) To prepare dissolve 1.834 mg of acetoacetyl/ ml o f phosphate buffer
b) The first day of the assay we prepared the 10 mg acetoacetyl bottle 
by adding 5.45 ml o fth e  phosphate buffer. Weigh out the phosphate 
buffer and with a pipet add to the bottle a couple o f drops of the buffer
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(the acetoacetyl is hydroscopic). Continue to do this until you have 
added enough buffer to mix the contents of the bottle. Transfer this 
mixture to a beaker and add the rest o fthe  buffer. 10 mg of 
acetoacetyl was enough to run approximately 46 samples.
c) For the second day o f the assay we prepared the 25 mg bottle in the 
same way except this time we used 13.63 ml o f phosphate buffer.
6) Running the assay
a) Allow 30 minutes for the spectrophotometer to warm up
b) Thaw out two homogenized samples
c) Place 1.4 ml of phosphate buffer in two labeled test tubes
d) Vortex the homogenized sample
e) Pipet amount of sample that will be used (100 pi) three times before 
using
f) Vortex sample again and pipet 100 pi o f sample into tube with 
phosphate buffer (1:15 dilution) Note: This dilution can change. We 
started with a 1:15 but then used a 1:10 dilution (100 pi of sample 
and .9 ml o f phosphate buffer).
g) Vortex again
h) Add to a 1.6 ml cuvette 700 pi o f 100 mM phosphate buffer, 100 pi of 
NADH, and 100 pi of diluted homogenate (1:10 dilution).
i) Place samples in spectrophotometer and allow to equilibrate (couple 
o f minutes)
j) Initiate reaction by adding 100 pi o f 2 mM acetoacetyl CoA.
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k) To start the reaction, invert the samples using a piece of parafilm.
I) Record absorbance every 15 seconds for 5 minutes 
m) Determine average change in OD/min by subtracting T i -Ts/4minutes 
n) Calculations: Net change in OD/min X 10 X 10 X 20/6.22 
uMoles/g/min o f activity
• 10 = cuvette dilution
•  10 = homogenate dilution (phospphate buffer)
•  20 -  homogenate dilution (homogenizing buffer)
SERUM INSULIN ANALYSIS
Three plain uncoated tubes (12X75 mm) were labeled (tubes 1-3) for 
the total counts. Insulin Ab-Coated tubes, for the calibrators, were labeled A 
(maximum binding, tubes 4-6) and B through G (tubes 7-24) in triplicate. 
Calibrators were prepared with lyophilized processed human serum. The 
calibrators were reconstituted at least 30 minutes prior to the assay by 
adding 6.0 ml o f distilled water to the zero calibrator (A) and 30 ml o f distilled 
water to the remaining calibrators. Table 3.7 illustrates the amount o f 
micro-units of insulin per m illiliter added to the calibrator tubes. Two coated 
tubes (tubes 25-26) containing rat serum were labeled as pool 1 and 2.
Four rat standards, in duplicate, were used for this assay and the coated 
tubes were labeled 27-34 (table 3.7). For the samples, only one coated tube 
(tubes 35-294) was labeled for each rat with its designated I.D. code. Week 
2 and 8 serum samples were analyzed the same day.
To the respective tubes, 200 pi o f calibrator, 200 pi o f control, and 
100 pi of sample was added. To ail tubes 1 ml o f1251 was added and the
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tubes were vortexed. The tubes were incubated for 18 hours at room 
temperature and the supernatant was decanted thoroughly except for tubes 
1, 2 and 3. A gamma counter was used to determine the amount o f insulin 
present in the sample.
Table 3.7 Calibrator and rat standard labeled tubes for insulin analysis.
| Tube Number Content Concentration (uU/ml)
1,2,3 Total counts
4,5,6 Calibrator A 0
7,8,9 Calibrator B 5
10,11,12 Calibrator C 15
13,14,15 Calibrator 0 50
16,17,18 Calibrator E 100
19,20,21 Calibrator F 200
22,23,24 Calibrator G 400
25
Pool i
26 Pool 2 -------
| 27,28 Rat standard 12.5
29,30 Rat standard 25
31,32 Rat standard 50
33,34 Rat standard 125
SERUM AMMONIA ANALYSIS
Ammonia samples for week 2 and 8 were each analyzed 24 hours 
after the blood was collected. To run the assay two blank and control cuvets 
were labeled. To the blank cuvets, 1 ml of Ammonia Assay Solution (3.4 
mmol/l o f 2-oxoglutarate and .23 mmol/l o f NADPH) and .1ml o f water were 
added. To the control cuvettes, 1 ml of Ammonia Assay Solution and .1ml 
of Ammonia Control Solution (5 pg/ml of ammonia) were added. Ammonia 
Assay Solution (1 ml) and serum (100 pi) were added to the sample cuvets. 
The samples were run in singles. The cuvets were covered with parafilm
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and mixed by gentle inversion. The initial absorbance o f each cuvet was 
recorded versus water, 100 pi o f L-glutamate dehydrogenase was added 
and the cuvets were mixed by gentle inversion. To allow for the reaction to 
proceed, approximately 5 minutes elapsed before the final absorbance was 
read. Final absorbance was read for each cuvet versus water.
To determine the ammonia concentration the change in absorbance 
was calculated (Final -  Initial). The change was then subtracted from the 
change in blank absorbance and multiplied by a factor, 30.3. The factor was 
calculated using the following formula:
Factor=Volume of liouid cuvet (1.11 ml) x Weight (ua) of 1 umol of NADPH (17) 
Millimolar absorptivity (6.22) x Volume of specimen (100 pi)
SERUM GLUCOSE ANALYSIS
The sampling interval used was determined based on the number of 
samples in the assay. In this study, a 15 second sampling interval was used 
(three standards plus 64 samples). Borosilicate glass tubes (12X75 mm) 
were labeled for standards and samples as shown in Table 3.8. The ICN 
DIGIFLEX pipetter was set in the sample/dispense mode. The syringes 
were set at 1.25 ml and 6.25 pi, left and right syringes respectively. The 
glucose trinder reagent, adjusted to room temperature was used to prime 
the samples. To the corresponding tubes 6.25 pi of water (blank), glucose 
(standards) or sample were added. The tubes were immediately vortexed 
and incubated at room temperature for 18 minutes. Samples were read in 
the spectrophotometer.
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Table 3.8 Standard concentrations for glucose analysis.








SERUM NONESTERIFIED FATTY ACID ANALYSIS
A standard curve was obtained using a 10 ml solution containing oleic 
acid at 1 mmol/l (Table 3.9). Borosilicate glass tubes (12X75 mm) for 
standards (A-F) and samples were labeled. To each tube, 300 pi of 
Reagent A (acyl-CoA synthetase, ascorbate oxidase, CoA, ATP, 4- 
aminoantipyrine) was added, the tubes were vortexed and incubated for 20 
minutes in a water bath at 37°C. Reagent B (acyl-CoA oxidase, peroxidase, 
MEHA; 750 pi) was added, the tubes were vortexed and incubated for 20 
minutes in the same water bath. The tubes were allowed to cool at room 
temperature for 5 minutes and then read on the spectrophotometer at 550 
nm. The concentrations of the samples were determined using the standard 
curve.
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Table 3.9 Standard Curve for nonesterified fatty acids
Tube Standard Concentration 
mEq/L* mmol/L
Stock NEFA Std (|il) Distilled water (pi)
A 0.000 0.0 1000.0
B 0.100 100.0 900.0
C 0.250 250.0 750.0
D 0.500 250.0 250.0
E .750 300.0 100.0
F 1.000 500.0 0.0
SERUM UREA NITROGEN ANALYSIS
Brosilicate glass tubes (12X75 mm) were labeled for 3 standards 
(Table 3.10) and for each sample. The ICN DIGIFLEX pipetter was placed 
in the sample/dispense mode, with the left syringe set at 100 pi and right 
syringe at 5 uL. To the respective tubes, 5 uL o f standard or sample was 
added and 100 uL o f deionized water. The Urease Buffer Reagent (100 pi; 
Sigma catalog No. 640-5; each 30-ml vial contains 100 units o f buffered 
ureased from jack beans and sodium azide is the preservative) was added, 
the tubes were vortexed and incubated for 10 minutes in a water bath at 
37°C. To each tube, 250 pi o f phenol-nitroprusside Solution (50 grams 
Phenol and .25 grams sodium nitroprusside) was added and the tubes were 
vortexed. Hypochlorite solution (250 pi; 25 grams sodium hydroxide and 
fresh 40 ml clorox bleach) was added and once again the tubes were 
vortexed. An additional 1000 pi of deionized water was added to all tubes. 
The tubes were incubated for 30 minutes at room temperature and the 
assay was read at 570 nm using the spectrophotometer.
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Table 3.10 Standard concentrations for urea-Nitrogen analysis
1 Tube Identification Number Urea-Nitrogen mmol/l
| Standard 1 0
| Standard 2 3.57
| Standard 3 10.71
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Figure 4.1 data: Food intake for rats fed high and low fat diets.
























Food Intake 6 63.92 ±1.79 
(n-31)
95.51 ± 1.79 
(n=31)




Figure 4.2 data: Energy intake for rats fed high and low fat diets.




I Energy Intake 1 832.5 ± 17.6 
(n=32)
600.18 ± 17.6 
(n=32)
Energy Intake 2 488.1 ±11.31 
(n=32)
372.27 ± 11.3 
(n=31)
Energy Intake 3 409.7 ± 9.7 
(n=32)
377.22 ± 9.7 
(n=31)
Energy Intake 4 427.8 ± 8.6 
(n=32)
424.18 ±8 .6  
(n=31)
Energy Intake 5 424.6 ± 8.6 
(n=31)
413.57 ±8 .6  
(n-31)
Energy Intake 6 346.3 ± 7.6 
(n=31)
369.38 ± 7.6 
(n=31)
Energy Intake 7 374.1 ±9.2  
(n=31)
405.63 ± 9.2 
(n=31)
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Figure 4.3 data: Energy intake for rats fed low and high fat with or without
carnitine.












Energy Intake 1 601.5 ±25.3 
(n=16)
826 ± 25.3 
(n=16)
598.9 ± 24.5 
(n=16)
839.0 ±4 .5  
(n=16)
Energy Intake 2 346.5 ±16.3 
(n=15)




470.8 ± 15.7 
(n=16)
Energy Intake 3 363.8 ±13.9 
(n=15)
404.8 ± 13.9 
(n=16)
390.7 ± 13.4 
(n=16)
414.6 ± 13.4 
(n=16)
Energy Intake 4 426.2 ±12.4 
(n=15)
417.4 ± 12.4 
(n=16)
422.2 ± 12.0 
(n=16)
437.9 ± 12.0 
(n-16)








Energy Intake 6 375.0 ± 10.9 
(n=15)














Figure 4.4 data (a): Initial and weekly body weig i t  for all dietary reatments.








I Body Weight 0 307 ± 7  
(n=8)
307 ± 7  
(n=8)
308 ± 7  
(n=8)
308 ± 7  
(n=8)
I Body Weight 1 317 ± 8 
(n=8)
320 ± 8  
(n=8)
340 ± 8  
(n=8)
340 ± 8  
(n=8)
I Body Weight 2 314 ± 7  
(n=8)
316 ± 7  
(n=8)
314 ± 7  
(n=8)
349 ± 7  
(n=8)
I Body Weight 3 315 ± 9 
(n=8)
321 ± 9  
(n=8)
349 ± 9  
(n=8)
350 ± 9  
(n=8)
Body Weight 4 314 ± 9  
(n=8)
320 ± 9  
(n=8)
352 ± 9  
(n=8)
352 ± 9  
(n=8)
Body Weight 5 315 ± 10 
(n=8)
319 ± 10 
(n=8)
351 ± 10 
(n=8)
357 ± 10 
(n=8)
Body Weight 6 309 ± 9  
(n=8)
312 ± 9  
(n=8)
346 ± 9  
(n=8)
352 ± 9  
(n=8)
Body Weight 7 309 ±10 
(n=8)
314 ±10  
(n=8)
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Figure 4.4 data (b): Initial and weekly body weig ht for all dietary reatments.








Body Weight 0 307 ± 7  
(n=8)
308 ± 7  
(n=8)
307 ± 7  
(n=8)
307 ± 7  
(n-8)
Body Weight 1 319 ± 8  
(n=8)
320 ± 8  
(n=8)
342 ± 8  
(n -8 )
339 ± 8  
(n-8)
Body Weight 2 312 ± 7  
(n=7)
312 ± 7  
(n-8)
354 ± 7  
(n -8 )
353 ± 7  
(n-8)




348 ± 1 0  
(n -8 )
356 ± 9  
(n-8)
Body Weight 4 315 ± 10 
(n=7)
314 ± 9  
(n-8)
351 ± 1 0  
(n -8 )
358 ± 9  
(n-8)








Body Weight 6 304 ± 10  
(n=7)
311 ± 9  
(n-8)
345 ± 1 0  
(n*7)
353 ± 9  
(n-8)
Body Weight 7 308 ± 11 
(n=7)






Figure 4.5 data: Body weight for rats fed high and low fat diets .
I Body weight High fat Low fat
(Grams ± SE) (Grams ± SE)
Body weight 0 307 ± 4 307 ± 4
(n=32) (n=32)
j Body weight 1 340 ± 4 319 ± 4
(n=32) (n=31)
Body weight 2 350 ± 4 314 ± 4
(n=32) (n=31)
Body weight 3 351 ± 5 316 ± 5
(n=32) (n=31)
Body weight 4 353 ± 5 316 ± 5
(n=32) (n=31)
Body weight 5 355 ± 5 315 ± 5
(n=31) (n=31)
Body weight 6 349 ± 5 309 ± 5
(n=31) (n=31)
Body weight 7 348 ± 5 312 ± 5
(n=31) (n=31)
185
Reproduced with permission o fthe copyright owner. Further reproduction prohibited without permission.
Figure 4.6 data: Weic ht gain for rats fed high and low fat diets.




Weight Gain 1 33.03 ±1 .6  
(n=32)
12.14 ±1 .6  
(n=32)












Weight Gain 5 1.40 ±1.03 
(n=31)
-0.10 ± 1.03 
(n=31)








Figure 4.7 data. Energy efficiency for rats fed high and low fat.
Energy Efficiency High Fat Low Fat
(wt gn/1000 kcal ± SE) (wt gn/1000 kcal ± SE)
Energy Efficiency 1 39.42 ± 2.0 19.90 ±2.0
(n=32) (n=32)
Energy Efficiency 2 17.67 ±5.8 -16.93 ±5.8
(n=32) (n=31)
Energy Efficiency 3 -1.35 ±5.3 4.74 ± 5.3
(n=32) (n=31)
Energy Efficiency 4 5.45 ± 2.6 -1.7 ±2 .6
(n=32) (n=31)
Energy Efficiency 5 2.06 ± 2.44 -0.62 ± 2.44
(n=31) (n=31)
Energy Efficiency 6 -17.62 ±3.16 -18.26 ±3.16
(n=31) (n=31)
Energy Efficiency 7 -4.81 ± 3.61 4.71 ±3.61
I (n=31) (n=31)
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Figure 4.8 data: Serum carnitine levels for rats fed diet with or without
carnitine.
Dietary Treatment Serum Carnitine Wk 2 
(nmol/ml ± SE)
Serum Carnitine Wk 8 
(nmol/ml ± SE)
Carnitine 59.63 ± 1.78 
(n=30)
58.75 ± 2.35 
(n=30)




Figure 4.9 data: Serum carnitine levels for rats fed high and low protein.
Dietary Treatment Serum Carnitine Wk 2 
(nmol/ml ± SE)
Serum Carnitine Wk 8 
(nmol/ml ± SE)








Figure 4.10 data: Serum carnitine levels for rats fed hiejh and low fat.
Dietary Treatment Serum Carnitine Wk 2 
(nmol/ml ± SE)
Serum Carnitine Wk 8 
(nmol/ml ± SE)
High Fat 41.50 ±1.70 
(n=33)
39.86 ± 2.23 
(n=29)
Low Fat 47.40 ±1.78 
(n=30)
50.78 ± 2.35 
(n=30)
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Figure 4.11 data. Serum carnitine levels for all dietary treatment groups.
j Dietary Treatment Carnitine Wk 2 
(nmol/ml ± SE)
Carnitine Wk 8 
(nmol/ml ± SE)




CPL 61.79 ±4.14 
(n=6)
60.03 ± 5.47 
(n=7)












NPL 27.29 ± 3.28 
(n=8)
30.73 ± 4.33 
(n=8)








Figure 4.12 data: Serum carnitine levels for rats fed high and low fat with or 
without carnitine.
Dietary Treatment Carnitine Wk 2 
(nmol/ml ± SE)
Carnitine Wk 8 
(nmol/ml ± SE)




Carnitine Low Fat 64.81 ± 2.64 
(n=30)
62.57 ± 3.49 
(n=32)








Figure 4.13 data: Serum ammonia levels for rats fed high and low protein 
diets.
Dietary Treatment Ammonia Wk 2 
(umol/l ± SE)
Ammonia Wk 8 
(umol ± SE)
High Protein 134.8 ±5.3 104.0 ±6.0
(n=31) (n=31)
Low Protein 116.1 ±5.4 93.1 ±6.1
I (n=31) (n=29)
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Figure 4.14 data: Serum ammonia levels for rats fed high and low protein
with or without carnitine.
Dietary treatment Ammonia Wk 2 Ammonia Wk 8
(umol/l ± SE) (umol ± SE)
Carnitine High Protein 122.4 ±7 .4 103.8 ±8 .5
(n=15) (n=16)
Carnitine Low Protein 117.2 ±7 .4 96.6 ± 8.5
(n=16) (n-15)
No Carnitine High Protein 147.2 ± 7.4 104.3 ±8 .5
(n=16) (n=15)
No Carnitine Low Protein 115 ±7.7 89.5 ± 8.8
(n=15) (n=14)
Figure 4.15 data: Serum ammonia levels for all c ietary treatment groups.
Dietary Treatment Ammonia Wk 2 
(umol/L ± SE)
Ammonia Wk 8 
(umol/L ± SE)
CLL 128.3 ±10.9 
(n=8)
98.1 ± 12.4 
(n=7)
CPL 110 ± 10.9 
(n=7)
108.8 ± 12.4 
(n=8)
CLF 106.1 ± 10.2 
(n=8)
95.2 ± 11.6 
(n=8)
CPF 134.79 ± 10.2 
(n=8)
98.7 ± 11.6 
(n=8)
NLL 115.8 ±10.9 
(n=7)
91.3 ± 12.4 
(n=7)
NPL 149 ± 10.2 
(n=8)
118.6 ±11 .6  
(n=8)
NLF 114.1 ±10.9 
(n=8)
87.7 ± 12.4 
(n=7)
NPF 145.4 ±10.9 
(n=8)
90.0 ± 12.4 
(n=7)
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Figure 4.16 data: Serum glucose levels for rats fed diet with or without
carnitine.
Dietary Treatment Glucose Wk 2 
(mmol/l ± SE)
Glucose Wk 8 
(mmol ± SE)
Carnitine 8.66 ± 0.31 8.64 ± 0.24
(n=30) (n=32)
No Carnitine 9.24 ± 0.31 8.16 ±0.24
(n=31) (n=30)
Figure 4.17 data: Serum glucose levels for rats fed high and low protein 
diets.
Dietary Treatment Glucose Wk 2 Glucose Wk 8
(mmol/l ± SE) (mmol ± SE)
High Protein 9.41 ± 0.30 8.63 ± 0.23
(n=31) (n=32)
Low Protein 8.49 ± 0.31 8.17 ±0.24
(n=30) (n=30)
Figure 4.18 data: Serum glucose levels of rats fed high and low protein with 
or without carnitine.
I Dietary treatment Glucose Wk 2 Glucose Wk 8
(mmol/l ± SE) (mmol ± SE)
Carnitine High Protein 8.86 ± 0.44 9.09 ± 0.34
(n=15) (n=16)
Carnitine Low Protein 8.47 ± 0.44 8.19 ±0.34
(n=15) (n=16)
No Carnitine High Protein 9.97 ± 0.42 8.17 ±0.32
| (n=16) (n=16)
No Carnitine Low Protein 8.52 ± 0.45 8.14 ±0.35
(n=15) (n=15)
Figure 4.19 data: Serum urea nitrogen levels for rats fed high and low 
protein diets.________________________________________________
| Dietary Treatment Urea Wk 2 Urea Wk 8
I (mmol/l ± SE) (mmol ± SE)
I High Protein 6.48 ±0.16 7.77 ± 0.21
I (n=31) (n=32)
I Low Protein 5.53 ±0.16 5.76 ± 0.22
I (n=31) (n=30)
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Figure 4.20 data: Serum urea nitrogen levels for rats fed diet with or without
carnitine.
Dietary Treatment Urea Wk 2 Urea Wk 8
(mmol/l ± SE) (mmol ± SE)
Carnitine 6.04 ±0.16 6.80 ± 0.21
(n=31) (n=32)
No Carnitine 6.00 ±0.16 6.73 ± 0.22
(n=31) (n=30)
Figure 4.21 data: Serum urea nitrogen levels for rats fed low and high fat.
Dietary Treatment Urea Wk 2 Urea Wk 8
(mmol/l ± SE) (mmol ± SE)
High Fat 5.76 ±0.16 6.27 ± 0.21
(n=32) (n=31)
Low Fat 6.25 ±0.16 7.26 ± 0.22
(n=30) (n=31)
Figure 4.22 data: Serum urea nitrogen levels for rats fed high and low fat 
with or without carnitine.
Dietary treatment Urea Wk 2 Urea Wk 8
(mmol/l ± SE) (mmol ± SE)
Carnitine High Fat 5.95 ± 0.22 6.53 ± 0.30
(n=16) (n=16)
Carnitine Low Fat 6.14 ±0.22 7.06 ± 0.31
(n=15) (n=16)
No Carnitine High Fat 5.58 ± 0.22 6.01 ±0.31
(n=16) (n=15)
No Carnitine Low Fat 6.36 ± 0.22 7.46 ± 0.31
(n=15) (n=15)
Figure 4.23 data: Serum urea nitrogen levels for rats fed high and low 
protein and fat.______________________________________________
| Dietary treatment Urea Wk 2 Urea Wk 8
(mmol/l ± SE) (mmol ± SE)
High Protein High Fat 6.00 ± 0.22 7.01 ± 0.30
(n=16) (n=16)
High Protein Low Fat 7.00 ± 0.22 8.53 ± 0.31
(n=15) (n=16)
Low Protein High Fat 5.52 ± 0.22 5.53 ± 0.31
(n=16) (n=15)
Low Protein Low Fat 5.54 ± 0.22 5.98 ± 0.31
(n=15) (n=15)
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Figure 4.24 data: Serum insulin levels for rats fed high and low protein
Dietary Treatment Insulin Wk 2 Insulin Wk 8
(MU/ml ± SE) (u U/ml ± SE)
High Protein 6.7 ±0 .5 5.9 ± 0.5
(n=13) (n=16)
Low Protein 5.4 ± 0.5 4.7 ± 0.5
(n=15) (n=13)
Figure 4.25 data: Serum insulin levels for rats fed high and low protein with 
or without carnitine.
| Dietary Treatment Insulin Wk 2 
(uU/ml ± SE)
Insulin Wk 8 
(MU/ml ± SE)
Carnitine High Protein 6.3 ±0 .7 6.5 ± 0.7
(n=14) (n=16)
Carnitine Low Protein 5.7 ± 0.7 4.4 ± 0.6
(n=16) (n=16)
No Carnitine High Protein 7.1 ±0 .7 5.4 ± 0.7
(n=15) (n=16)
No Carnitine Low Protein 5.2 ±0 .8 4.9 ± 0.7
(n=15) (n=13)
Figure 4.26 data: Serum insulin levels for rats fed high and low fat with or 
without carnitine.
I Dietary Treatment Insulin Wk 2 Insulin Wk 8
(MU/ml ± SE) (MU/ml ± SE)
Carnitine High Fat 6.6 ±0 .7 5.0 ± 0.7
(n=15) (n=16)
Carnitine Low Fat 5.4 ±0 .7 5.8 ± 0.7
(n=15) (n=16)
No Carnitine High Fat 4.8 ±0 .8 5.0 ± 0.7
(n=15) (n=14)
No Carnitine Low Fat 7.4 ±0 .7 5.3 ± 0.7
(n=15) (n=15)
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Figure 4.27 data: Serum insulin levels for rats fed high and low levels of 
protein and fat.________________________________________________
Dietary Treatment Insulin Wk 2 Insulin Wk 8
(MU/ml ± SE) (MU/ml ± SE)
High Protein High Fat 5.5 ± 0.7 5.0 ±0.7
(n=14) (n=16)
High Protein Low Fat 7.8 ± 0.7 6.9 ± 0.7
(n=15) (n=16)
Low Protein High Fat 5.8 ± 0.8 5.1 ±0 .7
(n=16) (n=14)
Low Protein Low Fat 5.0 ±0 .7 4.3 ± 0.7
—  -
(n=15) (n=15)
Figure 4.28 data: Serum nonesterified fatty acids level for rats fed high and 
low fat.
Dietary Treatment NEFA Wk 2 
(pEq/L ± SE)
NEFA Wk 8 
(pEq/L ± SE)
High Fat 636.7 ± 42.7 
(n=32)
628.8 ± 42.5 
(n=30)
Low Fat 792.2 ± 43.4 
(n=30)
820.1 ± 42.2 
(n=31)
Figure 4.29 data: Serum nonesterified fatty acid levels for rats fed diet with 
or without carnitine.
] Dietary Treatment NEFA Wk 2 NEFA Wk 8
| (pEq/L ± SE) (pEq/L ± SE)
I Carnitine 692.6 ± 43.4 753.3 ± 43.2I (n=31) (n=31)
j No Carnitine 736.3 ± 42.7 695.6 ± 42.5
I (n=31) (n=3)
Figure 4.30 data: HOAD activity for rats fed high and low 
protein with or without carnitine._____________________
I Dietary Treatment HOAD Activity 
(pmol/g/min ± SE)
Carnitine High Protein 5.82 ± 0.70 
(n=16)
Carnitine Low Protein 4.97 ± 0.68 
(n=16)
No Carnitine High Protein 5.44 ± 0.68 
(n=16)
No Carnitine Low Protein 6.77 ± 0.72 
(n=14)
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High Fat 24.7 ± 0.8 
(n=31)
20.3 ± 0.4 
(n=31)
54.2 ± 0.7 
(n=31)
4.4 ± 0.2 
(n=31)




59.8 ± 0.7 
(n=31)
4.7 ± 0.2 
(n=31)
Figure 4.33 data: Final body weight for rats fed high 
and low fat diets.
Dietary Treatment Final Body Weight 
(Grams ± SE)
High Fat 342 ± 5
(n=31)
Low Fat 304 ± 5
I (n=31)
Figure 4.34 data: Abdominal fat for rats fed diets with 
or without carnitine
1 Dietary Treatment Abdominal Fat
1 (Grams ± SE)
| Carnitine 20.4 ± 1.1
I (n=31)
I No Carnitine 18.4 ±1.2
I (n=31)
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Figure 4.35 data: Abdominal fat as percent o f body weight for rats fed diet 
with or without carnitine.
Dietary Treatment Abdominal Fat as % of
Body Weight
(% ± SE)
Carnitine 6.2 ± 0.3
(n=32)
No Carnitine 5.5 ±0 .3
(n=30)
Figure 4.36 data: Serum glucose levels for rats fed high and low fat before
(0 min) and after (120 min] glucose administration.
Dietary Treatment Glucose 0 min 
(mmol/l ± SE)
Glucose 120 min 
(mmol/l ± SE)
High Fat 10.43 ±0.35 16.80 ±0.63
(n=32) (n=31)
Low Fat 10.83 ±0.37 13.09 ±0.67
(n=32) (n=28)
Figure 4.36 data: Serum insulin levels for rats fed high and low fat diets 
before (0 min) and after (120 min) glucose administration.
| Dietary Treatment Insulin 0 min Insulin 120 min
I (MU/ml ± SE) (MU/ml ± SE)
I High Fat 4.4 ± 0.6 4.8 ± 0.3
I (n=32) (n=32)
| Low Fat 5.5 ± 0.6 3.3 ±0.3
I (n=30) (n=31)
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Figure 4.37 data: Serum glucose levels of rats fed high and low protein 
before (0 min) and after (120 min) glucose administration.___________
Dietary Treatment Glucose 0 min 
(mmol/l ± SE)
Glucose 120 min 
(mmol/l ± SE)








Figure 4.37 data: Serum insulin levels of rats fed high and low protein before
(0 min) and after (120 min glucose administration.
j Dietary Treatment Insulin 0 min 
(p ll/m l ± SE)
Insulin 120 min 
(MU/ml ± SE)
High Protein 5.6 ± 0.6 4.3 ±0.3
(n=32) (n=32)
Low Protein 4.3 ± 0.6 3.8 ± 0.3
(n=30) (n=31)
Figure 4.38 data: Serum insulin levels for rats fed high and low protein with 
or without carnitine before (0 min) and after (120 min) glucose 
administration.
Dietary Treatment Insulin 0 min Insulin 120 min
(MU/ml ± SE) (MU/ml ± SE)
Carnitine High Protein 10.7 ±0.8 4.7 ± 0.4
(n=16) (n=16)
Carnitine Low Protein 3.5 ±0.8 3.3 ± 0.4
(n=16) (n=16)
No Carnitine High Protein 4.9 ±0.8 3.9 ± 0.4
(n=16) (n=16)
No Carnitine Low Protein 5.1 ±0.9 4.2 ± 0.5
(n=14) (n=15)
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Figure 4.38 data: Serum glucose levels for rats fed high and low protein with
or without carnitine before (0 min) and after (120 min) glucose
administration.
I Dietary Treatment Glucose 0 min 
(mmol/L ± SE)
Glucose 120 min 
(mmol/L ± SE)
















Figure 4.39 data: Serum insulin levels for rats fed high and low protein and 
fat before (0 min) and after (120 min) glucose administration.
I Dietary treatment Insulin 0 min. Insulin 120 min.
(pU/ml ± SE) (pU/ml ± SE)
High Protein High Fat 4.4 ± 0.8 5.3 ± 0.5
(n=16) (n=16)
High Protein Low Fat 6.9 ± 0.8 3.3 ± 0.5
(n=16) (n=16)
Low Protein High Fat 4.4 ± 0.8 4.2 ± 0.5
(n=16) (n=16)
Low Protein Low Fat 4.1 ±0 .9 3.3 ± 0.5
(n=14) (n=15)
Figure 4.39 data: Serum glucose levels for rats fed high and low protein and 
fa t before (0 min) and after (120 min) glucose administration.
R Dietary treatment Glucose 0 min. 
(mmol/L ± SE)
Glucose 120 min. 
(mmol/L ± SE)
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